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Summary
Crucial to the development of multiple sclerosis and the animal counterpart 
experimental allergic encephalomyelitis (EAE) is loss of blood-brain barrier (BBB) 
integrity whereby systemic solutes and cells gain unregulated entry to neuronal tissue 
resulting in serious neurological sequelae. This thesis examines the control of EAE 
development through pharmacological restriction of BBB dysfunction with 
consideration of the mechanisms underlying the neurovascular perturbation.
A double radioisotope technique was developed to accurately and 
reproducibly quantitate BBB permeability to systemic albumin during the progression 
of EAE. Abnormal levels of protein transport were measured at the BBB concomitant 
with symptom onset in acute EAE. Disruption to the barrier was initially greatest in 
the spinal cord continuing throughout disease expression and persisting into early 
recovery where protein extravasation in the cerebellum was maximal.
Control of neurovascular permeability by dexamethasone (DEX), cyclosporin 
A (CSA) and FK506 was investigated following short-term dosing during both acute 
and recovery stages of EAE. DEX (0.1-lmg/kg), demonstrated a dose-dependent 
inhibition of neurovascular abnormalities which could be antagonised by 
administration of the anti-glucocorticoid RU38486. CSA (50mg/kg) partially 
suppressed abnormal neurovascular permeability in EAE following therapeutic 
administration and normalised barrier function when given during recovery. FK506 
(lOmg/kg) maintained BBB function within normal limits during both acute and 
recovery phases. Combined DEX and CSA therapy, using doses of minimal individual 
effectiveness, demonstrated improved suppression of neurovascular permeability.
Finally, administration of the N-methyl-D-aspartate receptor antagonist 
MK801 demonstrated a dose-related suppression of BBB permeability in acute EAE 
following both prophylactic and therapeutic dosing.
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Effective doses and drug combinations for the control of barrier breakdown in 
EAE have been shown for DEX, CSA and FK506, which may be applicable to the 
treatment of other neurological conditions. Furthermore, a candidate pathway in 
which the N-methyl-D-aspartate receptor is pivotal has been implicated in the loss of 
neurovascular function during EAE.
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1.1 The Mammalian Blood-brain Barrier
Central to the successful control of co-ordination and function of the higher 
vertebrate is the maintenance of a homeostatic cerebral environment in which 
neurological cells can perform their critical processing. In order to achieve a stable 
balance the central nervous tissue must remain distinct from the circulating blood 
plasma which is subject to both dietary and metabolically-mediated fluctuations in 
solute and ion concentrations.
1,1.1 Location
Studies recognising the unique isolation of the brain from the circulatory 
system have been regularly reported since the initial findings of Paul Ehrlich in the late 
nineteenth century. Ehrlich, who administered vital dye intravenously (i.v.) into 
laboratory animals noting that all internal organs but the brain took up the stain, 
concluded that the cerebral tissues lacked the cellular constituents necessary to absorb 
the dye. However, in 1913 Goldmann demonstrated that injection of dyes directly into 
the central nervous system (CNS) resulted in the colouration of neurological tissue 
alone with no dye entering the circulation to stain other organs. Therefore, the 
existence of a barrier between the brain and the bloodstream was inferred. The actual 
cellular location of the blood-brain barrier (BBB) remained a controversial topic until 
Reese, Kamovsky and later Brightman, performed a series of electron microscopy 
experiments during the 1960's employing the electron dense tracers horseradish 
peroxidase and microperoxidase (Reese & Kamovsky, 1967; Brightman & Reese, 
1969). The tracers showed that transport between the blood and the brain was halted 
at the capillary endothelial cell tight junctions, with no inter- or intra-cellular 
movement apparent, leading to the conclusion that the anatomical site of the BBB is 
the cerebrovascular endothelial cell.
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Collectively, within the CNS there are four types of barrier, not all located at 
the endothelium. They comprise: the endothelial BBB of the microvasculature 
(represented in Figure 1); the tight epithelia of the choroid plexus; the complex 
cellular arrangements of the meningeal compartments; and the ependymal tanycyte 
cells of circumventricular organs. Of the latter three (reviewed by: Krisch et. a l ,
1978, 1984; Van Deurs, 1980) the choroid plexus is of particular importance as the 
epithelial structure represents the blood to cerebrospinal fluid (CSF) barrier, 
responsible for the active secretion of 66% of the total CSF. By comparison, secretion 
at the endothelial BBB into the cerebral parenchyma occurs at a much lower rate. 
However, with a surface area 5000 times that of the choroid plexus and with 
individual neurons being no further from a capillary than 40-50pm the BBB directly 
serves 99% of the cerebral tissue (Scharrer, 1944; Crone, 1971; Brightman, 1977). 
Therefore, within the CNS the capillary endothelium is the main barrier structure 
exerting control over the local neural environment.
1.1.2 Unique Structure and Characteristics
Distinct from the general characteristics exhibited by the vascular 
endothelium elsewhere in the body (Renkin, 1977), the endothelial cells of the neuro- 
microvasculature possess unique properties which enable highly selective control to 
be exerted over solute entry into the CNS interstitial fluid. These specialised 
endothelial cells do not develop from the neuroectoderm, but evolve from invading 
capillary cells originating outside of the CNS, differentiating in response to the neural 
environment. The transplant experiments of Stewart & Wiley (1981) clearly showed 
that grafted neural tissue could induce angiogenesis and BBB characteristics in host- 
derived non-cerebral endothelial cells. The main source of the BBB-defming factors 
has since been recognised as the type I astrocyte (Janzer & Raff, 1987). The 
interdigitating astrocytic sheath, unique to the microvasculature (Figure 1), is 
implicated in embryonic barrier induction as its formation accompanies tightening of
19
Figure 1: Cross section of the blood - brain barrier
The schematic diagram illustrates the complex and unique cellular arrangement associated 
with the BBB. Capillary endothelial cells are joined by a continuous belt o f non-fenestrated 
tight junctions to occlude intercellular transport. Intracellular movement of solutes is highly 
regulated as indicated by the large number of mitochondria and limited pinocytotic vessicles 
viewed ultrastructurally. Astrocytic endfeet surround the endothelial cells, influencing BBB 














the BBB during development (Senjo et. al., 1986). Indeed, in vitro culture of cerebral 
capillary endothelial cells is significantly improved by co-culture with astrocytes or 
astrocyte-conditioned media, which increase the expression of BBB characteristics 
(DeBault & Cancilla, 1980; Tao-Cheng & Brightman, 1988).
By the first trimester of foetal life the endothelia form a continuous belt of 
occluding tight junctions which have 2-6 fusion points between cells and which lack 
fenestrations. These junctions preclude intercellular movement through the barrier as 
demonstrated by studies employing hydrophilic tracers horseradish peroxidase, 
cytochrome C and microperoxidase of molecular weights 40,000, 17,000 and 
l,800Da respectively (Reese & Kamovsky, 1967; Brightman & Reese, 1969; Reese 
et. al., 1971; Milhorat et. al, 1973). Pinocytotic activity is evident in the endothelia 
of the majority of organs. However, Reese & Kamovsky (1967) and Clawson et. al. 
(1966), using peroxidase and colloidal iron respectively, demonstrated an absence of 
vesicular uptake activity in the brain under normal conditions. A paucity of 
pinocytotic vesicle transport combined with the lack of junctional fenestrae places a 
great restriction on the bulk flow of solutes across the barrier. In addition the high 
electrical resistance exhibited by the tight cerebro-endothelium (2000flcm 2, 
compared to 430Q.cm2 in the perineurium in the frog) further restrains blood-bom 
solute entry into the CNS extracellular fluid (Crone & Olesen, 1982).
Histochemical analysis has recognised a number of identifying enzymes 
present in high concentration in the cerebral endothelium. These include Na+-K+- 
ATPase, y-glutamyl transpeptidase, butyrylcholinesterase, alkaline phosphatase and 
aromatic-L- amino acid decarboxylase (Betz et. al., 1980; Kreutzberg & Toth, 1983; 
Joo, 1985). Many of the enzymes are connected with the regulation of 
transendothelial movement and in conjunction with the abundant mitochondrial 
presence represent an active metabolic barrier within the physical BBB (Oldendorf & 
Brown, 1975).
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1.1,3 Normal Nutrient Transport
So far, the picture is of an impenetrable barrier, functional from birth, 
protecting the neural environment from contact with circulating plasma constituents. 
It is particularly important to shield the CNS tissues from the fluctuating levels of 
solutes and ions which the blood experiences during periods of active digestion, 
exercise and illness. Moreover, the circulation carries with it hormone and amino acid 
neurotransmitters whose unregulated entry into the CNS would be highly detrimental. 
Oldendorf (1971) has demonstrated that under normal physiological conditions the 
uptake of many of these compounds into the cerebral environment is low if not 
negligible. The only group of molecules to readily gain access to the neural 
parenchyma are lipid soluble compounds including alcohol, nicotine and heroine 
which explains the rapid action of these chemicals. It is however necessary for a 
number of non-lipid soluble molecules to reach the extracellular compartment of the 
brain and a range of selective transport systems exist to satisfy the metabolic and 
protein synthesis demands in addition to the homeostatic requirements of the central 
nervous tissue (Figure 2) (Bradbury, 1984).
The CNS requires glucose concentration to be maintained at 60-80% of the 
plasma concentration, from which cerebral oxidative metabolism can be sustained. 
The influx and efflux of the hexose is assisted by a self-saturable facilitated diffusion 
system that demonstrates a high degree of stereospecificity extracting only D-glucose 
from the blood (Crone, 1965; Betz et. al., 1978). The non-metabolizable D-glucose 
analogue, 3-O-methyl-D-glucose, readily penetrates the BBB using the glucose 
carrier-mediated system, indicating that metabolism by the neural tissues is not a 
prerequisite for transport (Oldendorf, 1971).
Amino acid transport is dependent on the chemical side groups present and of 
particular interest are the large neutral amino acids (NAA) and the small NAA 
(Oldendorf & Szabo, 1976; Betz & Goldstein, 1978). The CSF protein concentration 
is normally only 0.01% that of the plasma because systemic proteins do not usually
22
Figure 2: Transport at the Blood - brain Barrier
Movement of nutrients, ions, and waste products across the BBB is highly organised. The 
D-glucose and large neutral amino acid (NAA) transporters facilitate normal osmotic diffusion. 
Potassium and glycine are actively moved unidirectionaly from the CNS to the blood. L-DOPA 
entering the endothelium from the circulation is metabolically converted to forms unable to 
cross the albuminal membrane. Broken arrow or transporter lines indicate hypothetical routes. 
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(Where : DOPAC = Dihydroxyphenylacetate)
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traverse the BBB or the blood-CSF barrier. Large NAA are therefore required to 
cross the neurovasculature to satisfy the requirements of protein and neurotransmitter 
synthesis. The large NAA compete for a specific carrier-mediated transporter that is 
located in both the luminal and abluminal membranes of the endothelial cell so 
providing bi-directional transport as for glucose. Small NAA are not transported from 
blood to brain as the CNS has the capacity to synthesise them. However, the 
concentration within the brain interstitial fluid of selected members of this group, such 
as the potent inhibitory neurotransmitter glycine, require strict maintainance. 
Therefore, the cerebroendothelium has a small NAA carrier system located in the 
abluminal membrane to provide active unidirectional transport out of the CNS.
Further carrier mediated systems exist at the BBB for monocarboxylic acids, 
nucleosides, purines and amines, while the circulating peptides insulin and transferrin 
rely on receptor-mediated endocytosis (Fishman et. al.y 1987; Broadwell, 1989; 
Pardridge, 1991).
Cerebral levels of the potassium ion must be maintained at 3mM in 
comparison to a vascular average of 5mM to prevent the unregulated firing of nerves 
by exceeding threshold potentials. Neurovascular control is exerted through a 
saturable active process driven by a Na+-K+-ATPase pump asymmetrically located in 
the abluminal membrane (Jones & Keep, 1987). Potassium is transported from the 
brain into the endothelium as sodium is simultaneously transported out into the 
extravascular spaces from where it is recycled by coupling to the glycine transport 
system. In spatial conjunction with the ion pump is a membrane specialisation found 
at the glio-vascular interface of the abutting astrocytic endfeet termed the 'orthogonal 
arrays of particles' (Anders & Brightman, 1979). The 'orthogonal arrays of particles', 
of undefined function, are distributed in a similar pattern to that of the potassium ion 
conductance over the glial cell surface. Also, their formation corresponds with the 
timing of increased homeostatic regulation of potassium at the BBB observed during 
embryo development, supporting the hypothesis that they correspond to symmetrical
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high conductance potassium channels (Anders & Brightman, 1979; Newman, 1985; 
Jones & Keep, 1987).
In addition to regulation by selective transport, the BBB can exert metabolic 
control over the entry of certain substances into the CNS. The neurotransmitters 
dopamine and norepinephrine have a low brain uptake index (Oldendorf, 1971), 
however the precursor of these molecules dihydroxyphenyialanine (L-DOPA) can 
readily enter the cerebroendothelium through the large NAA carrier. Once 
internalised L-DOPA is enzymically modified firstly to dopamine by L-aromatic amino 
acid decarboxylase and then by monoamine oxidase to dihydroxyphenylacetate, 
neither of which can cross the abluminal membrane. Dopamine does have a specific 
carrier system located in the antiluminal plasmalemma, but the transport is 
unidirectional directing movement out of the brain parenchyma only (Betz & 
Goldstein, 1986).
Some provision is made within the cerebral capillary walls to control the 
otherwise unrestricted entry of some lipophilic compounds. The transmembrane 
glycoprotein, P-glycoprotein is the product of the multidrug resistance gene whose 
expression has been demonstrated in BBB capillary endothelial cells (Cordon-Cardo 
et. al., 1989).The function of P-glycoprotein would appear to involve the restriction 
of transport of highly lipophilic toxic substances across the neurovasculature by an 
energy dependent efflux pump (Hamada & Tsuruo, 1988). Drugs, such as 
anthracyclins and epipodophyllotoxins that are used in tumor treatment, are 
particularly prone to the restrictive actions of this protein (Fojo et. al., 1987).
1.1.4 Immunological Access to the CNS
The CNS has traditionally been viewed as an immunopriveledged site based 
on the extended survival time of skin allografts on the brain surface (Medawar, 1948). 
In support of this theory, the CNS lacks a true lymphatic system, possesses few 
immunocompetent cells, demonstrates only a limited expression of class II (la) major
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histocompatibility molecules and contains soluble immunoregulatory factors. 
However, isolation of the CNS from the immune system is not complete.
While the BBB presents a physical barrier to humoral immune factors and cell 
entry it has become apparent that the CNS is routinely surveyed by T cells. Access to 
the CNS compartment requires T lymphocytes to be in an active state, although the 
antigen-specificity displayed does not appear to influence extravasation. Lymphocytes 
have been demonstrated in low but consistent numbers in the connective tissue of the 
meninges and within the parenchyma of normal human and rodent brain tissues 
(Booss et. al., 1983; Lassmann et. a l , 1986). The neurovascular endothelial cells are 
capable of presenting lymphocyte adhesion molecules, such as intercellular adhesion 
molecule-1 (ICAM-1), on the luminal cell membrane (Fabry et. al., 1992). Whether 
ICAM-1 expression is involved in routine cell surveillance is uncertain, but it is clear 
that adhesion molecules can be upregulated in response to proinflammatory cytokines. 
Other immunological cells such as macrophages appear absent from normal adult rat 
brain (Sminia et. al., 1987), which may explain the presence of the resident 
phagocytic microglia. Withdrawal of the surveillance cells from the CNS is believed 
to occur via the subarachnoid space, which serves some nerve routes and drains into 
the peripheral lymph system (Wekerle et. al., 1986; Cserr & Knopf, 1992).
Major histocompatibility molecule class I expression is ubiquitous within the 
nervous system, but the expression of la is controversial. The endothelial cells of the 
BBB are beleived capable of Ia+ presentation, but reports have varied and positive 
results have been attributed to the close perivascular proximity of Ia+ locally resident 
monocytes (Sobel et. al., 1987; Fabry et. al., 1990; Lassmann et. al., 1986). Strong 
evidence of Ia+ cerebroendothelia was published by Wilcox et. al. (1989) who 
demonstrated constitutive la expression at the BBB of normal guinea-pigs with 
additional major histocompatibility epitope recruitment during CNS inflammation.
The cerebroendothelial barrier is therefore intimately involved in immune cell 
recruitment. Interactions between the CNS and the immune system are frequent but
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the immune reponse is modified thereby limiting the damage caused to the vulnerable 
neural tissue which has only a low regenerative capacity.
The BBB has been shown to play a crucial role in the maintenance of neural 
homeostasis and possesses a range of unique physical properties, transport systems 
and enzymic controls facilitating this function. The cerebral environment is reliant on 
the continuing strict regulation of the barrrier and can be markedly affected if the 
neurovasculature dysfunctions.
1.2 Abnormal BBB Function
1.2.1 BBB in Disease
Any medical condition which induces a breakdown of normal BBB function, 
whether related to physiological imbalance or disease, can lead to a range of highly 
detrimental neurological deficits. Symptoms may include impaired vision, muscle 
tremor, decreased mobility, headache, muscle stiffness and confusion. Examination of 
the CSF of a patient exhibiting signs of neurological impairment will generally show 
an elevated total protein concentration and in many infections a significant leukocyte 
count.
A pathological increase in CSF protein content can indicate:
1. dysfunction at the level of the BBB;
2. an increase in the plasma concentration of a specific protein such as transferrin;
3. a decreased CSF flow due to a spinal obstruction or blockage of the 
arachnoidal villi which allow CSF drainage into the venous blood supply;
4. an increase in the local synthesis of proteins within the CSF by either brain cells 
or invading inflammatory cells, such as local immunoglobulin (IgA) production 
during Tuberculosis meningitis (Reiber, 1986).
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A general dysfunction in the regulatory capabilities of the BBB can be demonstrated 
by i.v. administration of radiolabelled albumin (Cutler et. al., 1967; Leibowitz & 
Kennedy, 1972). Albumin acts as a good permeability marker as it is synthesised 
exclusively outside the CNS. Therefore, any labelled compound detected within the 
brain extravascular space or CSF would indicate an abnormal barrier function (Cutler 
et. a'l., 1967). Unrestricted BBB dysfunction may be caused by increased pinocytotic 
activity, separation of endothelial tight junctional complexes and inflammatory cell 
entry into the CNS, which were shown to occur during the course of experimental 
bacterial meningitis (Quagliarello et. al., 1986). The resultant bulk flow of plasma 
constituents across the capillary wall leads to the extravascular accumulation of 
vasogenic edema common to many neurological conditions including metastatic brain 
tumors, purulent meningitis and head injury (Beggs & Waggener, 1976; Grieg, 1988; 
Tunkel & Scheld, 1993). In addition, entry of primed leukocytes may result either in 
the formation of cellular perivascular cuffs and lesions characteristic of multiple 
sclerosis (MS) or in the purulent CSF typical of bacterial meningitis (Adams, 1976; 
Tunkel & Scheld, 1993).
BBB dysfunction need not cause an imbalance in the extracellular 
concentration of all plasma constituents but may be limited to specific transporter 
irregularities. In Alzheimer's disease a decrease in the cerebral metabolic rate for 
glucose occurs coincidentally with a marked reduction in the glucose transporter 
density (Harik, 1992). Lowered CSF glucose concentrations are also noted for 
meningitis, haemorrhage, cancer and spreading depression (Feldman, 1989). Other 
pathological cerebroendothelial cell aberrations include altered NAA transport during 
hepatic encephalopathy (James & Fischer, 1981), irregular expression of alkaline 
phosphatase on the abluminal as well as the luminal endothelial membrane during 
head injury (Pardridge, 1991) and stroke-related dysfunction of the choline carrier- 
mediated transport system (Kang et. al., 1990).
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1.2.2 Non-disease BBB Dysfunction
Experimental models of abnormal BBB function include focal cold injury, 
hyperosmotic barrier opening, heat stress, head trauma and acute hypertension (Trout 
et. a l , 1986; Koenig et. a l , 1989a; Sharma et. a l , 1992; Shuka et. a l , 1993; Shapira 
et. a l , 1993). While the stimuli are different, studies indicate that there are a number 
of shared features which may prove indicative of BBB dysfunction generally. On a 
broad scale increased water influx and plasma protein extravasation are typical of all 
models, although not all demonstrate increased pinocytotic activity (Petito & Levy, 
1980; Trout et. al, 1986). Biochemically, abnormal production of polyamines (PA) 
by ornithine decarboxylase (ODC) within the endothelial cells in both osmotically and 
cryogenically injured brain has been causally linked to barrier dysfunction (Koenig et. 
al, 1989a,b). Furthermore, during cold-induced barrier perturbation the activity of 
Na+-K+-ATPase is impaired, as shown by reduced enzyme affinities for Na+ and K+ 
(Averet et. al, 1984). As Na+-K+-ATPase is important in the maintenance of cell 
osmotic pressure, diminished function suggests a causal role in intracellular water 
uptake.
Neurovascular function during disease and under experimental conditions can 
be severely impaired. While the initial stimuli and resultant pathologies may vary, the 
observations available indicate that many conditions could have dysfunctional 
mechanisms in common, which would provide important sites for potential 
pharmacological correction.
1.3 Multiple Sclerosis
A neurological disease in which loss of BBB integrity is of paramount 
importance is MS (Grossman et. al, 1988; Koopmans et. al., 1989; Poser, 1992). 
While uncertainty stills exists regarding the epidemiology and mechanism of disease
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onset, it is clear that an improved understanding of the pivotal stages of pathogenesis 
which culminate in expression of neurological deficits may improve therapeutic 
options.
1.3.1 Prevalence and Epidemiology
MS is typically an unpredictable chronic disease characterised by acute 
exacerbations and spontaneous remissions although acute, progressive, benign and 
subclinical forms may also occur (McDonald & Halliday, 1977). The nature of the 
condition is still contested between infection, autoimmunity or a combination of the 
two. However, neither the presence of an infective agent nor the conclusive 
identification of a trigger antigen have been elucidated to date (McFarlin & 
McFarland, 1982a; Rodriguez, 1989). MS is predominantly a neurological condition 
of young adults reaching a peak onset during the thirties and with a bias towards the 
female population. High risk' areas for MS prevalence include Britain and the rest of 
northern Europe with 100/100 000 individuals affected, while areas of'low risk' 
include Africa and Asia, where 5/100 000 present with the condition. The 'risk' factor 
may be linked to the environment or a common agent within the environment as 
migration studies have indicated that peoples moving between high and low risk areas 
carry with them the exposure risk gained before the age of 15, which also implies that 
puberty plays an important part in disease acquirement (Acheson, 1977). Exposure to 
a viral infection is popularly believed to represent the 'risk' although what virus or 
group of viral agents are involved and whether their involvement is destructive or 
protective has not been proven. MS prevalence appears to be high in Caucasian 
groups and those populations which have been historically associated with European 
invasion or colonisation (Poser, 1992). In conjunction with information showing MS 
to be rare in black Africans and the Japanese, a genetically derived susceptibility to 
the condition would appear to be indicated. Indeed, familial studies have indicated an 
increased risk for close family members particularly for twins, although being a
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monozygotic sibling of an MS patient is not conclusive proof of the disease occurring 
(Ebers & Bulman, 1986). There is now good evidence that the histocompatibility 
antigens HLA-A3, B7, DR2 and DW2 occur at a significantly higher frequency in MS 
patients of European white decent than in controls. However this is not true of other 
ethnic groups suggesting that the HLA system is not alone in controlling the genetic 
transmission of MS susceptibility (Batchelor et. al., 1978).
1.3.2 Clinical Presentation
Clinically MS is highly variable, not only in its course of progression but also 
in the symptoms presented which vary from optical neuritis and ataxic gait to speech 
defects and spastic weakness. A patient's clinical status is defined by measurement of 
disability in line with the Kurtzke disability state scale, or other recognised grading 
system (Kurtzke, 1983). Diagnosis is difficult in the early stages as initial symptoms 
may be unremarkable and easily forgotten once remission occurs. Clinically definite 
disease is established after a minimum of two episodes that display differing 
symptoms which indicate the occurrence of lesions at two or more clinically separate 
sites within the CNS and with no other explanation of the observed abnormalities 
(McDonald & Halliday, 1977). Observation of neurological deficit is backed up by 
CSF analysis which generally demonstrates a mild increase in protein and lymphocyte 
levels plus a raised immunoglobulin concentration (Tourtellotte et. al., 1984; McLean 
et. al, 1993). Also magnetic resonance imaging (MRI) may now be used as a 
confirmatory tool to scan the CNS highlighting areas of abnormal composition which 
relate to lesion development (Papadopoulos et. al, 1987; Grossman et. al, 1988; 
Koopmans et. al., 1989; Muller al., 1989).
1.3.3 Cellular Pathology
Ultimate confirmation of the condition can be gained at post-mortem when the 
CNS pathology of this demyelinating condition can be scrutinised. The disease
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exclusively affects the white matter with a predilection for the periventricular, 
brainstem, spinal cord and optic nerve tissues. Early lesions develop around small 
blood vessels forming perivascular cuffs of inflammatory lymphocytes and 
macrophages surrounded by a vasogenic edema exudate. Myelin degradation is not 
associated with the initial perivascular pathology, but within the larger expanding 
lesions active demyelination of neuron sheaths is apparent. Myelin breakdown 
products appear in the surrounding parenchyma and within the cytoplasm of the CNS 
microglia and invading macrophages, which are implicated in the demyelination 
process. Axonal damage is minimal the majority remaining intact, however their 
conductive efficiency is dramatically impaired once myelin is lost. As the lesions 
coalesce they create large demyelinated areas termed plaques. Active plaques 
continue to spread through myelin degradation at their periphery while the tissue in 
the centre is characterised by a reduced or absent oligodendrocyte population and an 
intense astrocytic proliferation creating gliotic scarring (Figure 3). Some lesions may 
be observed to have undergone a degree of remyelination, but it is often incomplete 
and distinguished by abnormally short intemodes. Greater detail of the CNS cellular 
pathology of MS may be found in the comprehensive reviews of (Prineas & Wright, 
1978; McFarlin & McFarland, 1982b; McAlpines Multiple Sclerosis, 1985; Raine & 
Scheinberg, 1988; Adams, 1977; Cuzner et. al., 1988).
The pathology exhibited at post-mortem can only extend our knowledge of the 
progression of this human disease. To study the development of disease, the 
underlying dysfunctional mechanisms and to research potential therapeutic strategies 
an experimental alternative is required. The model most frequently used for this 
purpose is experimental allergic encephalomyelitis (EAE) (Paterson, 1978; Raine, 
1984).
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F igure  3: Schematic Representation of MS Plaque Pathology
Neurovascular dysfunction and perivascular inflammation characterise the expanding 
margins of MS plaques. Ongoing demyelination is also associated with peripheral areas. 






























Macrophages and resident 
microglia associated with 
areas of myelin destruction 







1.4 Experimental Allergic Encephalomyelitis
The model EAE is principally a T cell-mediated autoimmune disease affecting 
the CNS. The condition shares many similarities with MS, summarised in Table 1.
1.4.1 Model Development and Induction
The development of EAE arose from the studies instigated following reports 
of paralytic accidents associated with the Pasteur rabies vaccine termed 'postrabies 
immunisation encephalomyelitis' in the late nineteenth century. The disorder was 
thought to arise from contamination of the vaccine with remnants of the neurological 
tissue in which it was cultured. In the 1930's Rivers produced an acute disseminating 
encephalomyelitis in monkeys following repeated injections of normal rabbit CNS 
tissue and this represented the first work on EAE. Development of adjuvants in the 
1940's allowed the evolution of faster developing, highly reproducible models of EAE 
following a single inoculation (Freund et. al., 1947).
EAE can now be induced in a variety of species by modifying the combination 
of neurological encephalitogen and adjuvant in the emulsion. Immune cell activation 
occurs at the lymph nodes draining the subcutaneous injection sites and results in a 
range of clinical courses and tissue pathologies each dependant on the inoculum 
content and species susceptibility (Shaw & Alvord, 1984; Villas et. al., 1991).
Genetic susceptibility appears to be a prerequisite for successful manifestation of 
EAE, with both major histocompatibility complex and non-major histocompatibility 
complex-linked genes being implicated (Steinman, 1992; Toumier-Lasserve & Bach,
1993). The main encephalitogenic component of EAE inoculum has been identified as 
myelin basic protein (MBP) which when purified and administered in combination 
with complete Freund's adjuvant can also elicit EAE. MBP has been extensively 
studied resulting in the identification of a number of encephalitogenic peptide 
sequences of varying potency for different species and strains (Einstein et. al., 1972;
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Chronic relapsing course + +
Lesion Pathology:
BBB breakdown + +
Edema formation + +
Predilection of lesions for white matter + +
Perivascular inflammatory infiltrates + +
CD4+ T-cells + +
Macrophages + +
Meningitis + +
CNS demyelination ± +
Axonal survival + ±
Immune Responses:
T-cell mediated disease + ?
Linkage to MHC class II + +
Antibodies to CNS antigens in CSF + +
IgG deposition at lesion site ± +
Circulating myelinotoxic antibodies + +
MHC, major histocompatability complex 
Sources, Paterson 1978, Raine 1984
35
BrostofF, 1977). Other myelin components such as proteolipid protein and myelin 
oligodendroglia protein could all function as target antigens and have some success in 
EAE induction although they have been studied less extensively (Kuchroo et. al., 
1992; Linington et. al., 1993).
1.4.2 Neurological Deficits and Pathology
Following sensitisation with an antigenic emulsion EAE neurologically 
manifests itself 10-14 days post-inoculation (PI). An overnight decrease in body 
weight is followed progressively over subsequent days by tail droop, weakness of the 
hindlimbs leading to paralysis and incontinence (Simmons et. al., 1984). Some 
methods of EAE induction typically result in death, but in the acute monophasic 
Lewis rat model recovery ensues producing clinically well, weight gaining animals by 
day 20 PI. Recently chronic relapsing forms of the model have been developed in the 
guinea pig strain-13 and the Biozzi mouse, which mimic more closely the clinical 
course of MS (Raine & Stone, 1977; Baker et. al., 1990).
Evidence that EAE is a CD4+ T cell mediated disease comes from adoptive 
transfer experiments where stimulated lymph node cells from sensitised animals 
injected into naive histocompatible recipients elicit a typical acute disease and 
pathology (Paterson, 1960; Stone, 1961; Pettinelli & McFarlin, 1981). Further 
confirmation has come from encephalitogenic T cell line and monoclonal antibody 
studies (Ben-Nun et. al., 1981; BrostofF & Mason, 1984). The transfer of serum from 
sensitised animals into the circulation of uninoculated recipients does not effect the 
CNS, indicating that humoral factors do not initiate disease. Only by circumventing 
the blood-brain barrier can demyelination and mild EAE lesions be induced, although 
without neurological sign development (Jankowic et. al., 1965; Lassman et. al.,
1981).
In common with the human counterpart, EAE displays perivenular foci of 
mononuclear cell inflammation within the white matter, with a predilection for the
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spinal cord, brainstem and the ventricular area. The invading lymphocytes, 
macrophages and plasma cells are accompanied by a vasogenic plasma exudate and 
fibrin deposition (Levine et. al., 1966; Lassman et. al., 1986; Sobel et. al., 1988). 
There is limited perivascular myelin damage noted in some models including the 
appearance of macrophages within the lesion site containing myelin debris, although 
this is a rare event in the acute monophasic condition. The chronic relapsing models 
display greater myelin degradation, which may be the result of a longer experimental 
time course. Lesions from these models display demyelination, remyelination, 
oligodendrocyte loss and glial scarring however the plaque development seen in MS is 
not duplicated (Raine, 1983; Ohkawa, 1989). Reactive gliosis may occur 
independently of any myelin damage such as is seen in the early pathology of the 
spinal cord in the Lewis rat acute model (Smith & Eng, 1988).
1.5 BBB Breakdown During MS and EAE
A pivotal step in the development of pathological and neurological signs in 
both MS and EAE is the focal disruption of the BBB prior to lesion development.
1.5.1 BBB Pathology in MS
The characteristic loss of barrier function in MS was initially observed using 
trypan blue. The dye was extravasated into CNS lesions corresponding histologically 
to the white matter plaques of the MS brains analysed after death (Broman, 1964). 
Recent advances in brain scanning have led to the development of MRI which has 
allowed visualisation of MS lesion patterns. Further information may be gained by 
enhancing the image using an intravenous injection of gadolinium-dietheylene- 
triamine pentaacetic acid (Gd-DTPA). Gd-DTPA is a paramagnetic contrast agent 
which has the ability to cross the damaged BBB highlighting areas of vasogenic
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edema entry and inflammation as confirmed by parallel ultrastructural examination of 
tissues (McDonald & Barnes, 1989). Enhancement of the image locates active sites, 
marking new lesion development or older plaque enlargement (Bastianello et. al.,
1988). Gd-DTPA enhancement is noticeably greater in clinically active patients and 
while there can be good correlation between presented signs and enhancing lesion 
geography, Gd-enhancement often highlights clinically silent lesions, even during 
remission (Grossman et. al., 1988). BBB breakdown, as demonstrated by Gd-DTPA 
MRI, is a consistent early event and can be detected up to two weeks before 
conventional MRI abnormalities or clinical deficits are reported (McDonald & Barnes,
1989).
Neurological deficits appear to be linked to BBB breakdown and the 
subsequent inflammatory events. Indeed, cellular degradation of axonal myelin cannot 
alone account for the clinical course of MS as remyelination is unable to occur fast 
enough to explain the onset of remission (Grossman et. al., 1987; Levine et. al.,
1966). Vasogenic exudation of plasma constituents into the CNS may independently 
create a variety of clinical and pathological effects. An increase in intercellular tissue 
volume due to edema formation may (i) constrict nerve fibres, (ii) disrupt the layering 
of the myelin plus its proximity to the axon and (iii) alter the ionic environment at the 
nodes of Ranvier, all impairing the efficiency of neural conduction. Furthermore, in 
vitro studies using CNS cell cultures have demonstrated the existence of humoral 
neuroelectric blocking factors and myelinotoxic components in the plasma of MS 
patients, which would prove detrimental following extravasation (Bomstein & Crain, 
1965; Cerf & Carels, 1966; Raine et. al, 1973; Schauf et. al., 1978; Schauf et. al., 
1981; Wiley et. al, 1992).
1.5.2 BBB Pathology in EAE
The characteristic loss of barrier function, as for MS, was initially described 
using trypan blue which was extravasated into CNS areas corresponding histologically
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to inflammatory areas in EAE (Barlow, 1956). Radioactive tracer studies of BBB 
opening in EAE have demonstrated that increased neurovascular permeability to 
plasma protein occurs at the onset of neurological deficits (Rumjanek et. al., 1984a; 
Leibowitz & Kennedy, 1972), although some investigators have suggested that 
leakage occurs just prior to development of the disease (Butter et. a l , 1991; Juhler et. 
al., 1984). Indeed, tracer studies employing markers of small molecular weight such 
as 14C-mannitol indicate that barrier properties are abnormal as early as day 7 PI 
(Lam, 1986). The pattern of inflammatory cell extravasation appears not to coincide 
directly with plasma solute entry. The main leukocyte influx is generally reported as 
occurring slightly later than initial BBB opening (Rumjanek et. al., 1984a; Juhler et. 
al, 1984). However, a number of histology reports document cellular entry into the 
CNS as early as day 5 PI (Traugott et. al., 1982, 1985, 1996). A separation in time 
between BBB breakdown to solutes and the recruitment of inflammatory cells into the 
CNS parenchyma would therefore appear to be indicated for EAE.
Gd-DTPA enhancement of inflammatory lesions during EAE have 
demonstrated a linear relationship between lesion number and relapse and a direct link 
between the duration of enhancement and the duration of relapse (Hawkins et. al., 
1991). The connection between BBB dysfunction and the onset on neurological 
deficits is supported by observations from other experimental models. Tunicamycin- 
poisoned rats develop neurological signs typical of those seen in acute EAE. Using 
this model, Kerlero de Rosbo et. al. (1987) demonstrated elevated levels of albumin 
and IgG within the CNS of animals which occurred coincident with the onset of 
deficits, but no evidence of demyelination was observed. Furthermore, in an animal 
model of demyelination induced by cuprizone, no inflammation or increase in BBB 
permeability was found, demonstrating that cerebrovasculature disruption is not 
caused by demyelinating events (Bakker & Ludwin, 1987). Therefore while clinical 




Histological examination of CNS tissue from EAE animals has revealed an 
increase in the number of pinocytotic vesicles evident in endothelial cells within active 
lesion sites (Claudio et. a l , 1989; Hawkins et. al., 1992). Hawkins (1992) 
demonstrated that the raised vesicle production was energy-dependent as it could be 
suppressed by prior perfusion with the metabolic inhibitor 2,4-dinitrophenol. 
Additional support for a change in the metabolism of the endothelia was reported by 
Kato (1989) who showed that the Na+-K+-ATPase activity, which is normally 
confined to the abluminal membrane, was distributed both luminally and abluminally 
during the acute stage of chronic-relapsing EAE. Furthermore, during the inactive 
stage of this model no ATPase activity was apparent on either membrane indicating a 
different but continuing BBB impairment. Indeed, metabolic abnormalities may be 
further indicated by the decrease in the mitochondrial content of cerebrovascular 
endothelial cells, which at the height of disease are reduced to a level associated with 
non-neurovascular endothelia (Oldendorf et. al., 1977; Claudio et. al., 1989). Biopsy 
analysis of MS patient brains supports the observation of elevated vesicular activity in 
the neuroendothelia, but a corresponding decrease in mitochondrial number has not 
been validated (Brown, 1978).
Hawkins et. al. (1992) saw no evidence of tight junctional opening during 
their tracer studies, and following metabolic inhibition of the vesicular transport of 
lanthanide no deposition of tracer was discernible in the perivascular space. However, 
size-dependent extravasation of radioactive markers led Lam et. al. (1986) to suggest 
that if the barrier dysfunction was led by vesicular transport then the tracers should be 
deposited extravascularly at a similar rate. Therefore, a size-related disruption of the 
tight junctional complexes was implicated. Furthermore, impairment of BBB 
membrane integrity may have been indicated by the increased permeability induced in 
the tunicamycin-poisoning study of Kelero de Rosbo et. al. (1987) as the biological
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activity of this molecule is connected with impaired synthesis of structural 
glycoproteins.
1.5.4 Mechanisms o f BBB Perturbation
The biological trigger for these endothelial abnormalities is unknown. 
However, endogenous steroid levels are strongly linked with normal BBB control. 
Studies in normal rats and mice have demonstrated that administration of the synthetic 
glucocorticoid, dexamethasone, can decrease BBB permeability to labelled sucrose 
and large vascular tracer molecules (Hedley-Whyte & Hsu, 1986; Ziylan et. al,
1988). Furthermore, adrenalectomy in normal rats induces an increased 
cerebrovascular extravasation of albumin which can be reversed by exogenous steroid 
administration (Long & Holaday, 1985). Interestingly, basal corticosterone levels 
appear to be an important element in strain-susceptibility to EAE (Mason et. al.,
1990). One aspect of steroid control is the modulation of prostaglandin and 
leukotriene synthesis (Weidenfeld et. al, 1987). These molecules have been 
demonstrated to be important in inflammation and elevated levels of the potential 
barrier perturbators have been shown EAE (Bolton et. al, 1984b; Prosiegel et. al, 
1989; Fretland et. al, 1991). The coagulation cascade, which the endothelial cell has 
the capability to modulate, may be involved in either BBB opening or the ensuing 
inflammatory response. Perivascular fibrin deposition in EAE is associated with 
neurovascular permeability and symptom onset, both of which may be reduced by 
inhibition of the plasminogen activator (Koh & Paterson, 1987).
Barrier permeability may also be affected by a variety of biological mediators 
released by activated immunological cells. Mast cells release histamine, a potent 
vasodilator, during early or mild inflammation. Histamine levels have been reported to 
be raised at around days 11-13 PI in EAE and have been shown to increase 
pinocytotic vesicle activity in neural endothelial cells (Dux & Joo, 1982; Orr & 
Stanley, 1989). Inflammatory lymphocytes and macrophages release a variety of
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cytokines including tumor necrosis factor (TNF)-a and interleukin (IL)-1, both of 
which are raised in the CNS of EAE animals and have been shown to possess 
permeability-inducing properties in vitro (Henning et. a l , 1987; Brett et. al., 1989; 
Baker et. al., 1991).
Evidence indicating which mechanisms are involved in the breakdown of 
normal neurovascular function is limited at this time. However, alteration of normal 
BBB permeability is clearly an obligatory step in the appearance of clinical signs and 
the development of lesions in MS and its animal counterpart EAE. Therefore, 
correction of pathological barrier disruption could both improve clinical presentation 
and limit lesion development.
1.6 Treatment of MS
Therapeutic goals in the treatment of MS vary according to disease 
development. In relapsing-remitting MS the aims of therapy are: (1) to improve the 
patients rate of recovery from relapse; (2) to decrease the incidence of future relapses; 
(3) to reduce the accumulation of additional disabilities; and (4) to prevent the 
development of a chronic progressive course of disease. In patients who already 
display chronic progressive MS the primary objective is to halt the deleterious 
progression of the condition.
Current treatment of MS patients both to reduce the severity of clinical 
episodes and to limit long-term deterioration is far from satisfactory. The natural 
history of the disease is highly unpredictable due to the relapsing-remitting sequence 
of events and the additional possibility of chronicity or stabilisation developing at any 
time. Therefore, MS is one of the most difficult diseases in which to effectively judge 
the response to therapy (Kappos, 1988). An increase in the last decade of well- 
controlled and designed drug trials has provided greater definitive proof of the
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efficacy of individual pharmacological agents in this condition (Goodin, 1991; Ebers, 
1994). Furthermore, the extension of drug trials to include an MRI appraisal of 
pharmacological control of inflammatory lesion pathology will prove beneficial 
(Grossman et. al., 1988; Willoughby et. al., 1989; Kermode et. al, 1990; Ebers, 
1994).
Therapy of the human demyelinating condition has for many years been based 
upon the anti-inflammatory and immunosuppressive effects of steroids and the global 
immunosuppressive actions of drugs such as azathioprine. Recently, alternative 
strategies have been examined including immunomodulation with compounds such as 
cyclosporin A and a variety of cytokines plus targeting of T cell subsets with 
monoclonal antibodies and induction of peptide tolerance (Dijkstra, 1993; Ebers,
1994). While many therapeutic regimes have been applied to the treatment of MS 
only the major forms of treatment and emerging therapies will be considered in the 
following sections.
1.6.1 Current Drug Treatments
Adrenocorticotrophic hormone (ACTH) and adrenal corticosteroids are 
general anti-inflammatory agents as well as having immunosuppressive properties. 
Intramuscular ACTH and oral corticosteroid therapies have been favoured in MS for 
many years, with moderate doses generally being shown to increase the rate of 
recovery from relapse (Rose et. al, 1970; Troiano et. al, 1987; Milanese et. al,
1989). However, the long-term prognosis for MS does not appear to be favourably 
altered by steroidal intervention. Hoogstraten & Minderhound (1990) concluded that 
the initial benefit gained from 100 units ACTH tapered over 12 weeks was not 
evident at six months and that a higher relapse rate may even have been indicated. 
Recently, high dose intravenous methylprednisolone treatment of acute clinical 
episodes has found popularity. Typically, doses of 500-1500mg methylprednisolone 
per day are given over 3-7 days with a tapering dose of oral prednisone from 60-0mg
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over 10 days (Dowling et. al., 1980; Milligan et. al., 1987; Lyons et. al., 1988). 
Barnes et. al. (1985) report a more rapid improvement with this regime than that 
achieved with ACTH but finds no long-term benefit, while Milligan and workers 
(1987) found favourable clinical effects for both relapsing and chronic progressive 
patients.
Corticosteroid action is not limited to modulation of pathological events and 
suppression of the immune system. Steroids are biologically active throughout the 
body participating in the regulation of many normal processes. Therefore, chronic 
treatment with either ACTH or glucocorticoids may be associated with a variety of 
unwanted side-effects. Although high-dose intravenous methylprednisolone is 
reportedly free from serious adverse affects and generally produces fewer unwanted 
sequelae than ACTH, uncomfortable reactions are routinely experienced (Compston, 
1988; Miller et. al., 1992).
The active recruitment of non-specific inflammatory T cells and macrophages 
into the CNS of MS patients has led to many immunosuppressive or 
immunomodulatory drug trials. Azathioprine, which modifies nucleic acid or protein 
metabolism of cells, has the longest history of use in MS, but like many drugs has not 
always been studied in the context of well controlled and blinded trials. A controlled 
study by Ellison (1989) followed chronic progressive patients treated with 
azathioprine for three years. The resultant relapse rate was concluded to have been 
halved, but the adverse side-effects, which were increased by combined therapy with 
steroids, were found to out-weigh any beneficial results.
Cyclophosphamide, an alkylating agent which interferes with nucleic acid 
metabolism, is toxic to lymphocytes when used at a high concentration. The drug has 
shown variable success in the treatment of chronic progressive patients but the threat 
of long-term toxic effects has precluded its general use (Mauch et. al, 1989; Likosky 
et. al., 1991). Similarly, cyclosporin A (CSA), which down-regulates DL-2 production 
by T cells, showed moderate clinical improvement in trials when administered at 7-
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7.5mg/Kg body weight. However, the high incidence of hypertension, renal 
insufficiency and anaemia associated with the treatment prevented the proposal of 
further trials at higher doses (Rudge et. al., 1989; Ruutiainen et. al., 1991).
1.6.2 Emerging Drug Treatments
Monoclonal antibodies can target individual proteins which may mediate 
disease or be intimately involved in unwanted immunological responses including 
specific T cell surface receptors such as CD3, CD4, and CD25. Trials with anti-CD3 
antibodies were found to successfully deplete the appropriate T cell subsets in MS 
patients, but unacceptable side-effects including fever and hypertension, were also 
encountered (Weiner & Paty, 1989). The human immune response to the non-self 
murine monoclonal antibodies was believed to be the major cause of trial failure and 
less antigenic chimeric antibodies are currently being developed for use in future 
therapeutic trials.
Manipulation of the endogenous cytokine levels during disease is an area 
currently under investigation. Interferons (IFN), produced naturally by the body, 
possess immune-regulatory properties yet deficient levels are found in the circulation 
of the majority of MS patients. IFN-a and y proved ineffective or detrimental in tests 
while initial clinical trials of IFN-P were contradictory in their findings and used 
statistically limiting numbers of patients (Jacobs et. al., 1986; Baumhefher et. al., 
1987; Huber et. al., 1988; Milanese et. al, 1990). A large well-controlled multicentre 
study of IFN-P therapy recently reported a successful reduction in exacerbation rates 
in relapsing-remitting patients (IFNB MS Study Group, 1993). Similar success has 
not been indicated for chronic-progressive patients and the long-term effects of IFN-P 
have yet to be identified.
Finally, Copolymer-1, a synthetic peptide originally designed as an MBP 
analogue, was found to suppress the development of autoimmune disease and is now 
a leading compound in the development of peptide tolerance agents for use in MS. A
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double-blind pilot trial of the peptide in early relapsing-remitting patients found a 
favourable reduction in the number of relapses (Bomstein et. al., 1987).
1.6.3 Correction o f BBB Dysfunction in MS
Clinical deficits in MS are clearly linked to abnormal BBB function, therefore 
control of cellular infiltration and vasogenic edema would appear an obvious 
therapeutic strategy (Grossman et. al., 1988; Hawkins et. al., 1990; Hawkins et. al., 
1991). However, few drug studies other than those employing high dose steroids have 
analysed pharmacological efficacy at the level of the neurovasculature.
Evidence of glucocorticoid action at the BBB in MS comes from serial Gd- 
enhanced MRI images of MS patients. MRI analysis during and after high-dose 
steroid therapy has shown a reduction in enhancing image size following treatment, 
indicative of decreased barrier dysfunction, which correlated well with clinical 
improvement (Barkhof et. al., 1991; Burnham et. al., 1991). Conversely, no reported 
improvements were seen by Kesselring et. al. (1989) in enhanced MRI scans at 15 
days post-treatment. However, a more recent MRI study by Miller et.al. (1992) 
demonstrated that rapid improvement of BBB abnormalities were seen with steroid 
therapy but were not maintained as brain lesions re-enhanced within days of ending 
treatment although clinical remission persisted. Therefore while steroid treatment in 
response to clinical exacerbations may be appropriate, a role beyond abatement of 
symptoms is not demonstrated.
The recent multicentre trial of IFN-p therapy reported concurrent MRI 
analysis alongside traditional evaluation of exacerbation rate (IFNB MS Study Group, 
1993; Paty et. al., 1993). The study demonstrated a significant reduction in active 
lesion presentation over the course of a year in the treated groups, indicating 
diminished inflammatory activity possibly as a result of improved cerebrovascular 
function (Paty et. al., 1993).
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1.6.4 Targeting the BBB in EAE
Investigation of pharmacological agents in EAE enable correction of abnormal 
barrier permeability to be quantitatively analysed using a range of radioactively 
labelled markers tailored to the needs of the study. Nevertheless, few drugs have been 
analysed with correction of aberrant cerebrovascular function in mind. An isolated 
study by Reiber and Suckling (1986) found disease suppression and normal BBB 
permeability to proteins following prophylactic administration of CSA in EAE- 
sensitised guinea-pigs. However, determination of the effects of therapeutically 
administered CSA was not made.
EAE provides a unique opportunity to study the ongoing aberrant mechanisms 
present in immune-mediated neurological disease and to employ pharmacological 
agents in identifying the underlying abnormalities. Such an approach has been used to 
understand the mechanisms which lead to BBB breakdown in studies on the 
catecholamines noradrenalin and adrenalin, which have been shown to influence the 
development of EAE (Wesselman, 1987; Mackenzie et. a l , 1989; Leonard et. al.,
1991). The specific involvement of the adrenergic receptor was indicated in studies 
by Brosnan et. al. (1985) who sucessfully employed the a! receptor antagonist 
prazosin in suppression of acute EAE. Goldmuntz et.al. (1986) extended the analysis 
of prazosin in EAE examining cerebrovascular extravasation of radiolabelled albumin. 
BBB function was significantly improved and cellular infiltration into CNS tissue was 
delayed following antagonism of the a! - adrenergic receptor.
Non-immune models of neurovascular disruption have highlighted enzyme 
cascades and receptors potentially involved in barrier breakdown (Koenig et. al.,
1992; Ohnishi et. al., 1992; Sharma et. al., 1992). Examination of the suggested 
causes of BBB abnormalities, which include polyamine synthesis, arachidonic acid 
metabolism, Hj-histamine receptor stimulation and NMDA-receptor activity, may 
lead to a new understanding of the development and suppression of EAE. Antagonists 
of enzyme and receptor activity such as ifenprodil, MK801 (NMDA-receptor
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antagonists), a-difluoromethylornithine (inhibits polyamine synthesis), BW755C 
(lipooxygenase inhibitor) and cimetidine (Et^receptor antagonist), could therefore be 
employed as pharmacological tools to uncover abberrant mechanisms in 
neuroantigen-induced BBB breakdown.
Clearly there remains no satisfactory therapy for MS patients. Existing 
treatments carry unacceptable side-effects and / or demonstrate beneficial outcomes in 
only a small percentage of the treated MS patients. In general, the actions of therapies 
may be too broad-based, although recent developments in treatment are showing 
increasing specificity. Section 1.5 highlighted the primary importance of BBB 
breakdown in both MS and the experimental condition EAE and considered the close 
association between neurovascular dysfunction and the expression of neurological 
deficits. Analysis of therapeutic agents and design of new pharmacological strategies 
has however largely ignored this aspect of neurological disease
1.7 Aims of the Project
(i) Identification and development of a technique with sufficient sensitivity to 
quantitate BBB dysfunction during EAE and to detect beneficial improvements 
following drug administration.
(ii) Characterisation of glucocorticoid control of neurovascular function 
during EAE.
(iii) Assessment of the neurovascular regulatory capabilities of drugs shown to 
limit the severity and duration of neurological signs in EAE.
(iv) Investigation of abnormal mechanisms underlying the development and 






Inbred male Lewis rats, weighing 200-250g, were selected from either stock 
bred on site or animals purchased from Bantin and Kingman Ltd. Wistar rats were 
bred on site and used at approximately 300g body weight. Experimental rats were 
housed 4-6 per cage on wood flakes [Cardiff Sawdust Co.], with food [SDS, diet 
C.R.M.] and water available ad libitum.
Spinal cord neuroantigen for EAE-inoculation was obtained from both male 
and female Dunkin-Hartley guinea-pigs of body weight >600g, either bred on site or 
by Bantin and Kingman Ltd.
2.2 Inoculation for EAE
The acute Lewis rat model of EAE was induced using whole guinea-pig spinal 
cord as the source of neuroantigenic material. The spinal tissue of Dunkin-Hartley 
guinea-pigs killed by C02 asphyxiation was exposed and removed from the vertebral 
canal without meningeal or peripheral nerve attachments. The tissue was washed in 
phosphate buffered saline (PBS) [Sigma] and blotted prior to storage at -20°C.
Encephalitogenic inoculum was freshly prepared on the day of sensitisation. 
The spinal tissue was finely cut and homogenised in sterile PBS (lml/lg tissue) using 
a 1ml syringe. Incomplete Freund's adjuvant [Difco Laboratories] was introduced at 
lml/g whole tissue and supplemented with Mycobacterium tuberculosis H37Ra [Difco 
Laboratories] at a concentration of 20mg/ml adjuvant. The mixture was vigorously 
shaken prior to repeated aspiration between two connected syringes. Finally, the 
cohesive properties of the inoculum were tested on cold water. Using a 19 gauge 
x 1.5" needle, 1ml syringes were filled with 0.45ml inoculum and fitted with a 23 
gauge needle. Unsedated male Lewis rats received 0.1ml inoculum in each hindfoot 
pad.
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Control animals received 0.1ml per hindfoot pad of a complete Freund's 
adjuvant (CFA) emulsion. The CFA-inoculum was prepared as for EAE-inoculum but 
with lml PBS substituted for every lg guinea-pig spinal cord used. The cohesive 
properties of the final emulsion were again tested on water.
2.3 Clinical Assessment of EAE
Animal body weight was monitored daily throughout the course of study 
beginning on the day of inoculation - day 0 PI (DOP.I.). Weight loss in the acute 
phase of EAE was expressed as the percentage change in body weight between peak 
weight prior to disease onset and weight on the day of sampling.
Neurological signs were scored daily subsequent to observed weight loss, as 
follows: 0.5 = loss of tone at the tip of the tail: 1 = flaccid tail (FT); 2 = ataxic gait 
and hindlimb hypotonia (HLW); 2.5 = severe hindlimb weakness, unable to support 
own body weight; 3 = partial paralysis of hindlimbs (HLPP); 4 = complete hindlimb 
paralysis with associated urinary and faecal impaction incontinence(CHLP). 
Symptoms observed for a treatment group on the day of sampling were expressed as 
a mean neurological score (MNS).
Generally EAE-inoculated animals demonstrated weight loss approximately 
D10-11PI and displayed clinical signs for approximately 6 days thereafter, this was 
termed the 'Acute' phase. At D20 ± 2 PI previously affected animals, now free of 
neurological deficits, had resumed weight gain and were said to be in Early 
Recovery'. A Eate Recovery' time point was selected for study at D35PI.
CFA-inoculated control animals showed no neurological deficits and 
continued to gain weight throughout the study periods. However, adjuvant arthritis 
became apparent in rats when the length of investigation was extended to study 
timepoints PI equivalent to the Recovery' phases in EAE-sensitised animals.
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2.4 Iodination of Rat Serum Albumin (RSA) With 125Iodine (125I)
Iodination of RSA [Sigma] with 125I was undertaken using the McConahey & 
Dixon modification of the chloramine-T method originally described by Greenwood, 
Hunter & Glover (1963).
An equal volume of lOOmM HC1 was added to lmCi 125I [NEN: diluted in 
10-5MNaOH] followed by lOmg RSA dissolved in 200pl sterile PBS. Initiation of the 
radioiodination was achieved by addition of freshly prepared chloramine-T [Fisons, 
SLR grade: lOmg/ml sterile PBS] at a ratio of lOpg/mg RSA. Following mixing, the 
radioiodination was left to proceed for lOmin after which the reaction was terminated 
by addition of 20pl of freshly prepared sodium metabisulphite [BDH] / potassium 
iodide solution [Fisons, SLR grade][125mg/250mg in 10ml sterile PBS].
The unreacted radioiodine was removed by exclusion chromatography on a 
PD-10 column [Pharmacia] containing Sephadex G25. Separation by this method is 
size-dependent whereby large molecules, such as albumin, are excluded from the 
matrix pores and move rapidly through the interstitial spaces unlike smaller molecules 
which move at a slower pace passing within the pore spaces. The eluent was collected 
in 1ml fractions and 5 pi aliquots screened on an LKB gammamaster. Those fractions 
demonstrated to contain the iodinated albumin peak were pooled and stored at 4°C.
Activity of the iodinated product was determined by analysing dilutions of the 
stock in duplicate on an LKB Gammamaster [efficiency 70%] and processing the 
results using equation 0 .
(cpm x dilution factor) x 100 , . ,------------------------------------  = dpm/ml 0
70
Where: cpm = counts per minute;
dpm = disintegrations per minute;
2.23xl06 dpm = lpCi.
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Purity of the radiolabelled RSA was determined by addition of 20pl 20% 
trichloroacetic acid to an equal volume of the 125I-RSA stock. After 15min at room 
temperature the precipitated protein was removed by centrifugation at 10 OOOg and 
the activity remaining in the supernatant measured [LKB Gammamaster]. Typically, 
contamination of the iodinated product with unbound iodine did not exceed 7%.
2.5 Blood Volume Markers
2.5.1 U3mIndium (113mIn) and mIndium (ulIn) Labelling o f Transferrin
The eluate from a sterile 113mIn generator [Amersham] or an aliquot of ln In- 
chloride [NEN] was added to rat plasma and gently mixed to bind the isotope to 
transferrin (Adatepe et. ah, 1969; Hosain et. al., 1969). The final activity of 113mIn 
and m In radiolabelled plasma was 200pCi/ml and 20p.Ci/ml respectively. Both were 
administered i.v. in the tail vein using a 25 gauge needle, at a volume of 0.5ml per 
animal.
The percentage of isotope bound to plasma protein was determined by 
addition of an equal volume of 20% trichloroacetic acid to an aliquot of radiolabelled 
plasma. After 15min at room temperature the precipitated protein was separated by 
centrifugation at 10 OOOg and the activity of supernatant and pellet fractions counted 
on an LKB minigamma counter.
2.5.2 inIn-tropolonate Labelling o f Red Blood Cells (RBC)
The method was developed from the studies of Osman and Danpure (1987). 
Blood from adult Wistar rats was collected by cardiac puncture in citrate-phosphate- 
dextrose [Sigma], and centrifuged at 300g for lOmins. The plasma / white blood cell 
layer was collected and respun at llOOg for 15mins to generate cell-free plasma. The 
RBC layer was resuspended in Hepes saline buffer [20mM Hepes, Gibco; 0.8% NaCl]
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and washed three times at 300g to remove leukocytes, resuspending at a final 
concentration of 5 x 108 cells/ml. An addition of lOOpl/ml m In-tropolonate [4 x 
10‘3M tropolone containing 20(iCi m In (NEN) per millilitre] for every 5 x 108RBC 
was made, followed by incubation of the mixture at 37°C for 20mins. The labelled 
cells were washed three times and resuspended at 5 x 109 cells / 0.5ml cell-free 
plasma for in vivo use. Analysis of 10pi from each post-labelling wash and final 
radiolabelled cell preparation was routinely performed to confirm that adequate 
labelling had taken place.
2.6 Quantitation of Blood-brain barrier (BBB) Permeability
A variety of methods were explored to find a reliable technique which 
quantitated a large window of difference between normal and disease BBB 
permeabilities suitable for analysis of potentially corrective pharmacological agents. 
Section 2.6.1 lists all techniques tested for the measurement of edematous water 
accumulation in the CNS. However, section 2.6.2 details only the final method 
developed for the quantitation of BBB permeability to albumin which was 
subsequently used to analyse pharmacological restoration of neurovascular function. 
During development of the technique (2.6.2) a variety of radiolabelled tracers and 
circulation times had been considered for the blood volume determination. While 
these variations in methodology are not documented in the materials and methods 
they are reported in full in Chapter 3.
2,6.1 Edema Measurement
Three methods were considered for the quantitation of edematous water 
extravasated into inflammatory areas of the CNS.
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2.6.1.1 Dual Label Determination of Water Extravasation
To compare water and albumin extravasation within the same animal lOjiCi 
tritiated water ^F^O), diluted in sterile PBS, was injected i.v. in the tail with a 25 
gauge needle under halothane [RMB Animal Health Ltd.]/02 anaesthetic, 20-24 hours 
after 125I-RSA administration. Following a 30min circulation period a cardiac blood 
sample was collected from the anaesthetised animal into a heparin-coated tube 
[Sterillin] and the rat killed with a lethal dose of euthatol [RMB Animal Health Ltd.]. 
Cerebellum (C), medulla-pons (MP) and cervical spinal cord (CSp) tissues plus blood 
samples were stored at -20°C until use. Samples were solubilised with 1ml Optisolve 
[LKB]/200mg wet tissue over 2-3 days with continuous shaking. After the addition of 
lOmls scintillant [Optiphase Safe, LKB] samples were analysed using a dual count 
parameter on an LKB Rackbeta 1219. Blood equivalent values were calculated as per 
equation ©.
cpm /g  Tissue y = B£
cpm /mlBlood
2.6.1.2 Ethanol Extraction o f 3H20
The method was based on that detailed by Simmons et. al. (1982). Rats 
received lOjaCi 3H20  diluted in sterile PBS (pH 7.2) i.v., which circulated for 
30mins. Under halothane/02 anaesthetic a blood sample was collected by cardiac 
puncture using a 21 gauge needle followed by administration of a lethal dose of 
euthatal. The whole blood was stored in heparin-coated tubes. Weighed C, MP, CSp, 
thoracic spinal cord (TSp) and lumbar spinal cord (LSp) tissues were placed in 4mls 
analytical grade ethanol and agitated overnight at room temperature. Analysis of 1ml 
aliquots of ethanol-extracts and 0.1ml aliquots of plasma samples was performed on 
an LKB Rackbeta 1215 following the addition of lOmls scintillant.
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Results were expressed as plasma equivalents (PE) (Equation 0 ):
‘H cpm/g tissue x 100= HPE <3>
lH cpm / ml plasma
2.6.1.3 Tissue Weight
Increased water content of the CNS parenchyma due to the influx of 
inflammatory edema may be quantitated by calculating the difference between wet and 
dry weights (Levine et. al. 1966,1977). Tissue sections C, MP, CSp, TSp and LSp 
were dissected, weighed and placed in an oven at 80°C. Once a constant weight was 
achieved a final dry weight was recorded and the % water content determined 
equation ©;
2.6.2 Albumin Extravasation
Permeability of the cerebral vasculature was determined by quantifying the 
extravasation of radiolabelled RSA into CNS tissue, using a variation of the double 
radioisotope technique first described by Leibowitz and Kennedy (1972). The method 
employed a second isotope to correct for the 125I-albumin circulating within the 
vasculature of tissues analysed. Animals were routinely sampled between 2-4pm to 
limit variation in results due to fluctuating endogenous glucocorticoid levels.
Rats received lOjiCi 125I-RSA diluted in sterile PBS i.v. in the tail, using a 25 
gauge needle, while under halothane/02 anaesthetic. A day later 5 x 109 m In-RBC 
were injected by the same route under halothane/02, the animals remaining 
anaesthetised thereafter. Following 4.5mins circulation of the second isotope, a 
cardiac blood sample was collected using a 21 gauge x 5/8" needle and held in a
% Water Content =
Wet weight (g) - Dry weight (g)




heparin-coated tube. A lethal injection of 0.1ml euthatal administered direct to the 
heart followed immediately. C, MP, and CSp tissues were dissected, washed in PBS, 
blotted and weighed. The amount of inIn radioactivity present in each tissue and in 
lOOpl blood aliquots was recorded on the open channel of an LKB minigamma 
counter [settings = 100-450kev]. Samples were stored at -20°C and recounted 3 
weeks later on the 125I channel [settings = 20-80kev] following m In decay. The 
individual isotope counts for each tissue were expressed in arbitrary units termed 
'blood equivalents (BE)'.
cpm /g  Tissue x j 00 _ Bg  ©
cpm /mlBlood
The extravascular blood equivalent (EVBE), a measure of the radiolabelled albumin 
which has crossed the BBB and accumulated within the CNS, was calculated by 
equation ©.
m i b e  — " 'In  BE = EVBE ©
2.7 Drug Preparation and Administration
2.7.1 Dcxamethasone (DEX)
Dexamethasone sodium phosphate [4mg/ml, DBL, UK] was diluted in sterile 
PBS and administered subcutaneously with a 25 gauge needle. Administered doses 
ranged from 0.01-lmg/kg body weight. DEX was injected twice daily for 2 days 
starting on the day of weight loss in the acute phase and following the loss of 
neurological signs and two consecutive days of weight gain during the early recovery 
phase. Animals were sampled on the day following the conclusion of treatment. 
Vehicle-control groups received equivalent volumes of sterile PBS.
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2.7.2 Cyclosporin A (CSA)
CSA [supplied by, Sandoz Laboratories, Switzerland] was dissolved at a 
concentration of 25mg/ml in olive oil at 60°C and administered orally with an oral 
dosing needle. Drug treatments ranged from 25-75mg/kg body weight and were 
administered once daily for 2 days starting on the day of weight loss in the acute 
phase and following the loss of neurological signs and two consecutive days of weight 
gain during the early recovery phase. Animals were sampled on the day following the 
conclusion of treatment.
Vehicle-control groups received equivalent volumes of olive oil alone.
2.7.3 FK506 (Tacrolimus)
FK506 [supplied by, Fujisawa Pharmaceutical Co. Ltd., Japan] was initially 
prepared according to previously published work in rats as a suspension in sterile PBS 
and administered orally using an oral dosing needle (Nalesnik et. al., 1987; 
Venkataramanan et. al., 1987; Inamura et. al., 1988). Following receipt of a 
recommended protocol from Fujisawa, subsequent preparations of FK506 were 
dissolved in ethanol at lOmg/ml and diluted to 1 mg/ml with sterile PBS 2% Tween 
80 for intraperitoneal (i.p.) administration with a 25 gauge needle. Two 
concentrations of drug were studied: the 5mg/kg body weight dose was prepared for 
oral dosing; and the lOmg/kg body weight dose was prepared for i.p. injection. 
Treatment with both preparations was once dally for 2 days beginning on the day of 
weight loss in the acute phase and following the loss of neurological signs and two 
consecutive days of weight gain during the early recovery phase. Animals were 
sampled on the day following the conclusion of treatment.
Vehicle-control groups received equivalent volumes of vehicle preparations
alone.
58
2.7.4 MK801 (Dizocilpine maleate)
MK801 [supplied by, Dr. L.L. Iversen, Merck, Sharp and Dohme Research 
Laboratories, Harlow, England] was dissolved for use in sterile PBS and injected i.p. 
at a concentration within the range 0.15-0.6mg/kg body weight. The prophylactic 
schedule required administration of MK801 once daily from D7-12PI with sampling 
of treatment groups on D12PI. During the acute phase therapeutic treatment was 
given once daily for 3 days starting on the day of weight loss and concluding on the 
day of sampling.
Vehicle-control animals received equivalent volumes of sterile PBS alone.
2.7.5 RU38486 (Mifepristone)
RU38486 [supplied by, Dr. R. Deraedt, Roussel UCLAF, France] was 
suspended in 1% carboxymethylcellulose [BDH] containing 0.05% Tween 80 and 
administered using an oral dosing needle at 20 or 40mg/kg body weight. Dosing was 
twice daily D9-11PI with a single dose on D12PI. Doses on D10 and 11PI were 
administered lhr prior to DEX or DEX-vehicle (PBS) treatment. Animals were 
sampled on D12PI.
Vehicle-controls received equivalent volumes of vehicle alone.
2.8 Histology
To determine CNS tissue lesion load CSp tissues were dissected and stored in 
10% formyl saline. Histological processing was performed in collaboration with the 
staff at the Department of Cellular Pathology, Royal United Hospital, Bath. Tissues 
were transferred to 50% cedarwood oil in molten paraffin wax for 30min at 60°C 
after which 6 changes of molten paraffin wax of lhr duration were made. Finally, the 
sample was embedded in wax moulds and once hardened longitudinal horizontal
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sections, 6pm thick, were cut at a standard depth defined as the widest point in the 
tissue.
Sections were mounted onto glass slides and stained with haemotoxylin and 
eosin as follows. Samples were immersed twice in xylene for 2min and then briefly in 
50% xylene in alcohol, absolute alcohol, 95% alcohol, 70% alcohol, 40% alcohol and 
distilled water, each for 15 sec. Sections were then stained with Harris haemotoxylin 
(without acetic acid) for 15min followed by a distilled water rinse and brief exposure 
to 0.1M HC1 in 70% alcohol. Slides were counterstained with 1% eosin (yellowish) 
and returned to xylene from alcohol through graded solutions.
The number of perivascular infiltrates per section were determined under low 
power by light microscopy.
2.9 Corticosterone Radioimmunoassay (RIA)
Endogenous corticosterone levels in rat plasma samples were determined 
using a 125I-corticosterone RIA [IDS]. Plasma samples had been prepared by 
centrifugation of heparinised whole blood at 300g and stored at -20°C until use. The 
RIA uses a limited amount of corticosterone antiserum for which the 125I-labelled 
corticosterone and the endogenous steroid within the test sample compete. The 
percentage of bound radiolabelled antigen therefore decreases as a function of the 
increasing concentration of unlabelled endogenous antigen present in the test sample. 
The bound 125I-corticosterone is separated from the unbound by precipitation using a 
second antibody directed against the original antiserum.
The RIA has a range of 0.5 - 62.5ng/ml and was performed according to the 
manufacture's instructions with all standards and samples assayed in duplicate. Plasma 
was diluted 1 in 10 for analysis. To each 0.1ml standard or sample, 0.1ml 125I- 
corticosterone and 0.1ml anti-corticosterone were added, vortexed and left to 
incubate overnight at 4°C. A 0.1ml aliquot of the second precipitating antibody was
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incorporated and the tubes incubated for lhr at room temperature. Following the 
addition of 1ml of saline, tubes were centrifuged at 1500g for 15min at 4°C. The 
supernatant was decanted and the resultant pellet counted on an LKB 1277 
Gammamaster for 2min. Non-specific binding (NSB) controls, from which the 
corticosterone antiserum was omitted, were assayed alongside standards and samples.
The percentage of bound 125I-corticosterone (%B/B0) was calculated using 
equation ©. The unknown sample corticosterone values were then derived from the 
standard curve of %B/B0 against standard concentration (ng/ml) on semi-log graph 
paper. A representative standard curve is shown in Figure 4.
% B / = * cpm (s) - x  cpm (NSB)
/BO  x  Cpm go  - x cpm (NSB)
Where: %% 0 = % 125I - corticosterone bound
x cpm (s) = mean cpm of sample or standard
x cpm (NSB) = mean cpm of NSB control 
x cpm BO = mean cpm of Ong / ml standard 
(= 100% binding)
2.10 Creatinine Determination
Creatinine levels in plasma samples were determined using a quantitative 
colourmetric diagnostics kit [Sigma]. Plasma samples had been prepared by 
centrifugation of heparinised whole blood at 300g and stored at -20°C until use. To 
0.3ml of water (blank), 3mg/dL standard, or sample, 3ml of alkaline picrate solution 
was added, mixed and allowed to stand at room temperature for 8-12mins. Using the 
blank as the reference solution, absorbances were read at 500nm (A’) on a PU8610 
spectrophotometer. Addition of 0.1ml acid reagent was made to all cuvets which 
were inverted and allowed to stand for 5mins at room temperature. Solutions were 









Figure 4: 125I-Corticosterone Standard Curve
A typical standard curve achieved using a 125I-corticosterone RIA [IDS], The 
percentage of bound 125I-corticosterone (%B/B0) decreases as endogenous 
(unlabelled) corticosterone increases.
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,  , JTx _ Initial sample A' - Final sample A" .. ,
Creatinine (111^  /  cLLJ x  3
Initial standard A' - Final standard A"
To determine the limit of linearity of the procedure for the cuvet size and 
instrument employed, a range of standards (O-lOmg/dL) were tested as directed in the 
manufacturer's instructions. The linearity limit achieved for the PU8610 
spectrophotometer is shown in Figure 5.
Values obtained for plasma creatinine concentration were compared to the 
normal range for rat plasma, published in the Clinical Biochemistry of Domestic 
animals (1989).
2.11 Statistics
Results were initially analysed for homogeneity of variance using Levene's test 
which assesses data from continuous, but not necessarily normal, distributions. Data 
not demonstrating equal variance (p < 0.05), was either log transformed and 
reassessed, or evaluated with the Mann-Whitney U test for non-parametric data, 
employing the Bonferroni correction factor when more than two groups were 
compared. Data groups with equal variances were analysed using the T-test for single 
comparisons or a one-way analysis of variance (ANOVA) for multiple comparisons. 
Following the recognition of differences by ANOVA, comparisons were made either 
throughout all groups by Tukey's pairwise assessment, or to a single control by 
Dunnett's test. Log-transformed data was tested for significant linear regression and 
the findings expressed as 'p' values and %fit, which indicates how close the actual 
values are to the fitted regression plot.
All statistical operations were performed using the computer program 'Minitab 
for Windows' and differences were assessed to be significant when p < 0.05. Results 
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Figure 5: Standardisation of equipment for creatinine measurement. The limit 
of linearity was determined for the PU8610 spectrophotometer using macrocuvets.
All subsequent measurements of creatinine concentrations within the range 0- 
lOmg/dL would lie within the linear limits of the instrument.
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3.
Development of an In Vivo Technique 




A double radioisotope method for the determination of BBB permeability was 
chosen based on the original technique described by Leibowitz & Kennedy (1972) and 
subsequent modifications by Oldendorf & Towner (1974). The technique employs the 
neurovascular permeability tracer 125I-labelled albumin, which circulates for up to 24 
hours, crossing the barrier and accumulating at abnormal levels in regions of 
microvascular dysfunction. A second radiolabelled tracer is then injected systemically 
and allowed to equilibrate throughout the blood for up to 5 mins. This short time 
precludes significant extravasation of the second tracer at permeable sites and so the 
radiolabelled marker acts to measure blood volume within a test tissue. Calculation of 
the EVBE value corrects the total tissue 125I-RSA counts for isotope positioned 
within the vasculature. Therefore, the EVBE represents the extravascularly located 
125I-RSA, quantifying BBB permeability.
3,1.1.1113mIn-Transferrin as a Blood Volume Marker
125I radiolabelled RSA was used as the marker of BBB permeability 
throughout the double radioisotope experiments and a circulation time of20-24hrs 
was employed as in the studies of Leibowitz & Kennedy (1972).The initial blood 
volume indicator used was 113mIn-transferrin which had been proposed as a suitable 
blood volume marker for use in human studies and also used in multiple tracer in vivo 
experiments (Hosain et. al., 1969; Sisson & Oldendorf, 1971; Oldendorf & Towner, 
1974). From the in vivo studies utilising 113mIn-transferrin, a circulation time of 2mins 
was chosen (Oldendorf & Towner, 1974).
113mIn decays rapidly with a half life of lOOmins, necessitating correction for 
decay during the counting of samples. To assess the rate of decay 113mIn standards 
were placed at regular intervals in the sample count sequence. The standard in 
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Figure 6: Correction curve for 113mIn decay.
113mIn standards were placed at positions 1 and 6 in each 10 tube rack. The 
first standard in the count sequence was referred to as the 100% reference standard. 
All other standards were calculated as a percentage of the reference and plotted 
against position in the count sequence. Test samples were corrected according to 
position in the count sequence. The standard curve shown is taken from a single 
experiment and is representative of the graphs obtained.
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subsequently compared. The data was plotted as a percentage decay curve against 
position in count sequence and a representative curve is shown in Figure 6.
The primary aim of initial experiments was to repeat the observations of 
Leibowitz and Kennedy and demonstrate a marked difference in BBB function 
between normal uninoculated animals and EAE-sensitised rats presenting severe 
neurological deficits (CHLP). Based on the published data, expectations were of 
normal EVBE values close to zero and elevated figures for diseased animals.
The results obtained are shown in Figure 7a-c. EVBE values of BBB 
permeability were negative in all instances indicating over correction by the blood 
volume tracer. Furthermore, no significant difference was demonstrated between 
normal and diseased tissues in MP and CSp regions of the CNS. A review of the 
results omitting correction for the blood content of tissue samples revealed a clear 
distinction between normal and EAE animals with significance in all areas of the CNS. 
The results clearly demonstrated that the 113mIn tracer correction was adversely 
distorting the profile of neurovascular opening.
Comparison of 125I BE values from a number of separate experiments (Figure 
8), showed little variation between normal groups indicating a high reproducibility of 
the measurement of albumin within CNS tissue. The reliability of the primary isotope 
marker plus the detection of differences between normal and EAE groups with 
uncorrected 125I BE indicated that studies to find a suitable secondary radiolabelled 
tracer for blood volume correction were justified.
3.1,1,2 lllIn-Transferrin as a Blood Volume Marker
Replacement of 113mIn with U1ln for the labelling of plasma transferrin 
immediately improved the correction of 125I BE values (Figure 9a-c). The use of 
11 ^ -transferrin as the blood volume marker produced consistent EVBE results in 
normal tissues, demonstrating little variation (Figure 9). Results remained negative 
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Figure 7: Measurement of BBB permeability using 113mIn-transferrin to 
correct for blood volume. Quantitation of BBB permeability to protein was determined in 
normal and EAE-sensitised animals at the height of disease (CHLP). 125I-RSA was used as 
the permeability marker and 113mIn-transferrin was employed as the blood volume tracer. 
Open columns represent normals (n = 8) and hatched columns represent EAE animals (n = 8). 
The left-hand set of data is corrected for blood volume (EVBE) while the right-hand data is 
uncorrected (125I BE). Statistical significance was assessed by the Mann-Whitney U test, * 
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Figure 8: Comparison of Normal 125I BE values Measured in the Cerebellum.
The mean 125I BE values from groups of normal Lewis rats from five separate 
experiments are shown (n = 3;3;5;6;5 from left to right). Limited variation is 
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Figure 9a-c: Measurement of BBB permeability using in In-transferrin to 
correct for blood volume. Quantitation of BBB permeability to protein was determined in 
normal and EAE-sensitised animals at the height of disease (CULP). 125I-RSA was used as 
the permeability marker and 11 ^ -transferrin was employed as the blood volume tracer. Open 
columns represent normals (n = 5) and hatched columns represent EAE animals (n = 6). The 
left-hand set of data is corrected for blood volume (EVBE) while the right-hand data is 
uncorrected (125I BE). Statistical significance was assessed by the Mann-Whitney U test, * 
p<0.02, ** p<0.01, NSD = not significantly different.
CORRECTED (EVBE) UNCORRECTED (125IBE)
**
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-30 previously). Paralysed EAE animals generally expressed positive EVBE values 
and demonstrated a large variation within the group typical of a disease state. 
Furthermore, a difference was apparent between normal and EAE in MP and CSp 
tissues although neither was significant.
m In has a longer half-life than 113mIn and could therefore be employed at a 
lower activity level. Furthermore, no correction of isotopic decay was required for the 
time period over which the tissue samples were counted (Figure 10).
Analysis of the uncorrected 125I BE values once again indicates clear 
significant differences between normal and EAE tissues in all CNS areas examined (C 
and MP p<0.02; CSp p<0.01).
3.1.1.3 in In-Transferrin Circulation Times and Isotope Binding Efficiency
A variety of circulation times have been used for the blood volume tracer 
ranging from 2 - 5mins (Leibowitz, 1969; Sisson & Oldendorf, 1971). Therefore, an 
experiment was designed to analyse the effect of variations in 11 ^ -transferrin 
circulation time on the final EVBE results. Groups of normal Lewis rats were used to 
limit the variation when establishing a profile of BBB permeability for circulation 
times of 2, 2.5, 3, 5 and lOmins. The results from the 2min circulation, shown in 
Figure 11, produced EVBE values near to zero in C and CSp tissues but not in the 
MP (-2.4 ± 0.7). Increasing the duration of the tracer within the vasculature to 2.5 or 
3mins did not affect the EVBE except in the CSp where over correction was greater. 
Circulation times of both 5 and lOmins adversely decreased the EVBE to 
approximately -3, -5 and -2.5 in C, MP and CSp tissues respectively.
Analysis of u lIn binding to plasma protein demonstrated that 55.9% ±3.2 
(n = 7) of the label bound with a range of 53 - 63%. Similar determination of binding 
in blood from animals injected with the in In-labelled plasma demonstrated no 
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Figure 10: Correction curve for in In decay.
U1ln standards were placed at positions 1 and 6 in each 10 tube rack. The first 
standard in the count sequence was the 100% reference standard. All other standards 
were calculated as a percentage of the reference and plotted against position in the 
count sequence.
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Figure 11: n iIn-transferrin Circulation Times
Five groups of normal Lewis rats were used to determine the effect of circulation time of the blood volume marker m In-transferrin on 
the measurement of BBB permeability to 125I-RSA. The circulation times selected were 2min (n = 3), 2.5min (n = 3), 3min (n = 5), 
5min (n = 6) and lOmin (n = 5). ANOVA with a Tukey's pairwise comparison showed 5 and lOmin values were significantly increased 
in all tissues p<0.05.
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A final study of the suitability of m In-transferrin as a marker of blood volume 
was made by assessing the variability between normal and disease groups of m In BE 
correction values. Table 2 summarises the results from two representative studies. 
Clearly a large variation exists between experiments in the range of results calculated, 
particularly for normal groups. Furthermore, the mean correction values calculated 
for diseased groups are greater than those of normals in all but one comparison, 
although significance was not shown. Variability may therefore be linked to 
neurological status.
Table 2: m In-transferrin Correction of Blood Volume: Comparison between 
Normal and EAE-sensitised Lewis Rats
Mean mIn BE ±  SD
Group n c MP CSp
Normal4 3 3.32 ±0.95 6.52 ±3.74 5.20 ±2.74
EAE D12 PIa 6 5.32 ±4.73 7.71 ± 6.27 4.90 ±2.87
Normal5 6 2.89 ±0.88 3.90 ±0.67 2.56 ±0.68
EAE CHLP5 6 4.14 ± 1.86 5.78 ±3.88 3.60 ± 1.31
*»b : Indicates data from same experiment.
NSD was found between normal and EAE values in either experiment; Mann-Whitney 
U test.
3.1.1.4 m In-RBC as a Blood Volume Marker
The variable blood volume correction and unsatisfactory level of m In bound 
to plasma protein led to an alternative marker being sought. The tracer chosen should 
not be involved in or affected by the disease process and the amount of labelled tracer
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injected tightly controlled. RBC had previously been employed by Rumjanek et. al. 
(1984a) in a similar study and the cells met the listed criteria. Furthermore, 
methodology had been published describing the labelling of RBC with U1ln- 
tropolonate (Osman & Danpure, 1987). The circulation time for in In-RBC was 
raised to 5min according to the original methodology of Leibowitz and the study by 
Rumjanek employing radiolabelled RBC for blood volume determination (Leibowitz 
& Kennedy, 1972; Rumjanek et. al., 1984).
The corrected EVBE results achieved utilising the RBC marker demonstrated 
a marked improvement over previous methods. Figure 12 shows significant 
differences in BBB permeability between normal rats and EAE-sensitised animals at 
the height of disease (neurological status range 2 - 4) in all CNS areas examined 
(p<0.05). Indeed, the profile presented by the uncorrected 125I BE results remains 
after correction. Normal EVBE values are close to zero and variability within tissue 
groups is minimal (C = 0.8 ± 0.1; MP = 1.0 ± 0.3; CSp = 1.3 ± 0.4; n = 3). In contrast 
diseased animals demonstrate a high EVBE indicating enhanced neurovascular 
permeability to systemic albumin. The variability within the EAE group is increased 
due to the differing responses of individual rats to disease development (C = 4.0 ±
2.0; MP = 11.4 ± 6.9; CSp = 11.8 ± 4.9; n = 7). Interestingly, the extent of BBB 
opening is greater in both MP and CSp tissues than in the C.
Finally, Table 3 shows that no significant difference exists in m In-RBC 
correction values for blood volume (in In BE) between normal and EAE-inoculated 
groups at D 12 PI in any CNS tissue analysed.
Furthermore, the method of RBC labelling ensures that the U1ln endproduct is 
100% bound to cells, the unbound isotope having been washed out. Figure 13 
represents the typical level of activity achieved per 5 x 109 cell preparation. Daily, but 
minimal variations in activity exist between preparations of u lIn-RBC. However, the 
























Figure 12a-ci Measurement of BBB permeability using n iIn-RBC to correct 
for blood volume. Quantitation of BBB permeability to protein was determined in normal 
and EAE-sensitised animals at the height of disease (HLW - CHLP). 125I-RSA was used as 
the permeability marker and H1In-RBC were employed as the blood volume tracer. Open 
columns represent normals (n = 3) and hatched columns represent EAE animals (n = 7). The 
left-hand set of data is corrected for blood volume (EVBE) while the right-hand data is 





















Figure 13: Final Activity of n iIn / 5 x 109 RBC Preparations
Labelling of RBC on day 1 employed a fresh batch of m In. Radiolabelling on 
subsequent days used the same batch which had accumulated decay product with 
time. All groups (n = 5) are representative of the final activity achieved in all 
experiments conducted and a single batch of in In was typically only used for three 
consecutive days.
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Table 3: m In-RBC Correction of Blood Volume - Comparison between 
Normal and EAE-sensitised Lewis Rats
Mean mIn BE ±  SD
Group________n_________ C_________ M________ CSp
Normal* 6 0.98 ±0.16 0.87 ±0.13 0.97 ±0.13
EAE D 12 PIa 14 1.08 ±0.24 1.15 ±0.33 0.81 ±0.24
Normalb 5 0.87 ±0.39 0.62 ±0.51 0.63 ± 0.25
EAED12 PP 10 0.78 ±0.18 0.67 ±0.12 0.71 ±0.13
*■b : Indicate data from separate experiments
NSD was found between normal and EAE values in either experiment; Mann-Whitney 
U test.
The final method developed employing 123I-RS A as the marker of 
extravasation and m In-RBC as the blood volume tracer was able to quantitate 
protein accumulation in a range of CNS tissues. The technique is highly 
reproducibility and can demonstrate large differences in BBB permeability between 
normal and EAE-paralysed rats.
3.1.2 Water Extravasation
An alternative measure of BBB breakdown in the CNS during EAE is the 
quantitation of edematous water influx into CNS tissues. Such an approach could 
either be employed alone to provide a reliable method for examining pharmacological 
restriction of edema build-up, or be used to support the findings of 125I-RSA 
permeability studies. Three different techniques were employed to measure the 
edematous aspect of BBB dysfunction.
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3.1.2.1 Dual-tracer Analysis o f Edema Formation
To determine extravascular accumulation o f3H20  together with 125I-RSA in 
tissues from a single animal, a dual count parameter was constructed on an LKB 
Rackbeta 1219. A standardisation for quench error was performed for both 3H and 
125I when designing the parameter settings (Figurel4a,b). Analysis of combined 125I 
and 3H standards on the dual count parameter demonstrated an accurate recognition 
of 125I levels and a consistent yet slightly dampened dpm for 3H (Figure 14c). A 
reduced 3H value would not affect subsequent calculation of the BE ratio if the 
dampening was consistent as indicated.
Application of the dual count method to the quantification of BBB 
permeability during EAE did not provide a profile of water extravasation (Figure 15). 
The results obtained by the dual-tracer method highlight no significant difference 
between normal animals and experimental groups in any CNS area studied. 
Furthermore, the normal results appear generally higher than those of animals 
presenting neurological deficits.
The technique also produced unacceptable levels of chemiluminescence and 
colour quench in many samples. Furthermore, the possibility that 125I levels within 
samples may also have affected measurement cannot be ruled out. However, 
125I-RSA activity could not be reduced as the detection of radiolabelled protein would 
have been affected. The lack of a clear difference between normal and disease states 
deterred further investigation using this technique.
3.1.2.2 Ethanol Extraction o f SH20  for Edema Measurement
A modification of the method used by Simmons et. al (1982), avoided the 
chemiluminescence and colour quench problems encountered by the dual count 
method. A single isotope, ^ O ,  was injected into the circulation and the 
extravascularly accumulated water extracted from dissected CNS areas by 
dehydration with ethanol. The 3H content of ethanol extracts and plasma aliquots was 
subsequently assessed on a single count parameter.
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Figure 14: Standardisation of Dual Count Parameter for the Measurement of
3H and 125I Radioisotopes. The two line graphs (a) and (b) show the standardisation 
of spectral quench parameters (external) (SQP(E)) for 3H and 125I respectively, using 
a dual count parameter on an LKB Rackbeta 1219. Carbontetrachloride was used as 
the quenching agent in a range from 0 to 200pl per 10ml of scintillant. The histogram 
(c) shows the ability of the dual count parameter to detect both 3H and 125I within a 
mixed sample. Three standards were employed: A = 10 OOOdpm 3H; B = 2 500dpm 














Figure 15: Water Extravasation During EAE Measured by a Dual-tracer 
Technique. Water accumulation within CNS tissues of EAE, CFA control and 
normal groups was measured by liquid scintillation counting of 3H20  in solubilised 
samples, together with a determination of 125I-RSA extravasation (data not shown). 
Normal (open column, n = 9), CFA-inoculated (diagonally hatched column, n = 6), 
paralysed EAE-inoculated (black column, n = 8) and recovered (REC) EAE- 
inoculated D23 PI (cross hatched column, n = 6) animals were analysed. The data was 
subjected to an ANOVA resulting in no significant differences between experimental 
groups and normal values being shown.
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The first experiment assessed EAE-sensitised animals at a range of timepoints 
with comparison to normal and CFA-inoculated controls. Five CNS areas were 
examined producing a comprehensive profile of water extravasation (Figure 16a-e). 
Normal tissues showed low values in comparison to disease figures, with little 
variation within the tissue data groups of normal animals. The profile showed that 
brain water accumulation increased as early as D7 PI in EAE-inoculated animals. 
However, an increase in PE in CFA-inoculated controls at D7 PI was also 
noted, indicating non-specific adjuvant effects. The edema content of CNS tissues 
remained elevated throughout early (FT) and severe (CHLP) stages of neurological 
disease (p<0.05, compared to normal). The CNS water content decreased with loss of 
neurological deficits and was not found to be significantly different from normal 
values at D23 PI, during early recovery.
Confirmation of the initial findings could not be demonstrated in subsequent 
experiments, questioning the reproducibility of the technique. Figure 17 illustrates the 
variability of normal control values obtained from five representative experiments. 
Variation within individual groups is limited, but between experiments the differences 
are significant (p<0.05).
The technique not only produced discontinuity between experiments but also 
within studies. Figure 18a-b combines the results of three separate investigations 
using ethanol extraction to quantify edema formation. The differences highlighted 
between normal rats and animals with CHLP in the original profile - ( shown as study 
1 in Figure 18) - was not observed in later studies - (2 and 3, Figure 18). The 
differences in experiments 2 and 3, were either reduced to a non-significant level or 
abolished in both the C and TSp tissues. The technique lacked the reproducibility 
required for pharmacological studies and a third approach to edema measurement was 
assessed.
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Figure 16: Water Extravasation During EAE Measured by Ethanol 
Extraction Technique. Accumulated was removed from CNS tissues (a) 
cerebellum, (b) medulla-pons, (c) cervical spinal cord, (d) thoracic spinal cord and (e) 
lumbar spinal cord, by ethanol extraction and the results expressed as plasma 
equivalents (PE). Six groups of Lewis rats were examined: normals (n = 5); CFA- 
inoculated D7 PI (n = 4); EAE-inoculated D7 PI (n = 6); EAE- FT (n = 7); EAE- 
CHLP (n = 8); and EAE- recovery D23 PI (n = 3). All groups were significantly 
different from normals in all tissues examined (p<0.05) with the exception of recovery 
groups in all areas and EAE D7 PI in the lumbar spinal tissue (NSD); ANOVA 
followed by Dunnett's multiple comparison to a single control.
(e) Lumbar Spinal Cord
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Figure 17: Variability of Normal 3HzO Values in the Cerebellum following 
Ethanol Extraction. Estimation of water extravasation by ethanol extraction of 
accumulated 3H2 0  in the cerebellum of normals from five separate experiments (n = 
5, 3, 3, 6 and 6 left to right). Differences were shown to exist by ANOVA at p<0.05. 















Figure 18: Variability within Experiments when comparing Normal and EAE 
Values of Water Extravasation by the Ethanol Extraction Technique.
The results of three studies comparing normal Lewis rats (open column) with EAE- 
animals showing neurological deficits (hatched column) are illustrated for the (a) 
cerebellum and (b) thoracic spinal cord tissues. Study 1 represents the results from 
the initial profile reported in Figure 16a and d; normal (n = 5), EAE (n = 8). Studies 2 
and 3 aimed to repeat the findings of study 1; normal (n = 3, 6), EAE (n = 6, 3) 
respectively. Highly significantly differences were found in study 1 (**** p = 0), but 
no significant difference (NSD) was observed between normal and EAE groups in 
either study 2 or 3; T-Test.
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3.1.2.3 % Water Content
Levine had previously reported edema formation within the CNS by 
calculating % water content from tissue wet and dry weights (Levine et. al 1966, 
1977). Assessment of CNS tissue water content in EAE-sensitised animals by weight 
was made at timepoints D7PI and D12PI which had both been implicated in water 
accumulation in the CNS by the ethanol extraction technique. At D7 PI no difference 
in the water content of C or CSp tissues from normal and EAE animals was noted 
(Figure 19a,b), a result typical of other CNS areas (Table 4). Moreover, the trend in 
the CSp was for a lower % water content in the disease group compared to the 
normals.
Table 4: Assessment of CNS % Water Content in Normal and EAE- 
inoculated Lewis Rats at D7 and D12 PI
%Water Content ± SD
Group n MP TSp LSp
Normal* 3 73.4 ± 1.5 71.4 ± 1.38 73.2 ±1.22
EAED7PI* 7 73.4 ±0.4 70.6 ±0.8 73.5 ± 1.6
Normalb 3 73.0 ±0.5 70.1 ±1.7 73.4 ±0.8
EAED12PIb 7 73.7 ± 1.5 73.9 ±0.7 76.1 ± 1.0*
Normal0 6 75.6 ±0.5 71.8 ±0.7 75.8 ± 1.7
EAED7PI0 5 75.5 ± 1.9 72.0 ±1.8 77.3 ± 2.9
EAED12PI0 3 75.2 ± 1.4 73.3 ±0.9 77.2 ± 1.8
a_c: Indicates data from same experiment.
No significant differences between normal and EAE groups were found except 
between normal and EAE D 12 PI in the lumbar spinal cord in one out of two replicate 


















71 ?01— 1 l l l l l l l l  I l l l l l l l l l l l l l l l i l
Experiment
Figure 19: Water Extravasation During EAE Assessed by % Water Content - 
Comparison of Normal and EAE at D7 PI.
From wet and dry weight measurements the % water content of CNS tissues (a) 
cerebellum and (b) cervical spinal cord was assessed in normal (open column) and 
EAE at D7 PI (Vertical line column) animals. The results o f two independent 
experiments are shown. Study 1: normal, n = 3; EAE D7 PI, n = 7. Study 2: normal, n 
= 6; EAE D7 PI,





The results of the comparison between normal and early neurological disease 
in EAE were also inconclusive (Figure 20a,b).Values in the C indicated a lower % 
water content in diseased animals (78.2% ± 0.6; 79.2% ± 0.55) compared to normals 
(79.1% ± 0.8; 80% ± 0.5). A significant increase in the water content of EAE tissue 
at D12 PI was noted in the LSp (p<0.05), but could not be consistently shown (Table 
4). In conclusion, analysis of % water content as a measure of edema accumulation 
was unsatisfactory showing no reliable indication of a significant difference between 
normal and disease states in any tissue.
In summary, the measurement of water influx into the CNS parenchyma as a 
result of EAE development has been analysed by three separate techniques. All 
methods lacked significant reproducibility and a difference between normal and EAE 
states were not necessarily shown. However, the procedure developed from published 
methodology to quantify protein extravasation across the BBB is reliable and 
consistently demonstrates a large difference in permeability between normal and 
disease states. Therefore, measurement of albumin movement across the BBB is the 





















Figure 20: Water Extravasation During EAE Assessed by % Water Content - 
Comparison of Normal and EAE at D12 PI.
From wet and dry weight measurements the % water content o f CNS tissues (a) 
cerebellum and (b) cervical spinal cord was assessed in normal animals (open column) 
and EAE-sensitised rats D12 PI (cross hatch column). The results of two independent 
experiments are shown. Study 1: normal, n = 3; EAE D12 PI, n = 7. Study 2: normal, 
n = 6; EAE D 12 PI, n = 3. NSD - no significant difference was found between normal 
and EAE groups, T-test.
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3.2 Discussion
The T cell mediated neuropathology of EAE presents many potential sites for 
assessing the progress of disease and the performance of pharmacological agents. 
Abnormal BBB function is consistently a key development in the progression of EAE 
and therefore an ideal parameter to study and control.
As a result of BBB perturbation vascularly-derived water, proteins and 
immune cells influx into the inflammatory EAE lesion. Measurement of the 
accumulation of any systemically-derived inflammatory components in the CNS 
parenchyma could be used to indicate disease progression. Analysis of water and 
albumin build-up in extravascular sites was chosen as, unlike cellular infiltrates, the 
pharmacological findings pertaining to these components may be applicable to other 
conditions involving impaired neurovasculature, including head injury and meningitis.
The ideal experimental design would have assessed both water and albumin 
movement across the BBB within the same CNS samples. However, the scintillation 
counting of radioisotopes 125I and 3H contained in whole blood and CNS tissue 
samples, presented a range of variables and errors, amongst which the greatest 
problems were chemiluminescence and colour quench. Chemiluminescence is the 
conversion of chemical energy to molecular electronic excitation energy which creates 
a photon of light. Consequently, the additional light interferes with the accurate 
detection of photon emissions derived from nuclear particle kinetic energy. 3H 
determinations are particularly affected. The high levels of chemiluminescence 
associated with the dual radioisotope technique were attributed to the chemical 
solubilizer used and the high lipid content of the CNS samples. Colour quench of the 
scintillant-signal was an inherent feature of the samples under examination. Bleaching 
of samples with hydrogen peroxide was considered, but further aggravation of the 
chemiluminescence by chemical addition was determined to be inappropriate.
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The lack of distinction between normal and diseased animals by the dual 
scintillation measurement of both albumin and water, indicated that the protocol was 
not suited to the tissues under assessment. Lengthy chemical manipulations to reduce 
the complicating quench and chemiluminescence errors were therefore not 
investigated.
A single isotope method adapted from work by Simmons et. al. (1982) 
enabled measurement of water extravasation in CNS tissues without the 
complications encountered in the dual radioisotope procedure. Extraction of tritiated 
water from tissue with ethanol and the calculation of plasma rather than whole blood 
equivalents omitted colour quench of the scintillation counting. The results from the 
Simmons study in acute EAE distinguished a small definition between normal and 
disease states at the distal end of the spinal cord (Simmons et. al. 1982). The adapted 
method presented here recognised edema formation in all areas of the CNS examined. 
While subsequent analysis using the procedure demonstrated an unacceptable 
variability, a number of aspects relating to the original profile were found to be in 
agreement with published observations.
The current study found elevated neurovascular permeability for water at D7 
PI prior to the onset of EAE symptoms, which confirmed previous work using Gd- 
DTPA and mannitol (MW 550 and 182Da respectively) (Daniel et. al., 1981; Lam, 
1986; Hawkins et. al., 1991). Furthermore, Gd-DTPA leakage returned to normal 
levels by recovery (D20PI), which agrees with the present observations (Hawkins et. 
al. 1991).
Increased CNS tissue water content in samples from CFA-inoculated animals 
D7PI is in agreement with a report by Suckling et. al. (1984), who measured elevated 
CSF albumin concentrations in CFA controls at an identical timepoint. CFA-induced 
changes are not regularly reported for large proteins at pre-disease timepoints 
(Oldendorf & Towner, 1974; Traugott, 1989). However, the water extravasation seen
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at D7PI in CFA controls may implicate adjuvant-induced perturbation of barrier 
function during the initiation of EAE.
The majority of small tracer studies in EAE report significant changes in BBB 
permeability at the distal end of the spinal cord at D7PI and only limited involvement 
of other CNS regions during an acute attack (Oldendorf & Towner, 1974; Daniel et. 
al., 1981; Simmons et. al., 1982). However, the edema measurements reported here 
express a general fluid accumulation in all CNS areas. The disparity with published 
findings may be indicative of a methodological anomaly rather than a greater 
sensitivity, which when considered with the inconsistency of results, renders the 
technique unsuitable for assessment of drug actions at the BBB.
Calculation of tissue water content by wet and dry weight measurements has 
been successfully implemented by investigators assessing CNS edema formation 
following induction of hyperacute EAE (Levine et. al., 1966), chemical irritation 
(Levine & Torrelio, 1977) and compression head injury (Yamaguchi et. al., 1976). 
Published values in the range 78-79% for normal brain water content are in close 
agreement with the normal levels reported in the present study (Levine & Torrelio, 
1977; Yamaguchi et. al., 1976). Edematous CNS tissues typically demonstrate a 1- 
4% increase in water content above normal values when calculated by this method 
(Levine et. a l, 1966; Yamaguchi et. al., 1976; Levine & Torrelio, 1977). The current 
study in the Lewis rat model of acute EAE demonstrated no distinction between 
normal and diseased tissues. The size of tissue analysed was notably smaller than the 
areas studied by Levine et. al. (1966) and Yamaguchi et. al. (1976). Furthermore, the 
proteinaceous plasma exudate and inflammatory cells entering an EAE perivascular 
lesion area may significantly contribute to the dry weight measurements, obscuring 
the increase in tissue water. Indeed, a number of reports detect a measurable increase 
in tissue DNA as a result of inflammatory cell infiltration (Oldendorf & Towner,
1974; Smith ef. al., 1984; Honegger et. al, 1989b).
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Determination of neurovascular dysfunction by recording accumulated levels 
of 125I-RSA successfully and reliably distinguished between normal and acute EAE 
states, agreeing with the single isotope measurements made by Leibowitz & Kennedy 
(1972). However, a number of trials were necessary to identify a suitable second 
tracer for the correction of tissue blood volume.
Indium labelling of plasma transferrin had been successfully employed by 
Hosain et. al. (1969), Sisson & Oldendorf (1971) and Oldendorf & Towner (1974) to 
measure blood distribution spaces. However, in this study following a 1:1 (v/v) 
binding procedure only 50-60% of the in In label was protein-bound, indicating a 
saturation of binding to plasma protein, which has been reported to be transferrin 
(Adatepe et. al. ,1969). Therefore, a significant amount of the isotope was either 
unbound or attached to a non-protein plasma constituent, potentially increasing the 
access of the label to the extravascular compartment of the CNS. Indeed, the 
concentration of 113mIn employed was ten-fold greater than the amount of in In used 
to compensate for the rate of decay. Consequently, the binding of 113mIn to protein 
might be expected to be even lower than that achieved with m In. A difference in 
protein labelling would explain the improvement in blood volume correction observed 
when in In replaced 113mIn as the blood volume tracer radiolabel.
Oldendorf & Towner (1974), did not report limited binding of 113mIn to 
plasma transferrin when employing 100-200p,Ci 113mIn-transferrin / animal following a 
1:1 (v/v) labelling procedure. Other studies using 113mIn-transferrin as a marker have 
not indicated the ratio of isotope to plasma or whole blood required to obtain 
satisfactory binding (Hosain et. al., 1969; Sisson & Oldendorf, 1971). Investigation of 
the optimal ratio for maximum binding may have improved the final vascular 
correction factor achieved with the tracer. However, if as indicated a substantial 
increase in plasma volume was required, the final quantity of injectate may have 
proved inappropriate for in vivo administration.
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Interestingly, the transferrin molecule may not be ideally suited as a control 
marker in CNS tissue studies. The brain has a large requirement for iron (Pollitt & 
Leibel, 1982) and a high density of transferrin receptors has been reported on the 
luminal surface of neurovascular endothelial cells by immunostaining experiments 
(Friden, et. al., 1991). Therefore, at CNS locations transferrin may be diverted from 
the blood, into the endothelium to deliver iron, to a greater extent than at other 
vascular sites. Furthermore, as part of a cerebrovascular transport system, changes in 
receptor density may exist as part of BBB dysfunction during EAE. Of note is the 
trend towards an increased 11 ^ -transferrin correction value in diseased animals 
compared to data from normal animals, observed during the study. Implementation of 
radiolabelled RBC as the blood volume marker did not indicate variation between 
normal and disease correction values.
RBC labelling provided a method by which 100% binding could be ensured. 
Furthermore, RBC are not involved in EAE disease pathology and there are no 
reports showing that RBC activity changes as a result of disease. The correction of 
125I BE values for blood volume achieved using labelled RBC compared well with the 
normal range reported in the original study by Leibowitz & Kennedy (1972).
By using 125I-RSA and U1ln-RBC in combination differences between normal 
and disease states were consistently observed. Measurements of BBB permeability in 
EAE animals were in agreement with those of Leibowitz & Kennedy (1972) and 
Rumjanek et. al. (1984), who used similar regimes. Furthermore, the limited variation 
within normal tissue groups consistently found by Leibowitz & Kennedy (1972), 
Rumjanek et. al. (1984) and Butter et. al. (1991) has now been routinely 
demonstrated by the modified technique in the Lewis rat. Normal EVBE values 
obtained by Leibowitz & Kennedy (1972) were generally lower than figures reported 
here. However, Butter et. al. (1991) expressed similar baseline figures, suggesting 
that any variability may be due to experimental procedure.
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The CNS tissues, C MP and CSp, selected for routine analysis include high 
and low lesion densities at the height of disease (Bolton et. al. ,1984b). Furthermore, 
the chosen areas display a range of neurovascular permeabilities to plasma protein as 
determined by the modified double radioisotope technique.
From published methodology a robust technique for the measurement of BBB 
permeability to plasma protein has been established. The method is highly 
reproducible and recognises a large difference between normal and EAE conditions. 
Therefore, the technique is suitable for detecting changes in abnormal neurovascular 
leakage following the administration of standard and novel drugs.
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4.
Characterisation of BBB Dysfunction 




4.1.1 Profile o f Neurovascular Breakdown during Acute EAE
Following the development of a reproducible method for the measurement of 
neuroantigen-induced BBB permeability, it was necessary to perform a series of 
studies to characterise the breakdown of normal neurovascular function during the 
course of acute EAE. The Lewis rat model of EAE has been fully characterised in 
terms of the development of disease symptoms (Paterson, 1976). However, body 
weight and neurological scores were observed daily to enable direct comparison 
between the development of these parameters and BBB permeability.
4.1.1.1 Body Weight Changes and Development o f Neurological Deficits
Typically both EAE and CFA-inoculated animals demonstrate a small weight
loss immediately following sensitisation. Subsequently, CFA-inoculated rats gain 
weight at a rate comparable to normal uninoculated animals. EAE-sensitised rats 
initially accrue weight at a normal rate, but a marked weight loss is noted around DIO 
± 1 PI immediately prior to the onset of early neurological signs (Figure 21a). Weight 
loss continues rapidly over the next 8 ± 1 days while disease symptoms are apparent 
(Figures 21b & 22). Typically the height of disease occurs at D14 PI (Figure 22) 
afterwhich the neurological deficits begin to resolve. Weight gain resumes 2 -3  days 
after all neurological deficits have disappeared.
4.1.1.2 BBB Dysfunction
Analysis of BBB permeability in CFA-inoculated controls was performed at a 
range of timepoints from DO - D35PI (Figure 23). No significant elevation of BBB 
permeability due to CFA-inoculation was noted at any time following sensitisation in 
the CNS tissues examined. Protein extravasation across the neurovasculature at 
timepoints 10 and 23 PI was seemingly raised in 2 or 3 tissues. However, the 
elevation corresponded to a high baseline and values were not found to be 
significantly different from normal controls analysed in the same experiment. These
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Figure 21: Body Weight Profiles for EAE and CFA-inoculated Lewis Rats 
with Comparison to Normals, (a) Groups of animals were weighed daily and mean 
body weights plotted against day number PI. Profiles shown for: normal group 
recorded for 14 consecutive days — ■— (n = 6); CFA group recorded from DO PI to 
D35 PI — • —  (n = 4); EAE group recorded from DO PI to D37 PI —A— (n = 6).
(b) The percentage decrease in body weight from the peak body weight at D9-10 P.l. 













Figure 22: Development of Neurological Symptoms in EAE-sensitised Lewis 
Rats. Animals inoculated for EAE were weighed daily and assessed for disease 
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Figure 23: Profile of Protein Extravasation in the CNS of CFA-inoculated 
Lewis Rats. 125I-RSA accumulation within the (a) cerebellum, (b) medulla-pons and (c) cervical 
spinal cord tissues, was measured in CFA-inoculated animals at a range of timepoints PI. The 
histograms combine the data from four experiments. The normal column (black) combines the 
normal values from all four experiments thereby presenting a full range of normal results (n = 14). 
CFA-inoculated animals were sampled at days 5 PI (n = 5), 10 PI (n = 5), 12 PI (n = 5), 14 PI (n = 
5), 20 PI (n = 4), 23 PI (n = 4) and 35 PI (n = 5). The Mann-Whitney U test with Bonferroni 
correction for multiple comparisons found no significant differences between normal and CFA 
groups. Individual CFA groups were compared to the normal controls corresponding to the original 
experiment and not to the combined value plotted above.
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results demonstrate that a non-specific increase in BBB permeability to protein does 
not occur. Therefore, any significant elevations in neurovascular dysfunction 
measured in EAE-sensitised animals will result from neuroantigen-mediated effects.
BBB dysfunction during EAE was examined in the C, MP and CSp tissues at 
timepoints DO, 5, 10, 11, 12, 15, 23 and 35-7 PI. In all tissue areas BBB permeability 
to protein remained within normal limits at D5 PI (Figure 24). At the time of weight 
loss the integrity of the BBB was maintained and although the EVBE values appear 
raised in relation to the combined normal results, no significant elevation was noted 
compared to normal and CFA controls run simultaneously. Neurovascular 
permeability is raised but not significantly in MP and CSp tissues at D11 PI, 
corresponding with symptom onset. The BBB within the MP and CSp tissues reachs a 
maximum permeability at D12PI (CSp D12 PI 8.3 ± 2.9 compared to DO PI 1.35 ± 
0.66; p<0.05). However, while BBB dysfunction in the C is significant at D12 PI 
(p<0.05) a marked protein extravasation does not develop until D15 PI. At D15 PI, 
the MP maintains the BBB dysfunction seen on D 12 , but the CSp barrier 
permeability is reduced.
Analysis of the early recovery phase (D23 PI), following loss of neurological 
deficits and resumed weight gain, presents an unexpected tissue profile of 
neurovascular breakdown (Figure 24). Interestingly, the neurovasculature remains 
abnormally permeable to albumin in all CNS areas examined (C and CSp p<0.1, MP 
p<0.05). Furthermore, the C demonstrates BBB dysfunction greater than that seen 
during the acute phase (D23 PI, 7.61 ± 4.66; D12 PI, 2.18 ± 0.47), while MP and 
CSp tissues have reduced EVBE values (D23 PI - 6.32 ± 3.77, D 12 PI - 8.4 ± 2.77; 
and D23 PI - 4.8 ± 1.98, D12 PI - 8.3 ± 2.89 respectively).
Examination of CNS tissues at D35-37 PI during the late recovery phase 
demonstrated a return to normal levels of BBB permeability to plasma protein in MP 
and CSp tissues and a marked reduction in dysfunction in the C (C, p = 0.032; MP, p 
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Figure 24: Profile of Protein Extravasation in the CNS during the Development of 
Acute EAE in the Lewis Rat. 125I-RSA accumulation within the (a) cerebellum, (b) medulla- 
pons and (c) cervical spinal cord tissues, was measured in EAE-inoculated animals at a range of 
timepoints PI. The histograms combine the findings of five experiments. The normal column (black) 
combines the normal values from all five experiments thereby presenting a full range of normal 
results (n = 17). EAE-sensitised animals were sampled at days 5 PI (n = 6), 10 PI (n = 5), 11 PI (n =  
3), 12 PI (n = 7), 15 PI (n = 4), 23 PI (n = 9) and 35-37 PI (n = 8). Statistical analysis of differences 
from normal BBB permeability was performed using the Mann-Whitney U test with Bonferroni 
correction for multiple comparisons; * p < 0.05, ** p < 0.01. Individual EAE groups were compared 




4.1.2 Neurovascular Dysfunction: Comparison o f Routes o f Vehicle 
Administration
The pharmacological studies reported in later sections employ a variety of 
drug administration routes. As the effect of different regimes on abnormal BBB 
permeability is unknown a comparison of results from oral, i.p. and s.c. routes 
employing PBS alone was made early in the examination of drug studies.
EVBE values were elevated at D12 PI for all EAE-sensitised treatment 
groups and showed greatest neurovascular permeability in the MP and CSp areas as 
found in the tissues of untreated diseased animals (Figure 25). Furthermore, 
examination of the data by ANOVA demonstrated no significant difference between 
treatments at p<0.05.
4.1.3 Neurovascular Dysfunction: Correlation with Neurological Signs
Subsequent to the pharmacological studies performed in the acute model of 
EAE and reported in the following chapters, a comprehensive review of the extent of 
BBB dysfunction and the presentation of disease symptoms was undertaken (Figure 
26a-c). Interestingly, the results demonstrate an absence of significant differences 
between any neurological grouping of EVBE results confirmed by the failure to show 
a linear regression between the two parameters in C or MP tissues. A minor trend 
towards increasing permeability with intensifying severity of disease is indicated in the 
CSp, but only 8% of the variation in results in the tissue fell within the 95% 
confidence limits of the regression. The data indicates that a full range of EVBE 
values can be obtained at both weight loss (C 0.98 to 10.66; CSp 1.33 to 16.48) and 
at the height of disease (CHLP: C 1.67 to 9.12; CSp 3.24 to 17.29). Consequently the 
neurological deficits displayed do not appear to be indicative of the extent of 
neurovascular breakdown.
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Cerebellum M ed ulla-Pons Cervical Spinal C ord
Figure 25: Route of Vehicle Administration: Effect on the Permeability of the BBB to Protein
Animals inoculated for EAE were dosed with sterile PBS via three different routes according to the therapeutic dosing regime for the acute 
phase (Section 2.7). The histogram compares oral (diagonal hatch column; n = 7), s.c. (vertical hatch column; n = 6) and i.p. (cross hatch 
column; n = 7) administration of PBS from separate experiments with an untreated time-matched EAE-sensitised control (open column; n = 5). 
Dosing began on the day of weight loss and continued for two days, dosing once daily for oral and i.p. administrations and twice daily for the 
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Figure 26: Correlation between Neurovascular dysfunction and Severity of 
Neurological Deficits in EAE-sensitised Lewis Rats.
A comprehensive review of the EAE-sensitised vehicle control groups from drug 
investigations has provided the data for this study. Three areas of the CNS have been 
assessed (a) cerebellum, (b) medulla-pons and (c) cervical spinal cord. Individual 
EVBE values are assigned to the symptom of greatest severity observed in the 
corresponding animal at the time of sampling. Individual EVBE values are shown by 
filled circles, while the histograms represent the mean EVBE ± SD for each 
neurological state. Statistical analysis using a one-way ANOVA shows that no 
difference exists between EVBE groupings in any tissue. Furthermore, no significant 
regression was demonstrated for C and MP tissues with only a minor regression 
accounting for 8% of the variation in results noted for the CSp.
108
4.2 Discussion
The double radioisotope technique for the determination of protein 
extravasation across the BBB, demonstrated a clear profile of elevated neurovascular 
dysfunction during the course of EAE. The extent of permeability enhancement 
compared well with profiles previously published for EAE in the guinea-pig 
(Leibowitz, 1969; Leibowitz & Kennedy, 1972), Biozzi mouse (Butter et. a l, 1991) 
and the Lewis rat (Rumjanek et. al, 1984a; Lam, 1986). Furthermore, 
characterisation of body weight profiles and neurological scores demonstrate a typical 
progression of acute disease (Bolton & Flower, 1989).
A study of BBB permeability in CFA controls clearly demonstrated the 
absence of non-specific protein extravasation at the neurovasculature at any stage PI 
in the acute Lewis rat model. This is in agreement with the double radioisotope 
assessment of barrier dysfunction by Butter et. al. (1991). However, the finding is in 
contradiction to the observations of Reiber and Suckling who, by a determination of 
CSF protein content, found CFA to influence normal barrier function at D5-7PI 
(Reiber et. al., 1984; Suckling et. al., 1984). The disagreement between findings may 
be due to the methods employed as Reiber and Suckling analyse CSF composition 
which is more applicable to the study of blood-CSF barrier function than to BBB 
investigations.
Neurovascular abnormalities in EAE-sensitised rats were not observed prior 
to the onset of neurological deficits in the current study. Similarly, tissue uptake 
studies using large radiolabelled tracers have not demonstrated abnormal BBB 
permeability prior to symptom onset for either albumin (MW 60 OOODa) or dextran 
(MW 60-90 OOODa) (Leibowitz & Kennedy, 1972; Oldendorf & Towner, 1974; Lam, 
1986). However, before development of disease symptoms smaller tracers such as 
mannitol (MW 182Da), DTPA (MW 550Da) and inulin (MW 5500Da) may be 
detected in the CNS compartment at abnormal levels (Oldendorf & Towner, 1974;
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Daniel et. al., 1981; Hawkins et. al., 1991). Whether neurovascular damage could be 
detected by smaller molecules at a pre-disease timepoint during the Lewis model of 
acute EAE was not addressed by the present study.
Interestingly, Traugott, (1989) detected albumin deposits at timepoints prior 
to D9PI in acute EAE, by immunocytochemical analysis of frozen CNS sections. The 
technique enabled small focal areas of protein to be identified which would not have 
influenced an assessment of whole tissue albumin uptake. The importance of small 
protein and immunoglobulin deposits within the CNS prior to disease onset is unclear. 
However, as this coincides with a low grade increase in T cell surveillance of CNS 
tissue, the protein detected may be extravasating together with the penetrating cells 
(Traugott, 1989).
Increased neurovascular permeability was typically observed one day post­
weight loss, concomitant with the onset of neurological deficits. These findings 
support those of Leibowitz (1969) and Leibowitz & Kennedy (1972) in the acute 
guinea pig model, and the MRI analysis by Seeldrayers (1993) in adoptively 
transferred EAE. Analysis of BBB dysfunction by other groups was evaluated by 
severity of disease and not day number PI, obviating direct comparison of barrier 
abnormalities. However, all models of EAE demonstrate elevated protein 
extravasation during the expression of symptoms (Rumjanek et. al., 1984a; Butter et. 
al, 1991; Hawkins et. al., 1991). Indeed, in the present study, neurovascular 
permeability increased as the disease progressed.
An interesting and consistent aspect of the acute EAE profile was the 
continuance of BBB disruption in early recovery for all tissues studied following the 
loss of neurological deficits. Rumjanek et. al. (1984a) also observed barrier 
abnormalities in the brain tissue of convalescent animals. However, other studies 
employing isotopic tracers (Cutler et. al., 1967; Juhler et. al, 1984) and MRI analysis 
(Hawkins et. al., 1991) in acute EAE, failed to demonstrate a continued BBB 
dysfunction. Resolution of disease abnormalities may occur at different rates
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according to inoculum and species employed, accounting for the conflicting reports of 
neurovascular disruption during recovery.
The extent of BBB permeability in different CNS tissues was noted to change 
between acute and recovery stages of EAE. During disease onset the CSp and MP 
displayed markedly greater protein extravasation than the C. However, when analysed 
during early recovery following loss of all neurological deficits the vasculature of the 
C was disrupted to a greater extent than the brainstem and spinal cord regions. 
Interestingly, this profile correlates with the distal development of inflammatory 
lesions (Juhler et. al., 1984; Bolton et. a l, 1984b). Furthermore, Rumjanek et. al. 
(1984a) also observed greater vascular permeability in the spinal cord during onset 
and in the brain during recovery. A predilection for elevated neurovascular 
permeability in spinal cord regions during the acute phase of EAE has been a common 
finding in many tracer studies (Oldendorf & Towner, 1974; Simmons et. al., 1982; 
Butter et. al.y 1991).
The inference from onset and height of disease measurements of protein 
extravasation is that neurovascular abnormalities increase according to disease 
severity (Leibowitz & Kennedy, 1972; Rumjanek et. al.y 1984a; Butter et. al.y 1991). 
However, it is clear from analysis of results in the present investigation that no 
correlation exists between EVBE and neurological score. Once BBB dysfunction is 
triggered, individual animals may express different levels of elevated cerebrovascular 
permeability. Alternatively, the length of time since the loss of neurovascular integrity 
could be linked with increased tracer extravasation. Interestingly, in agreement with 
the earlier correlation between lesion distribution and tissue vascular permeability, 
Hawkins et. al. (1991) found a linear relationship between the number of enhancing 
lesions by Gd-DTPA MRI and the severity of disease. The lack of correlation 
between BBB breakdown and the extent of disease expression is similar to the 
situation observed in MS. Brain imaging techniques have highlighted the disparity 
between symptoms and plaque geography (Tourtellotte et. al.y 1984) demonstrating
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the abundance of clinically silent lesions (Engell 1989). Indeed, actively enhancing 
lesions, indicative of a dysfunctional neurovasculature, may be found at all times in 
the brain of MS patients even during remission and immediately following successful 
treatment (Willoughby et. a l, 1989; Kesselring, 1989).
In summary, a comprehensive assessment of protein extravasation across the 
BBB during the course of EAE has demonstrated a marked increase in permeability 
above normal values during onset, height of disease and recovery phases. Analysis of 
several CNS regions has demonstrated that the extent of neurovascular dysfunction is 








The use of DEX in EAE is well documented (Komarek & Dietrich, 1971; 
Desai & Barten, 1989; Bolton & Flower, 1989), but effects by the steroid on 
neuroantigen-induced BBB dysfunction has not been determined. However, 
glucocorticoid control of neurovascular function has been demonstrated in normal 
mice, experimental non-disease models of cerebro-microvascular abnormalities and 
indicated by reduced enhancing MRI scans following administration to MS patients 
(Hedley-Whyte & Hsu, 1986; Koenig et. al., 1989b; Barkhof et. al., 1991). DEX was 
therefore employed as a standard agent for analysing pharmacological control of 
abnormal BBB function in EAE.
5.1.2 Therapeutic Administration of DEX in the Acute Phase o f  
Disease
To achieve a determination of glucocorticoid function of relevance to the 
therapy of MS, a therapeutic dosing regime was chosen for study. Dosing began on 
the first day of weight loss, approximately DIO PI, and continued for two days. The 
effect of DEX at concentrations between 0.01 and l.Omg/kg body weight on 
development of abnormal neurovascular permeability in the acute phase of EAE was 
studied over the course of three experiments and the results are detailed in Figure 
27a-c. Low dose treatment (O.Olmg/kg body weight) failed to modify neurovascular 
permeability in the CNS tissues studied or to influence the final MNS (Table 5). A 
ten-fold increase in concentration (0.1 mg/kg body weight) produced an improvement 
in barrier function in the CSp, which was complemented by a reduced MNS (p < 
0.05). Increasing the dose to l.Omg/kg body weight completely prevented 
neurovascular dysfunction in all sampled tissues (C, MP p < 0.01; CSp, p < 0.001). A 
lower steroid dose of 0.5mg/kg DEX significantly reduced the microvascular 
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Figure 27: Inhibition of BBB breakdown by DEX Administered During the 
Acute Phase of EAE. DEX was administered twice daily for two days beginning on 
the day of weight loss. BBB dysfunction was measured on the day following the 
conclusion of treatment in (a) cerebellum, (b) medulla-pons and (c) cervical spinal 
cord tissues. The treatment groups were pooled from three experiments. Normal 
animals (black column; n = 9), vehicle-dosed EAE controls (open column; n = 18), 
0.01 mg/kg DEX (diagonal hatch column; n = 5), 0.1 mg/kg DEX (horizontal hatch 
column; n = 11), 0.5mg/kg DEX (vertical hatch column; n = 7) and l.Omg/kg DEX 
(cross hatch column; n = 7). Statistical analysis of individual points used the Mann- 
Whitney U test with Bonferonni correction for multiple comparisons: ** p < 0.01 
compared to vehicle control; *** p <0.001 compared to vehicle control; ♦ no 
significant difference to normal group; # p < 0.05 compared to normal group. The 
reduction seen with DEX at 0.1 mg/kg in the CSp was not significant following 
correction for multiple comparisons. Regression analysis of the log response showed 
a significant linear relationship in all tissues (p = 0.0). Figure (d) illustrates how 
closely the actual data for the CSp aligns with the fitted regression plot (61% fit).
116
different from normal in the CSp (p < 0.05). Both 1.0 and 0.5mg/kg doses 
demonstrated highly significant suppressive effects on the presentation of neurological 
deficits (p < 0.001; Table 5). The dose-dependent restriction of BBB opening by 
DEX was most apparent in the CSp and was reflected in the regression analysis which 
found a significant linear relationship and a 61% fit of data points (Figure 27d).
Histological examination of the CSp from animals treated with 0.1 mg/kg DEX 
showed no significant effect on cellular infiltration (Table 5). However, high dose 
administration (l.Omg/kg DEX) markedly reduced the occurrence of perivascular 
cuffs (p < 0.01), but did not abolish lesion presentation.
Table 5: Summary of Neurological Status , Histological Scores and Plasma 
Corticosterone Levels following DEX Administration in the Acute Phase of EAE
CSp Lesion no. Corticosterone
n MNS ± SD n ±SD n ng/ml ± SD
Normal - - - - 8 41.0 ± 9.7
D13 EAEa 8 1.63 ±1.75 8 117.0 ± 61.0 - -
Vehicle 19 2.76 ±1.08 - - 3 131.0 ± 39.6
O.Olmg/kgDEX 5 2.80 ±1.79 - - - -
0.1 mg/kg DEX 9 1.33 ±1.00* 5 99.6 ±37.0 - -
0.5 mg/kg DEX 7 0.14 ±0.38# - - 6 10.8 ± 1.7
1.0 mg/kg DEX 7 0# 6 8.7 ±5.0* - -
*p<0.05; * p <0. 01; #p  <0.001
a Two days post-weight loss.
MNS was recorded on the day of sampling and results were analysed using ANOVA 
and Dunnett's multiple comparison to a single control. Lesion numbers relate to the 
total number of inflammatory cuffs seen per section of CSp; T-test comparison with 
EAE control. Endogenous corticosterone plasma concentrations analysed by Mann- 
Whitney U demonstrated DEX treatment at 0.5mg/kg to be significantly different 
from vehicle (*) and normal (*) controls.
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The endogenous corticosterone level in animals dosed with 0.5mg/kg body 
weight DEX was significantly reduced from vehicle control and normal baseline 
concentrations (p < 0.05 and 0.01 respectively), suggesting a typical negative 
feedback response (Table 5).
The doses of DEX used in the study did not affect body weight profiles during 
the dosing period (Figure 28a). Previous work had shown that a dose of lOmg/kg 
body weight DEX, given from D6 PI to D8 PI, initiated a dramatic weight loss in 
EAE-sensitised animals at a time when weight gain is typical (Figure 28b). No 
enhancement of weight loss above that normal for the progression of EAE in the 
acute phase was experienced at the highest dose of l.Omg/kg body weight.
Calculation of the mean percentage weight loss showed no significant difference 
between vehicle and drug treatments with the exception of the O.Olmg/kg group. 
However, this dose was ineffective in improving aspects of EAE and as significant 
weight loss was not experienced at higher concentrations of DEX no adverse drug 
effect was suspected.
5.1.2 Administration o f DEX during the Early Recovery Phase 
o f Disease
The initial study of BBB breakdown during EAE highlighted the continued 
neurovascular dysfunction during the early recovery phase. An investigation was 
undertaken to determine the effect of DEX on the continuing BBB disruption of the 
recovery phase, in the absence of symptoms.
The results in Figure 29 demonstrate an enhanced BBB permeability to 
radiolabelled protein in vehicle controls confirming previous observations in early 
recovery. A dose of O.Olmg/kg body weight DEX had no corrective effect on 
neurovascular function, which was comparable to the effect during the acute phase. 
Administration of 0. lmg/kg body weight DEX had shown a minor effect on the CSp 



























7 81 0 1 2 3 4 5 6 9
Days P.l.
(C) Vehicle15 0.01c 0.10 0.50 1.00
% Change in Body Weight3 5.9 9.7* 8.6 7.9 5.5
SD 2.3 2.1 2.7 2.0 2.1
n 7 5 6 7 7
a : % Body weight loss incurred between peak weight prior to symptom onset and the day of 
sampling
b : The vehicle treatment group was taken from the same experiment as 0.5mg/kg DEX and is 
representative of other vehicle treatment groups
c : Individual treatments include animals receiving a single batch of inoculum
Figure  28: Comparison of Weight Profiles and % Weight Loss in DEX and 
Vehicle Treated animals. Graph (a) shows the weight profiles of lmg/kg DEX and vehicle 
treated EAE-sensitised animals. Treatment began on the day of weight loss (arrow) and 
continued for two days dosing twice daily. Sampling (0) occurred on the day following the end 
of treatment. Graph (b) shows the weight profiles of lOmg/kg DEX and vehicle treated EAE- 
sensitised animals compared to normals. Dosing was for two days dosing twice daily 
beginning on D6 P I (arrow) with sampling on D8 PI. Table (c) compares % change in weight 
between groups dosed from weight loss twice daily for two days within the range 0.01 to 
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Figure 29\ The Effect of DEX on Abnormal BBB Function during Early Recovery in 
the Acute Model of EAE. The results are compiled from two experiments and show profiles 
in (a) cerebellum, (b) medulla-pons and (c) cervical spinal cord tissues. Animals had shown a 
minimum neurological score of 2 during the acute phase of disease. Following the 
disappearance of signs and two consecutive days of weight gain the drug was administered 
twice daily for two days, sampling on the day following the final injection. Normals (black 
column; n = 6), vehicle control (open column; n = 8), O.Olmg/kg DEX (diagonal hatch 
column; n = 4), 0. lmg/kg DEX (vertical hatch column; n = 9) and 0.5mg/kg DEX (cross 
hatch column; n = 5). Significant differences to vehicle controls were determined by Mann- 
Whitney U with Bonferroni correction; * p< 0.01, ** p< 0.01. Regression of the log response 
against dose was significant in the C only (p = 0.0; MP, p = 0.12; CSp, p = 0.07).
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BBB function in the C of EAE animals was demonstrated (p < 0.01). DEX at a dose 
of 0.5mg/kg body weight lowered the EVBE score in the MP and CSp and 
significantly in the C (p < 0.05). This is in contrast to the therapeutic effect of a 
0.5mg/kg dose, which was highly significant in all tissues. A linear dose response was 
only shown in the C region of the CNS (regression; p = 0.0 , 47% fit).
The sensitivity of BBB function to glucocorticoid control appears to vary 
between acute and early recovery phases of EAE. These results suggest that different 
mechanisms may be responsible for the abnormal extravasation of protein during the 
recovery stage of disease in the Lewis rat.
5.1.3 Reversal o f DEX Control by Administration o f the Steroid 
Antagonist R U 38486
To demonstrate that DEX was mediating an effect on BBB permeability 
through binding to the type II glucocorticoid receptor, two experiments were 
conducted using the steroid antagonist RU38486. Dosing of the antagonist was twice 
daily to obtain maximum efficacy (Bolton & Flower, 1989).
The glucocorticoid receptor antagonist was unable to significantly counteract 
the suppressive effect of 0.5mg/kg DEX on BBB permeability in any tissue when used 
at 20mg/kg, although the mean EVBE was raised in all tissue profiles (Figure 30). 
Furthermore, the neurological condition remained the same as DEX/vehicle controls 
(Table 6). Increasing the concentration of RU 38486 to 40mg/kg body weight, caused 
a significant reversal of the inhibitory effect of DEX on BBB dysfunction in all tissues 
(p < 0.01) and was within the vehicle/vehicle range of EVBE values. The 
neurological deficits of the 40mg/kg RU 38486 plus DEX group were also elevated, 
but no significant difference was demonstrated from the DEX/vehicle control, 
indicating that abolition of the DEX effect may not have been complete. Further 
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Figure 30: Effect of the Glucocorticoid Antagonist RU38486 on the Control 
of BBB permeability by DEX. RU38486 was employed at doses of 20 and 40 mg/kg to 
prevent the DEX-mediated suppression of abnormal BBB permeability to protein. The 
histogram combines the results of two experiments detailing three CNS areas (a) cerebellum, 
(b) medulla-pons and (c) cervical spinal cord from: normal (black column, n = 9); vehicle / 
vehicle (open column, n = 12); 20mg/kg RU38486 / vehicle (horizontal hatch column, n = 6); 
40mg/kg RU38486 / vehicle (vertical hatch column, n =6); vehicle / 0.5mg/kg DEX (cross 
hatch column, n = 12); 20mg/kg RU38486 / 0.5mg/kg DEX (left-hand diagonal hatch column, 
n = 6); and 40mg/kg RU38486 / 0.5mg/kg DEX (right-hand diagonal hatch column, n = 6). # 
no significant difference from vehicle / vehicle, ** p < 0.01 significantly different from DEX / 
vehicle; Mann-Whitney U with Bonferroni correction for multiple comparisons. Log responses 
demonstrated significant linear regression against RU38486 concentration; C, p = 0.005, MP 





all tissues with 30, 56 and 56% of response variation being attributed solely to dose in 
C, MP and CSp tissues respectively.
Examination of the effects ofRU 38486 administered in the absence of DEX, 
did not demonstrate significant variation in barrier dysfunction from the EAE vehicle 
control (Figure 30). Neither did the compound cause significant alteration of disease 
symptoms (Table 6).
Table 6: Antagonism of DEX-mediated Suppression of EAE by RU38486: 
Summary of Neurological Status and Weight Loss
Group_________________ n____ MNS ± SD____ %WeightLoss ± SD#
Vehicle / Vehicle 12 1.79 ±1.54* 8.32 ±2.85
RU 20mg/kg / Vehicle 6 2.33 ± 1.97* 8.32 ±3.37
RU 40mg/kg / Vehicle 6 1.67 ±1.47* 7.68 ± 4.66
Vehicle / DEX 0.5mg/kg 12 0.04 ± 0.14* 10.83 ±4.60
RU 20mg/kg / DEX 0.5mg/kg 6 0* 8.73 ±2.34
RU 40mg/kg / DEX 0.5mg/kg 6 0.75 ± 0.88 8.78 ± 1.02
The experimental observations made in the table complement the EVBE results
shown in Figure 30. MNS represent symptoms of disease recorded on D12PI when 
sampled and were analysed by Dunnett's test post-ANOVA: * p < 0.05 significantly 
different to vehicle/DEX treatment; * p < 0.05 significantly different to




The findings presented clearly demonstrate a dose-related suppression of 
abnormal neurovascular function by DEX during EAE. Furthermore, the dose- 
dependent inhibition of clinical signs and reduction of histological lesions previously 
shown in EAE following prophylactic dosing regimes for DEX (Komarek & Dietrich, 
1971; Desai & Barten, 1989; Bolton & Flower, 1989), has now been confirmed for 
short-term therapeutic administration.
Glucocorticoids readily penetrate the neurovasculature and may therefore 
reach and modify both the components comprising the BBB and the inflammatory 
cells within CNS lesions (Pardridge & Mietus, 1979). Previous studies of 
neurovascular integrity in healthy rats and mice demonstrated the ability of DEX to 
reduce permeability below normal levels for a range of circulating tracers (Hedley- 
Whyte & Hsu, 1986; Ziylan et. al., 1988). Moreover, a loss of neurovascular control 
is experienced following removal of endogenous glucocorticoids by adrenalectomy, 
which may be overcome by administration of DEX (Long & Holaday, 1985). A role 
for both endogenous and exogenously applied glucocorticoids in the maintenance of 
an intact neuroendothelium is therefore indicated.
A number of models of experimentally-induced brain edema have reported 
successful resolution of abnormal CNS water accumulation and barrier function 
following steroid administration (Pappius, 1972; Herrman et. al., 1972; Koeing et. al., 
1989b). The results reported here now extend the observations of glucocorticoid 
action at the BBB to acute EAE. Furthermore, the findings are in agreement with 
reports of resolving enhancing lesions following steroid treatment of MS ( Sears et. 
al. ,1978 ; Troiano et. al. ,1987 ; Barkhof et. al. ,1991 ; Miller et. al. ,1992).
Particularly interesting was the observation that DEX did not apparently 
restore normal barrier function to the same extent when administered during the 
recovery phase. In the acute stage of disease DEX had successfully normalised barrier
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function, particularly in the MP and CSp regions, whereas significant restoration of 
neurovascular integrity was only achieved in the C during early recovery. The 
histological profile of lesions shown by Bolton et. al (1984b) corresponds to the 
tissue and time distribution noted here for the development of BBB permeability. 
Control of an inflammatory cell component may therefore be pivotal to the correction 
of barrier abnormality by DEX. Alternatively, the mechanisms causing neurovascular 
dysfunction during disease expression may differ from those mediating BBB 
perturbation during convalescence. Consideration of the endogenous steroid profile of 
untreated EAE-sensitised rats, shows that corticosterone levels increase gradually 
during the onset of neurological deficits, peaking at the height of disease (Mackenzie 
et. al., 1989; MacPhee et. al., 1989).While the peak in endogenous steroid production 
is considered to initiate a clinical recovery, it is now clear that the elevated 
corticosterone levels are insufficient to restore normal BBB function within 5-8 days 
of maximum output. Therefore, a glucocorticoid-insensitive neurovascular 
permeability may be implicated for the later stages of EAE disease.
DEX primarily acts through the intracytoplasmic type II glucocorticoid 
receptor although some affinity towards the mineralcorticoid receptor, type I, has 
been noted. The steroid-receptor complex translocates to nuclear binding sites where 
gene transcription is either up- or down-regulated, often interacting with other 
signalling pathways. The type II receptor is located throughout the rat CNS, but is 
absent from the circumventricular organs (Ahima et. al, 1992). Most glia express the 
glucocorticoid receptor (Ahima et. al, 1992; Jung-Testas et. al., 1992) including the 
astrocyte, which influences the integrity of the BBB endothelium. Furthermore, DEX 
has been implicated in the control of cellular protein synthesis within the vascular 
endothelium during global ischaemia (Tosaki, 1985).
The anti-glucocorticoid RU38486 binds to the type II glucocorticoid receptor 
with a greater affinity than DEX, thereby antagonising steroid activity (Kawai et. al., 
1989). Administration of RU38486 in the present study was observed to dose-
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dependently reverse the control over abnormal barrier opening imposed by short-term 
therapeutic dosing of DEX during acute EAE. Therefore, a type II receptor-steroid 
interaction, potentially involving control of gene transcription, is suggested for the 
action of DEX on BBB function during EAE. The concentration of RU38486 
employed was greater than that used by Bolton & Flower (1989) to abrogate 
glucocorticoid effects during EAE. However, the previous study did not analyse 
short-term therapeutic treatment or the control of BBB function. Also, the current 
work has demonstrated that a higher steroid dose is required to significantly effect 
neuro-endothelial integrity than is needed to reduce neurological deficits.
The site and mechanism of action of DEX in the control of neurovascular 
permeability is unclear. DEX has multiple actions and the method of regulating 
endothelial cell permeability at the BBB may differ between normal and pathological 
conditions. Furthermore, the cause of aberrant neurovascular function may dictate the 
routes by which DEX may exert an effect. Two main areas of possible steroid action 
can be considered when manipulating barrier function in EAE. Firstly, suppression of 
immune system activation and regulation of neurovascular perturbator synthesis by 
immune cells may result in the indirect control of barrier function. Secondly, DEX is 
able to control BBB permeability under both normal and non-immune mediated 
pathological conditions suggesting a regulatory role directed at the cells comprising 
the BBB. The location of neurovascular action may be directly at the vascular 
endothelial cell (Cronstein et. al, 1992)) or on cells in close regulatory contact such 
as the astrocyte or pericyte (Jung-Testas et. al., 1992). In vitro DEX has been shown 
to inhibit astrocyte-influenced microvessel morphogenesis, an action blocked by the 
glucocorticoid antagonist cortexolone, but not to exert an effect on non-astrocyte 
induced capillary-like formation (Wolff et. al, 1992).
The anti-inflammatory capabilities of glucocorticoids are well recognised. 
Redistribution of inflammatory cells and edematous material away from inflammatory 
sites clearly reduces the damage to tissue and reduces clinical symptoms as a
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consequence (Long et. al., 1972; Reulen et. al., 1972; Guseso & Jellinger, 1975; 
Barkhof et. al., 1991). While in EAE such actions may account for the improvement 
in neurological deficit seen, they do not directly explain the restoration of BBB 
function. The actions of DEX which may indirectly influence neuroendothelial 
permeability will be considered first, with subsequent discussion of steroid effects 
directly at the BBB.
Glucocorticoid suppression of the T cell response is an important feature in 
the prevention of cell-mediated disease such as EAE (Serrano et. al., 1993).
However, while immunosuppression of lymphocyte activation is a major component 
of prophylactic treatment (Desai & Barten, 1989; Bolton & Flower, 1989), 
modulation of cytokine and vasoactive compound production will be of greater 
significance during therapy. The variety of prophylactic regimes for DEX, explored by 
Bolton & Flower (1989), indicated that the drug was most effective when 
administered from D7-11PI and not D0-4PI. Therefore, an important role in 
controlling inflammatory and vasoactive mediator synthesis is suggested for DEX. 
Inhibition of cytokine transcription by steroids has been demonstrated for IL 1, 2, 3 
and 6, TNF and IFNy (Arya et. al. ,1984; Reed et. al. ,1986; Culpepper et. al., 1985; 
Helfgott et. al., 1987; Lew et. al., 1988; Lee et. al, 1988; Waage & Bakke, 1988). 
Immunocytochemical techniques have demonstrated elevated levels of TNFa, IL-1, 
IL-2, IL-3 and IFNy in CNS inflammatory sites during chronic-relapsing EAE (Baker 
et. al, 1991). Furthermore, administration of IL-1 to EAE-sensitised Lewis rats was 
demonstrated to exacerbate both the severity and duration of disease (Jacobs et. al., 
1991). Similarly, analysis of MS brain lesions has identified increased expression of 
IL-1, IL-2 (Hofrnan et. al., 1986) and TNF-a (Cannella & Raine, 1995). The 
monokines IL-1 and TNF are of particular interest as both have demonstrated 
vascular permeability inducing properties on endothelial cell lines (Brett et. al., 1989; 
Royall et. al. ,1989). Furthermore, the elevated expression of lymphocyte adhesion 
molecules in the CNS of EAE animals (Wilcox et. al, 1990; Barten & Ruddle, 1994;
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O'Neill et al, 1991) can be demonstrated by addition of IL-1, TNF and IFNy to 
endothelial cells in vitro (Dustin et al., 1986; Pober et al, 1986; Hughes et al, 
1988; Carlos et al, 1990). Moreover, in a study ofMS patients a correlation 
between BBB damage and circulating levels of intercellular adhesion molecule-1 and 
TNFa were found (Sharief et al, 1993). A restriction of inflammatory cytokine 
production by glucocorticoids could therefore limit both barrier breakdown and 
lymphocyte trafficking.
The potent vasoactive nitrogen intermediate nitric oxide (NO) appears to 
increase blood flow and plasma exudation at inflammatory sites. Indeed, elevated 
levels of nitrite have been detected during the onset and progression of EAE (Bolton 
et al., 1994; Scott et. al, 1994). Moreover, administration of NO-releasing 
compounds has been demonstrated to alter BBB permeability in the normal rat brain 
(Shukla et al, 1996). Macrophages produce large quantities of inducible NO 
synthase when activated and following recruitment during EAE into perivascular 
inflammatory sites, are ideally located to influence BBB function through excess NO 
production. Furthermore, the macrophage inducible NO synthase is potently inhibited 
by steroids, indicating a potential action for DEX in maintaining barrier function 
during EAE (Radomski et. al, 1990). In addition to the production of NO by 
inflammatory cells, the neuroendothelium also has the potential to release the 
mediator in response to cytokine stimulation (Durieu-Trautmann et. al, 1993). 
Indeed, glucocorticoids have also been shown to reduce NO production and suppress 
associated cytotoxic effects when added to endothelial cell cultures (Radomski et. al, 
1990; Palmer et al, 1992).
Control of vasoactive amine release by mast cells is another putative site for 
steroid suppression of neurovascular dysfunction during EAE. Indeed, glucocorticoid 
administration has been demonstrated to inhibit histamine release from rodent mast 
cells (Fahey et al, 1981; Daeron et. al, 1982). Orr & Stanley (1989) demonstrated 
elevation of histamine concentration in the CNS tissues of EAE-sensitised Lewis rats
128
at D11 and D13PI. Furthermore, the percentage of degranulated mast cells has been 
shown to be significantly increased in EAE brains beginning concomitant with the 
onset of symptoms at D10PI and peaking at D16PI (Bo et. al, 1991). In non-disease 
models elevated endogenous histamine has also been implicated in the loss of BBB 
integrity following heat stress, where pretreatment with the histamine Hj receptor 
antagonist cimetidine inhibited neurovascular perturbation (Sharma et. al., 1992). In 
addition, exogenous histamine administered by the carotid artery was found to 
increase pinocytotic vesicle activity and albumin extravasation at brain capillary sites, 
through receptor interaction (Dux & Joo, 1982), findings typical of EAE BBB 
pathology (Claudio et. al., 1989; Leibowitz & Kennedy, 1972).
A potential BBB permeabilising action of histamine or indeed cytokine release 
is the induction of arachidonic acid metabolism at the neuroendothelium through 
increasing phospholipase activity (Blackwell et. al., 1978). Ohnishi et. al. (1992) 
clearly demonstrated that arachidonic acid could initiate neuro-endothelial dysfunction 
in normal rats. Furthermore, the study indicated a role for DEX in the control of 
barrier permeability through suppression of the de novo protein synthesis of 
vasoactive metabolites. Endogenous steroid levels are normally sufficient to moderate 
prostaglandin synthesis as adrenalectomy causes increased levels of arachidonic acid 
metabolites in carrageenin pleurisy (Flower et. al., 1986). Elevated concentrations of 
permeability inducing leukotrienes and prostaglandins have been reported during 
disease onset in acute EAE and in the CSF of MS patients (Bolton et. al., 1984a,b,c; 
Neu et. al., 1988). Glucocorticoid suppression of phospholipase is well 
documented (Blackwell et. al., 1978; Russo-Marie et. al., 1979; Hirata et. al., 1980) 
and control of EAE with inhibitors of arachidonic acid metabolism is widely reported 
(Prosiegel et. al., 1989; Fretland et. al., 1991). However, Weber et. al. (1991) found 
that the cyclooxygenase inhibitor piroxicam was only effective in EAE 
prophylactically, with therapeutic administration being highly detrimental. The late 
blocking of the cyclooxygenase arm of arachidonic acid metabolism may therefore be
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ineffective. Indeed, prostaglandins PGE and PGF2o are reduced in the CSF of MS 
patients during a relapse (Bolton et. al., 1984c). Moreover, if eicosanoid production 
varies during the course of autoimmune disease it may indicate why the ability of 
DEX to control neurovascular permeability also alters in acute and recovery stages.
The neurovascular protective actions suggested for glucocorticoids above, 
may be linked to immune cell actions. However, the neurovasculature has the ability 
to synthesise both NO and eicosanoids independent of an immunological stimulus 
(Joo, 1985; Radomski et. al., 1990)) and histamine damage of BBB function has been 
recorded in a non-immune model (Sharma et. al., 1992).
Whether induced by immune-derived mediators or vasoactive compounds, the 
resultant abnormal mechanisms leading to neurovascular disruption must focus at the 
level of the BBB. Analysis of abnormal barrier activity in non-immune models has 
provided a candidate pathway which may be controlled by glucocorticoid 
administration. Studies in hyperosmolar and cold injury induced models of BBB 
breakdown report increased activity of the enzyme ornithine decarboxylase (ODC) 
and elevated polyamine(PA) end products, concomitant with CNS microvascular 
permeability elevation (Koenig et. al., 1989a; Koenig et. al., 1989b). Furthermore, 
increased PA levels have been detected in the brains of EAE animals displaying 
neurological deficits (Bolton et. al, 1994; and unpublished observations). 
Administration of DEX at the time of cold injury inhibited both enhanced ODC 
activity and PA concentration concurrent with an attenuation of BBB dysfunction 
(Koenig et. al, 1989b). The mechanism of action proposed for DEX by Koenig and 
co-workers was through the suppression of arachidonic acid release which precedes 
ODC increases in the cold-injured brain. However, the molecular mechanisms 
underlying the two events remain to be clarified. Interestingly, while large steroid 
doses successfully abolish abnormal levels of arachidonic acid (Politi et. al., 1985; De 
Kloet et. al., 1983), low concentrations reportedly enhance ODC levels in normal or 
adrenalectomised rats (Ikeno et. al, 1978) and fail to inhibit acute release of
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arachidonic acid in cryoinjured brain (Pappius & Wolff, 1983). The effect noted with 
the lower doses of administered glucocorticoid may be indicative of normal 
homeostatic control of ODC activity by endogenous steroids (Meyer, 1985). Indeed, 
ODC control appears to closely correlate with steroid affinity for brain glucocorticoid 
receptors (Cousin et. al, 1982).
The present work has shown that therapeutic administration of DEX dose- 
dependently suppresses BBB opening during the acute phase of EAE and restricts 
BBB permeability during recovery. The action of the steroid primarily involves 
binding to the type II glucocorticoid receptor. While the mechanism of control of 
neurovascular permeability in EAE by therapeutically administered DEX remains to 
be defined, the ODC cascade has been recognised as a key neuroendothelial target.
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6.
Modulation of BBB Dysfunction by 
Immunosuppressive Agents 
Cyclosporin A and FK506
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6.1 Results
6.1.1 Therapeutic Administration o f CSA in the Acute Phase o f 
Disease
Therapeutically administered CSA has been reported to reduce the severity 
and incidence of symptoms and decrease the number of CNS inflammatory lesions 
that develop during EAE (Bolton et. al., 1982; Rumjanek et. al., 1984b). Whether the 
drug works in part through actions at the BBB has not been investigated and no study 
of the modulatory effect of therapeutic CSA on neurovascular permeability has been 
reported.
Experiments were conducted to evaluate the efficacy of a range of CSA doses 
to control the abnormal neurovasculature function during an acute episode of EAE. 
Doses ranged from 25 to 75mg/kg body weight and were administered in a short-term 
therapeutic regime starting on the day of weight loss.
The results show CSA dose-dependently restricts the irregular BBB opening 
associated with acute EAE (Figure 3 la-c). Low doses of 25 and 35mg/kg body 
weight CSA did not alter neurovascular permeability. However, the 35 mg/kg dose of 
CSA did significantly reduce the MNS for the treatment group. Increasing the 
concentration of immunosuppressant to 50mg/kg body weight was sufficient to lower 
the EVBE value in the C and to significantly limit neurovascular dysfunction in the 
MP and CSp tissues (p < 0.01 and p < 0.001 respectively). A marked reduction in 
MNS was also observed (Table 7). A further increase in dose to 75mg/kg CSA 
achieved significant inhibition of BBB breakdown in all tissues including the C (p < 
0.001), but the improvement from the 50mg/kg dose was unremarkable and barrier 
permeability remained significantly different to normal control values (Figure 31). 
Analysis of CSA log response data showed a significant linear regression in all tissues 
(C, p = 0.002, 21% fit; MP, p = 0.0, 46% fit; CSp, p = 0.0, 62% fit).
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Figure 31: Inhibition of BBB breakdown by CSA Administered During the 
Acute Phase of EAE. CSA was administered at doses of 25 (n = 5), 35 (n = 6), 50 (n = 7) 
and 75 (n = 6) mg/kg body weight, alongside normal (n = 15) and vehicle (n = 21) controls. 
Dosing was once daily for two days starting on the day of weight loss. The graphs show BBB 
dysfunction in the (a) cerebellum, (b) medulla-pons and (c) cervical spinal cord. Analysis of 
key doses was by Mann-Whitney U test with Bonferroni correction where required; ** p < 
0.01 and *** p < 0.001 compared to vehicle control. The 75mg/kg dose was found to be 
significantly different from normal in all CNS areas, C p = 0.036, MP p = 0.028 and CSp p = 
0.005; Mann-Whitney U. Analysis of the log data showed a significant linear regression in all 




The effect of CSA on lesion formation in the CSp was analysed at two 
concentrations. Low dose treatment with 25mg/kg CSA did not affect the 
accumulation of perivascular infiltrates. However, high dose CSA (50mg/kg) 
significantly reduced lesion formation in the CSp compared to the untreated EAE 
controls (p < 0.05). Complete suppression of cellular inflammation was not achieved.
Table 7: Summary of Neurological Status, Histological Scores and Plasma 
Corticosterone Levels following CSA Administration in the Acute Phase of EAE




Normal - - - - 5 76.8 ± 18.9
D13PIEAE 8 1.63 ± 1.75 8 117.0 ± 61.0 - -
Vehicle 21 1.7 ±1.0 - - 5 179.2 ± 64.0
25 mg/kg CSA 5 1.2 ±1.6 5 148.4 ±56.1 - -
35 mg/kg CSA 6 0.2 ±0.4* - - - -
50 mg/kg CSA 7 0.2 ± 0.4* 5 50.8 ±20.1# 7 110.9 ±48.2
75 mg/kg CSA 6 0* - - - -
Experimental groups match those described in Figure 31. CSA was dosed once daily 
for two days starting on the day of weight loss and concluding on the day prior to 
sampling. MNS were recorded on the day of sampling and analysed by Dunnett's test 
following ANOVA; * p < 0.01 compared to vehicle control. Histology values 
represent the number of lesions seen per whole section of tissue; # p < 0.05, T-test 
compared to control. No significant difference between drug and vehicle groups was 
demonstrated for the corticosterone data; Mann-Whitney U.
In order to exclude the possibility of CSA administration modifying aspects of 
disease, including barrier function, through elevation of endogenous steroid 
production, plasma samples from experimental groups were analysed to determine 
corticosterone levels. Results showed no significant difference between the amounts
135
of corticosterone measured in 50mg/kg body weight drug treatment and vehicle 
control groups (Table 7).
An elevated plasma creatinine concentration is a characteristic feature of renal 
dysfunction, a potential side effect of CSA treatment (Schulman et. al., 1981; 
Mihattsch et. al., 1988). Therefore, to assess the tolerance of the rats to the short­
term therapeutic regime the plasma creatinine level and body weight profile of treated 
animals were analysed. A study of plasma from EAE-sensitised animals dosed with 35 
and 75mg/kg CSA did not show significant elevation of creatinine levels above 
normal and vehicle control values (Figure 32). Furthermore, the data obtained was 
within the normal concentration range for plasma creatinine of 0.4-3.7mg/dL for rats 
(Clinical Biochemistry of Domestic Animals, 1989). Figure 32 shows that the body 
weight profile of animals receiving 50mg/kg body weight CSA compared closely to 
the vehicle dosed control group. Further analysis of the change in body weight over 
the period of dosing found no difference in weight loss between any of the treatment 
groups under study. Therefore, CSA doses administered therapeutically appear to 
have been well tolerated.
6.1.2 Administration of CSA during the Early Recovery Phase 
of Disease
The sensitivity of BBB function to control by DEX appeared to vary between 
acute and early recovery phases of EAE. Therefore, a study was undertaken to 
determine whether the efficacy of CSA action at the neurovasculature also altered 
between acute and recovery timepoints. Administration of CSA at 25 and 50mg/kg 
began after the loss of neurological deficits using groups of EAE-sensitised animals 
which had displayed severe signs of disease during the acute phase.
EVBE calculations of barrier permeability to protein show a marked 
improvement in all tissues with the administration of 25mg/kg CSA (Figure 33). Low 
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n [Creatinine] mg/di
Normal - - 6 0.335 ±0.074
Vehicle 21b 9.5 ±3.0 10c 0.341 ±0.114
25 mg/kg CSA 5 7.5 ±3.8 - -
35 mg/kg CSA 6 8.0 ±2.8 5 0.388 ±0.062
50 mg/kg CSA 7 8.7 ±3.3 - -
75 mg/kg CSA 6 5.5 ±2.6 6 0.384 ±0.128
a : Percentage change in body weight between peak weight prior to disease onset and 
the day of sampling.
b : Combined vehicle results from four experiments 
c : Combined vehicle results from two experiments
Figure 32: Analysis of Body Weight Changes and Plasma Creatinine 
Concentration in CSA Treated EAE-sensitised Animals, (a) Weight profiles of 
rats treated with 50mg/kg CSA (— ■— n = 7) and vehicle-dosed controls (— • — n 
= 6). Treatment was initiated at weight loss (arrow) and continued for two days, (b) 
Percentage body weight change over treatment period for all CSA doses plus plasma 
creatinine concentrations from control and 35 and 75mg/kg dosed animals. ANOVA 
of both % weight change and plasma creatinine concentration found no differences 
between groups.
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Figure 33: The Effect of CSA on Abnormal BBB Function during Early 
Recovery in Acute EAE. CSA was administered at 25 or 50mg/kg body weight for two 
days beginning after the loss of disease symptoms and two consecutive days of weight gain. 
Animals had shown a minimum neurological score of 3 during the acute phase. The 
histograms show pooled data from two experiments for (a) cerebellum, (b) medulla-pons and 
(c) cervical spinal cord tissues, where: normals (black column, n = 5), vehicle controls (open 
column, n = 8), 25mg/kg CSA ( horizontal hatch column, n = 4) and 50mg/kg CSA (cross 
hatch column, n = 5). Mann-Whitney U analysis of data: * p < 0.05 compared to vehicle and 
# no significant difference to normal. Analysis of the log data showed a significant linear 
regression in all tissues (C, p = 0.0, 68% fit; MP, p = 0.0, 62% fit; CSp, p = 0.0, 66% fit).
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phase of disease but significantly lowered BBB permeability in C and CSp tissues (p < 
0.05) during recovery. Administration of CSA at 50mg/kg did not normalise barrier 
permeability in acute disease, but reduced EVBE values to normal levels when given 
during the early recovery phase (C, p = 0.403; MP, p = 0.296; CSp, p = 0.295). The 
linear regression of log response against drug concentration was significant with a 
>60% fit in all tissues. An increase in neurovascular sensitivity to administered CSA is 
therefore indicated during early recovery in EAE.
6.1.3 Therapeutic Administration ofFK506 in the Acute Phase 
o f Disease
The novel macrolide FK506 has a suppressive action in both active and 
adoptively transferred EAE (Deguchi et. al., 1991; Bolton, 1992). In addition, FK506 
is approximately 100-fold more effective than CSA at inhibiting passive transfer of 
neuroantigen-induced disease (Bolton, 1992). Therefore, it was of interest to discover 
whether FK506 could inhibit abnormal neurovascular function to an equal or greater 
degree than CSA.
EVBE values show no reduction in abnormal barrier extravasation of protein 
for the 5mg/kg FK506 oral preparation (Figure 34a). Indeed, a significant increase 
above the mean EVBE value for the vehicle group was found in the CSp tissue (p < 
0.05). Neurological symptoms were not suppressed.
An increase to lOmg/kg body weight FK506 administered i.p., dramatically 
improved the ability of FK506 to restrict BBB opening in the acute phase of EAE 
(Figure 34b). The dose significantly reduced barrier abnormalities in the MP and CSp 
tissues (p <0.05) maintaining the mean EVBE within normal limits. The experiment 
was unusual in that no elevation in BBB permeability was noted in the C. However, 
the neurovascular opening in MP and CSp tissues attained levels of dysfunction 
typical for acute EAE and a significant drug effect could be demonstrated for these 
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Figure 34: Inhibition of BBB breakdown by FK506 Administered During the 
Acute Phase of EAE. The effect of FK506 on BBB permeability in C, MP and CSp 
tissues was studied over the course of two experiments. Graph (a) FK506 
administered at 5mg/kg as an oral suspension in PBS (diagonal hatch column, n = 6) 
and compared to normal (black column, n = 4) and vehicle (open column, n = 7) 
controls. Graph (b) FK506 administered at lOmg/kg i.p. dissolved in PBS with 10% 
ethanol and 2% Tween (cross hatch column, n = 7) and compared to normal (black 
column, n = 6) and vehicle (open column, n = 5) controls. Dosing was once daily for 
two days starting at weight loss. Statistical analysis showed differences of * p < 0.05 
between drug and vehicle groups and # no significant difference between drug and 
normal groups; Mann-Whitney U test.
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preventing a reduction in symptoms from being seen in the drug treated animals 
(Table 8). However, histological assessment of CNS lesions did show a marked 
inhibition of inflammatory infiltrates following FK506 administration (Table 8). 
Furthermore, plasma corticosterone was not elevated in the drug-treated group, 
eliminating the possibility of FK506 administration suppressing EAE development 
through upregulation of endogenous steroids (Table 8).
Analysis of the body weight profile of EAE-sensitised animals receiving 
lOmg/kg FK506 did not show extensive weight loss during treatment compared to the 
vehicle-treated EAE rats (Figure 35). The maximum dose of FK506 employed 
therefore seemed well tolerated.
Table 8: Summary of Neurological Status, Histological Scores and Plasma 
Corticosterone Levels following FK506 Administration in the Acute Phase of 
EAE
n MNS ± 
SDC




Normal - - - - 3 63.0 ±41.7
D13PIEAE 8 1.6 ±1.8 8 117.0 ± 61.0 - -
Vehicle4 7 1.1 ±1.5 - - - -
5 mg/kg FKa 6 2.1 ±1.9 - - - -
Vehicle1* 5 0.5 ±0.5 - - 3 94.7 ± 34.3
10 mg/kg FKb 7 0.1 ±0.2 2 2.5 ±2.1 5 59.2 ± 13.8
"• b : Denote groups from same experiment
c : MNS observed on the day of sampling. No significant difference between vehicle 
and drug groups was shown by Mann-Whitney U assessment. 
d : Lesion numbers reflect the number of inflammatory cuffs seen in a whole CSp 
section.
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n 7 6 5 7
* b : Denote groups from same experiment
c : % weight change between pre-disease weight and that measured on the day of 
sampling
Figure 35: Analysis of Body Weight Changes in FK506 Treated EAE- 
sensitised Animals, (a) Weight profiles of rats treated with 10mg/kg FK506 (— ■—•, 
n = 7) and vehicle-dosed controls (— • — n = 5). Treatment was initiated on the day 
of weight loss (arrow) and continued for two days, (b) Percentage body weight 
change during treatment. No differences between vehicle and drug groups were 
shown; T-test.
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6.1.4 Administration of FK506 during the Early Recovery Phase 
o f Disease
The efficacy of lOmg/kg FK506 was investigated in the recovery phase of 
EAE where the neurovascular abnormalities are continued in the absence of disease 
symptoms. The animals studied had displayed severe neurological symptoms during 
the acute phase of disease.
Figure 36 describes BBB dysfunction in the experimental groups. Dosing with 
FK506 at lOmg/kg demonstrated a correction of barrier function in C and CSp tissues 
equal to that seen during treatment in the acute phase (p < 0.05). Neither the MP or 
the CSp were determined to be significantly different from normal values. However, 
a single value greater than 1.2 EVBE prevented significant inhibition of neurovascular 
permeability from being attained in the MP when compared to vehicle control values. 
Therefore, the results suggest a similar correction of neurovascular abnormalities by 
FK506 atlOmg/kg in both the acute and recovery stages of disease.
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Figure 36: The Effect of FK506 (lOmg/kg body weight) on Abnormal BBB 
Function during Early Recovery in Acute EAE. FK506 was administered at 
lOmg/kg body weight for two days beginning after the loss of symptoms and two 
consecutive days of weight gain. Animals had shown a minimum neurological score of 
2.5 during the acute phase. The graphs show the normal (black column, n = 4), 
vehicle (open column, n = 5), and lOmg/kg FK506 (vertical hatch column, n = 6) 
results in (a) cerebellum, (b) medulla-pons and (c) cervical spinal cord tissues. Mann- 
Whitney U analysis of data showed, * p < 0.05 compared to vehicle and # no 




CSA administered by short-term therapy demonstrated a significant 
suppression of BBB abnormalities, neurological symptoms and histologically 
recognised lesions, during the acute phase of EAE. Interestingly, administration of the 
drug during the recovery stage demonstrated a greater ability to normalise BBB 
function.
The dose-dependent reduction of neurological and histological signs of EAE 
reconfirms the observations of therapeutic studies previously reported (Bolton et. al., 
1982; Rumjanek et. al., 1984b). Furthermore, reports of CSA use in other 
experimental inflammatory conditions also demonstrate therapeutic control at 
comparable doses (Borel et. al., 1976; Pozo et. al., 1992). Significant suppression of 
EAE has been reported at lower concentrations of CSA, but only in prophylactic 
dosing regimes (Hinrichs et. al., 1983; Reiber & Suckling, 1986).
An isolated study by Reiber & Suckling (1986) had previously examined BBB 
function following CSA administration in EAE. The investigation found that CSA 
treatment, from one day pre-sensitisation, suppressed disease development and 
inhibited the increases in CSF protein concentration, which normally indicates barrier 
dysfunction. In the present study CSA has been shown to reduce the opening of the 
BBB when administered for a short time period therapeutically. Moreover, while the 
maximal effect of CSA in the acute phase does not achieve complete correction, the 
immunosuppressant can normalise protein extravasation at D23PI. Indeed, the 
observed difference between EAE timepoints reinforces the observations made with 
DEX treatment, indicating that the neurovascular response to drug administration 
alters between acute and recovery phases.
FK506 administered therapeutically, significantly restricted BBB opening, 
neurological deficits and histological lesions in the Lewis rat model of acute EAE.
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The effect of FK506 on the pathological breakdown of neurovascular function has not 
previously been shown. This study has demonstrated that the macrolide can both 
prevent BBB perturbation in the acute phase and restore barrier function at D23PI 
after only a short dosing regime. Previous work in EAE has shown that FK506 can 
successfully suppress onset of disease when administered at low doses from DOPI 
(Inamura et. al., 1988; Deguchi et. al, 1991). However, Deguchi et. al (1991) 
reported irritability and death in animals treated with lOmg/Kg of FK506 for 12 
consecutive days. Intolerance to FK506 was not noted at this concentration during 
the current study when used in a short dosing regime. Furthermore, a similar dose 
was well tolerated in collagen-induced arthritis when given as a single injection (Arita 
et. al, 1989, 1990). The adverse reaction to FK506 at the dose reported by Deguchi 
et. al (1991) maybe as a result of an accumulative effect. Accumulation of drug may 
explain why a lower dose of FK506 produced a response prophylactically in EAE, but 
was not successful in the short therapeutic regime reported here. In contrast to CSA 
and DEX, the efficacy of FK506 correction of BBB permeability was not found to 
alter between acute and recovery phases. Therefore, FK506 may target an aspect of 
neurovascular abnormality of equal importance in both BBB breakdown and 
continued vascular dysfunction. A full dose-response study in both acute and recovery 
stages of EAE could not be undertaken due to restricted availability of the compound.
The application of immunosuppressants CSA and FK506 to inflammatory and 
immune-mediated conditions is continually widening (reviews: Hess, 1993; Thomson 
et. al, 1993). However, the mechanisms by which the compounds mediate 
improvement in disease are not clearly defined.
Pharmacological control of initial BBB breakdown and the sustained 
dysfunction of the microvasculature, may be exerted at various stages following 
inoculation for EAE. A primary target of CSA and FK506 in EAE is the inhibition of 
T cell activation and proliferation. While CSA and FK506 have distinct cellular
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binding proteins, cyclophilins and FK-binding proteins respectively, the two drugs 
exhibit essentially identical effects on T cell inactivation. Inhibition of T cell 
proliferation by the immunosuppressants is essentially mediated by a down-regulation 
of IL-2 synthesis, as summarised in Figure 37.
The successful prophylactic suppression of CSA and FK506 in acute EAE 
and the inhibition of adoptively transferred EAE and antigen arthritis by T cell culture 
with immunosuppressants, may be attributed to the restriction of lymphocyte 
activation by the drugs (Hinrichs et. al. ,1983; Inamura et. al., 1988; Bolton, 1992; 
Griffiths et. al. ,1992). However, therapeutic administration of CSA and FK506 
occurs after lymphocyte priming and the early contact between activated surveillance 
cells and the CNS environment (Daniel et. a l , 1981; Traugott, 1989), suggesting that 
the compounds therapeutically suppress EAE by actions other than the inhibition of T 
cell activation.
Suppression of vasoactive mediator synthesis by immune cells could result in 
control of vascular permeability, particularly if the release from perivascular 
inflammatory cells was restricted. Both CSA and FK506 inhibit a variety of immune 
cells from producing cytokines (Goldfeld et. al., 1992; Lafferty et. al., 1983), 
including IL-1, TNFa and IFNy, which have been implicated in microvascular 
permeabilisation and upregulation of adhesion molecules on the endothelium (Royall 
et. al., 1989; Brett et. al., 1989; Dustin et. al., 1986). Release of proinflammatory 
mediators histamine, prostaglandin D2 and leukotriene C4 by mast cells and basophils 
are also inhibited by CSA and FK506 (Marone et. al. ,1988; Cirillo et. al. ,1990). 
Furthermore, CSA-induced inhibition of prostacyclin production from endothelial 
cells has been demonstrated in vitro (Brown et. al., 1990). However, the suppression 
of arachidonic acid metabolite synthesis would not appear to be a general effect but 
directed at specific eicosanoids. Prostaglandins, particularly of the E series, inhibit IL- 
2 synthesis, a known target for immunosuppressants (Hess, 1993) and reports by
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Figure 37: Proposed mechanism of CSA and FK506 inhibition of IL-2 stimulated 
T-cell proliferation
CSA and FK506 bind to soluble intercellular isomerases, cyclophilins and FK-binding 
proteins respectively. The drug-isomerase complex associates with the Ca2+ and 
calmodulin (Cal)-dependent phosphatase, calcineurin, inhibiting enzyme activity. As a 
consequence dephosphorylation of substrate proteins, including the cytoplasmic 
component of'nuclear factor of activated T-cells’ (NF-AT) does not occur. Translocation 
of NF-AT to the nucleus is subsequently prevented and IL-2 transcription down-regulated. 











Whistler et. al. (1984) and Schultze et. al. (1984) demonstrate CSA enhancement of 
prostaglandin synthesis in the monocytes.
Access of immunosuppressants to the neuroendothelium and the CNS 
parenchyma is possible, but restricted to a greater extent than elsewhere in the body. 
The lipophilic nature of CSA allows drug uptake to the brain at the same rate as 
uptake into the kidney (Nooter et. al., 1984), although CNS concentrations are 
reportedly below detection limits (Palestine et. a l , 1985). One explanation may be the 
affinity of the drug to P-glycoprotein, a transmembrane efflux transporter located on 
the luminal membrane of neuroendothelial cells, which actively prevents many 
lipophilic molecules from gaining access to the CNS (Sakata et. al., 1994; Wang, 
1995; Schinkel et. al., 1995). However, removal of drugs by the pump may be slow 
as Begley et. al. (1990) report quantifiable accumulation of CSA within the 
neuroendothelium from where direct control over BBB events may be initiated. 
Macrolides possess a poor blood to brain penetration yet the greater potency of 
FK506 may explain why the drug can exert a neuroprotective effect at CNS sites 
(Kitamura et. al., 1994). Indeed, rat brain has demonstrated very high levels of FK- 
binding protein with co-localisation of calcineurin, indicating a possible physiological 
link through which FK506 may exert an effect (Steiner et. al., 1992).
The ability of FK506 and CSA to act on the vascular endothelium is 
demonstrated in a number of toxic side-effects linked to administration of the drugs 
following transplant including hypertension (Rego et. al., 1991) and vasculitis (Thriru 
et. al., 1987). However, drug actions detrimental in normal tissues may be of benefit 
under pathological conditions. Indeed, CSA-induced nephrotoxicity appears to result 
from a suppressed NO production, which can be overcome by addition of the NO 
substrate L-arginine (Gallego et. al., 1993). Nitrite levels, an indirect measure of NO, 
have recently been shown to be elevated in brain homogenates from EAE-sensitised 
animals at the time of disease onset. (Bolton et. al. ,1994; Scott et. al., 1994). 
Furthermore, as a potent vasodilator NO has been linked to perturbation of vascular
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endothelium in other systems (Palmer et. al., 1992; Schukla et. al., 1996). While CSA 
and FK506 may affect endothelial NO production the drugs could also reduce the 
level of the vasodilator released by macrophages situated within inflammatory CNS 
lesions in EAE (Conde et. al., 1995).
Decreased mitochondrial content is a recognised ultrastructural change 
in the neuroendothelial cells of EAE-sensitised animals (Claudio et. al., 1989), which 
has also been observed in biopsy samples from chronic progressive MS recently 
(Claudio et. al., 1995). Mitochondria are sensitive to oxidative damage which 
inactivates mitochondrial enzymes and disrupts mitochondrial calcium metabolism, 
contributing to cell damage (Packer & Murphy, 1995). Interestingly, CSA has the 
potential to protect mitochondria by blocking the induction of calcium efflux and 
thereby may prevent endothelial changes in EAE (Packer & Murphy, 1994, 1995; 
Schweizer & Richter, 1996).
In addition to the cyclophillin proteins, CSA may also bind other cytosolic 
proteins including ODC (Ryffel, 1993). The ODC cascade and endproduct PA have 
been implicated in the neurovascular dysfunction of non-disease models (Koenig et. 
al. ,1989b) and more recently in EAE (Bolton et. al., 1994; Paul et. al., submitted 
1996). Therefore, CSA binding to ODC may reduce neurovascular perturbation by 
suppressing enzymic activity. Indeed, CSA has been observed to inhibit ODC activity 
(Fidelius et. al, 1984), although a mechanism of action was not defined.
The mechanisms of action of therapeutically administered FK506 and CSA in 
EAE are uncertain although a number of actions of potential relevance to the control 
of BBB permeability have been suggested. A further area for investigation could 
include the analysis of the related immunosuppressants rapamycin and cyclosporin H 
on BBB function during EAE. Rapamycin also targets the cytosolic FK-binding 
proteins but demonstrates an alternative method of immunosuppression to FK506 and 
may indicate the extent of FK-binding protein involvement in the mechanisms 
controlling BBB improvement. Cyclosporin H is an analogue of CSA and possesses
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no immunosuppressive actions. Therefore, restriction of BBB dysfunction during 
acute and recovery phases of EAE with this analogue would indicate a direct and 
non-immunosuppressive action of CSA on the neuroendothelium.
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7.
Combined Administration of 
Cyclosporin A and Dexamethasone 
during the Acute Phase of EAE
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7.1 Results
The contrasting efficacies of CSA and DEX during acute and early 
recovery stages of EAE suggest the compounds restore barrier permeability by 
different routes. Studies were therefore instigated to consider the effect of combined 
therapy in neuroantigen-induced disease.
A study was undertaken using DEX at a dose with negligable inhibitory effect 
on abnormal BBB function - 0. lmg/kg body weight - in combination with CSA doses 
of 25, 35 and 50mg/kg body weight, which range from ineffective to partially 
corrective concentrations. DEX plus 25mg/kg CSA was unable to improve the 
function of the BBB displaying a tissue profile similar to that of CSA alone and losing 
the minor effect in the CSp displayed by single DEX administration (Figure 38). 
Surprisingly, the combination of 0. lmg/kg DEX and 25mg/kg CSA was able to inhibit 
the development of symptoms unlike the individually administered drugs (Table 9).
Treatment with DEX (0. lmg/kg) and CSA at 35mg/kg body weight caused a 
dramatic improvement in neurovascular permeability (p < 0.05), which was 
determined to be within normal limits in all tissues (Figure 39). Complete 
normalisation of barrier function was not achieved by any CSA dose alone. Moreover, 
the % inhibition of BBB opening by the combined drugs was far greater in all CNS 
tissues than the predicted additive effect from single dose studies, indicating a 
synergistic effect of the two compounds at these concentrations (C: single 7%; 
combined 95%. MP: single 21%; combined 88%). In addition, neurological deficits 
were significantly reduced (Table 9).
A further increase of CSA to 50 mg/kg body weight in the combined dose 
maintained normal barrier function, reducing the group variation (SD) still further 
(Figure 40). A synergistic effect was again produced in the C and MP tissues (C: 




C erucal Spinal Cord
Figure 38: 0.1mg/kg DEX and 25mg/kg CSA, Combined Dose during the 
Acute Phase of EAE. Histograms show the effect of combined 0. lmg/kg DEX and 
25mg/kg CSA administration on BBB restoration in (a) cerebellum, (b) medulla-pons 
and (c) cervical spinal cord tissues. Results are shown for normal (black column, n = 
6), vehicle (open column, n = 5) and combined drug (cross hatch column, n = 8) 
groups. No significant difference between vehicle and combined drug treated mean 
EVBE values was shown; Mann-Whitney U. The far right-hand column (vertical 
hatch) illustrates the calculated additive effect of the two drug concentrations, taken 
from the differences between drug and vehicle means in the single drug studies. The 






Table 9: Summary of Neurological Deficits, Plasma Creatinine and 
Weight Loss following Joint Administration of CSA and DEX




O.Olmg/kg DEXa 5 2.80 ±1.79 9.7 ±2.1 -
0. lmg/kg DEXa 6 1.33 ± 1.00* 8.6 ±2.7 -
25mg/kg CSAa 5 1.20 ±1.60 7.5 ±3.8 -
3 5 mg/kg CSAa 6 0.17 ±0.40* 8.0 ±2.8 0.388 ±0.062
50mg/kg CSAa 7 0.20 ± 0.40* 8.7 ±3.3 -
Normal 3 - - 0.327 ± 0.063
Vehicle (0.1/25) 6 2.10 ±1.75 5.6 ± 2.1 -
0.lmg/kg DEX/ 
25mg/kg CSA 8 0* 9.5 ± 2.4® -
Vehicle (0.1/35) 5 1.40 ±0.96 10.7 ±3.0 0.300 ±0.038
0. lmg/kg DEX/ 
3 5mg/kg CSA 6 0* 10.8 ±3.3 0.484 ± 0.095§
Vehicle (0.1/50) 6 2.42 ±1.50 7.4 ±2.8 -
0.lmg/kg DEX/ 
50mg/kg CSA 6 0.08 ± 0.20# 10.5 ±2.4 -
Vehicle (0.01/50) 8 0.81 ± 1.00 9.9 ±2.7 -
O.Olmg/kg DEX/ 
50mg/kg CSA 6 0* 9.4 ±2.4 -
a : Summary of single drug results.* significantly different from respective vehicle 
controls.
b : MNS observed on the day of sampling. # p < 0.05 significantly different to 
vehicle, Mann-Whitney U. ^  Complete suppression of neurological deficits. 
c : % difference between body weight prior to disease onset and the day of sampling.
® p < 0.01 significantly different to vehicle control, T-test. 
d : Creatinine analysis was conducted on the combined drug group demonstrating the 
greatest improvement in pharmacological response at the BBB. § p < 0.05 





Figure 39: 0.1mg/kg DEX and 35mg/kg CSA, Combined Dose during the 
Acute Phase of EAE. The histogram shows the effect of combined 0. lmg/kg DEX and 
35mg/kg CSA administration on BBB restoration in (a) cerebellum, (b) medulla-pons and (c) 
cervical spinal cord tissues. Results are shown for normal (black column, n = 4), vehicle 
(open column, n = 5) and combined drug (cross hatch column, n = 6) groups. Mean EVBE 
values analysed by Mann-Whitney U found significant differences of * p < 0.05 between 
vehicle and combined drug treatments and # no significant difference between drug and 
normal groups. The far right-hand column (vertical hatch) illustrates the calculated additive 
effect of the two drug concentrations taken from the differences between drug and vehicle 
means in the single drug studies. The combined drug effect (cross hatch) is apparent above the 


































Figure 40l 0.1mg/kg DEX and 50mg/kg CSA, Combined Dose during the Acute 
Phase of EAE. The histogram shows the effect of combined 0. lmg/kg DEX and 50mg/kg CSA 
administration on BBB restoration in (a) cerebellum, (b) medulla-pons and (c) cervical spinal cord 
tissues. Results are shown for normal (black column, n = 3), vehicle (open column, n = 6) and 
combined drug (cross hatch column, n = 6) groups. Mean EVBE values analysed by Mann- 
Whitney U found significant differences of * p < 0.05 between vehicle and combined drug 
treatments and # no significant difference between drug and normal groups. The far right-hand 
column shows the calculated additive effect of the two drug concentrations (vertical hatch) taken 
from the differences between drug and vehicle means in the single drug studies. The combined drug 
effect (cross hatch) is apparent above the vertically hatched column where the combined drug 









Finally, manipulation of the DEX component to a level ineffective in single 
drug studies - O.Olmg/kg body weight - was analysed in combination with 50mg/kg 
body weight CSA. Figure 41 shows a marked reduction in the permeability of the 
neurovasculature in all tissues (p < 0.05), with the barrier function in the C being 
reduced to within normal limits. Furthermore, the % inhibition measured in the C is 
greater than the predicted additive effect from the single drug studies (C: single 62%; 
combined 89%). Augmentation of the single drug effects of CSA can therefore be 
achieved with doses of DEX as low as O.Olmg/kg body weight.
A study of the log responses against variation in CSA concentration showed a 
significant linear regression in all areas of the CNS ( C, p = 0.0, 45% fit; MP, p = 0.0, 
62% fit; CSp, p = 0.0, 71% fit). Similar results were achieved for DEX variation and 
log response (C, p = 0.0, 46% fit; MP, p = 0.0, 56% fit; CSp, p = 0.0, 69% fit).
Analysis of body weight changes shows a significant difference only between 
vehicle and 0. lmg/kg DEX and 25mg/kg CSA in combination and is unlikely to be 
indicative of toxicity as no other drug combination using higher CSA concentrations 
display the same trend (Table 9). Measurement of plasma creatinine highlighted a 
significant difference between vehicle and 0. lmg/kg DEX and 35mg/kg CSA in 
combination, although neither value was shown to be significantly different to normal 
rat values. Therefore, the improvement in barrier integrity seen with low-dose DEX 





Figure 41: O.Olmg/kg DEX and 50mg/kg CSA Combined Dose during the 
Acute Phase of EAE. The histogram shows the effect o f combined O.Olmg/kg DEX and 
50mg/kg CSA administration on BBB restoration in (a) cerebellum, (b) medulla-pons and (c) 
cervical spinal cord tissues. Results are shown for normal (black column, n =  4), vehicle (open 
column, n = 8) and combined drug (cross hatch column, n = 6) groups. Mean EVBE values 
analysed by Mann-Whitney U found significant differences of * p < 0.05 between vehicle and 
combined drug treatments and # no significant difference between drug and normal groups. The far 
right-hand column shows the calculated additive effect o f the two drug concentrations (vertical 
hatch), taken from the differences between drug and vehicle means in the single drug studies. The 
combined drug effect (cross hatch) is apparent above the vertically hatched column where the 







The combination of low-dose glucocorticoid and immunosuppressant 
successfully improved barrier integrity during acute EAE in a dose-dependent manner. 
Furthermore, at selected doses a marked synergy between the two agents was noted. 
Indeed, only a limited steroid addition to the CSA dose was required to normalise 
neurovascular function, a response not seen when CSA was administered alone during 
the acute phase of disease. By jointly administering DEX and CSA the concentrations 
could be reduced to a tenth or half - respectively - of the individual effective dose.
The use of CSA as an immunosuppressant can be associated with a number of 
adverse side-effects. Renal dysfunction, due to a decreased glomeruler filtration rate 
(Shulman et. al., 1981; Mihatsch et. al., 1988) and hypertension (Rego et. al., 1991; 
Gerkens et. al., 1989; Brown et. al., 1993) are common during treatment. Indeed, in 
conditions where CSA is administered to patients with normal CNS function adverse 
neurological reactions including encephalopathy, cerebral blindness and a diffuse 
disorder of the white matter determined by MRI, have been noted (Rubin & Kang, 
1987; DeGroen et. al., 1987; Davenport et. al., 1988). Withdrawal, or a reduced dose 
of immunosuppressant is often sufficient to reverse toxic effects. Glucocorticoid 
administration may also produce detrimental effects particularly when administered in 
high concentrations for long periods (Stubbs & Morrell, 1973; Lyons et. al., 1988; 
Villareal et. al., 1996). Importantly, following discontinuation of steroid treatment 
prolonged suppression of the hypothalamic-pituitary-adrenal axis occurs (Graber et. 
al., 1965; Calogero et. al., 1990). Furthermore, as immunosuppressants, DEX and 
CSA both compromise immunological function rendering the patient vulnerable to 
common and opportunistic infections (Aucott, 1994; Kim & Perfect, 1989; Williams 
et. al., 1982).
No indication of renal or neurological side-effects was found during the 
course of CSA or DEX studies in the Lewis model of EAE. Moreover, the work
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presented here illustrates that when administered jointly the concentrations of both 
compounds can be reduced while maintaining corrective control of BBB function.
Interaction between CSA and glucocorticoids may occur at common targets 
including arachidonic acid metabolism and the ODC cascade (Koenig et. al., 1989b; 
Ohnishi et. al., 1992; Fidelius et. al., 1984; Marone et. al., 1988). Interestingly, 
components of the PKC signalling pathway may be regulated by both compounds. 
Glucocorticoid receptor complexes are thought to interact with the PKC 
phosphoregulatory cascade in some steroid-activated nuclear transcriptions and the 
transduction signal ‘activator of DNA replication’ is CSA-sensitive (Ahima et. al, 
1992; Kimball et. al, 1993).
The value of combined steroid and immunosuppressant treatment has 
been recognised in a number of conditions (Bijlsma et. al, 1986; Alexander et. al, 
1992; Leovey et. al, 1993). The present work now indicates that a joint low-dose 
glucocorticoid and immunosuppressant regime may also be of benefit in controlling 
BBB dysfunction in neurological disorders such as MS.
FK506 may also be a potential candidate for combined administration with 
corticosteroids. Indeed, a synergistic effect between low-dose DEX and FK506 has 
already been demonstrated for steroid-regulated gene expression in plasmids (Ning & 
Sanchez, 1993). Moreover, DEX suppression of histamine paw edema can be 
enhanced by pretreatment with FK506 (Oyanagui, 1994). The FK binding proteins 52 
and 59 are found in association with heat shock proteins in untransformed 
mammalian steroid receptor complexes (Peattie et. al, 1992; Tai et. al, 1992). 
Therefore, FK506 may augment the corrective DEX effect on abnormal BBB 
function, possibly by upregulating glucocorticoid receptor binding to nuclear sites or 
by increasing the regulatory sites recognised by the steroid-receptor complex.
Furthermore, combinations of immunosuppressants can demonstrate well 
tolerated additive if not synergetic actions, without glucocorticoid inclusion (Morris
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et. al, 1989; Zeevi et. al, 1987; Strepkowski & Kahan, 1993). Evaluation of further 
drug interactions may be of value in EAE with a view to future treatment of MS.
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8.
The Role of the N-methyl-D-aspartate 





A number of biological molecules released during inflammation demonstrate 
vasoactive properties on isolated capillary endothelial cells or in models of 
inflammatory edema formation. Two such examples are the short-lived NO molecule 
and the PA spermidine, spermine and putrescine produced as endproducts of the 
ODC cascade. These compounds have been identified as primary mediators of 
cerebral vessel disruption in non-immune models of BBB damage (Koenig et. al., 
1983; Trout et. al., 1986; and Faraci & Brian, 1994).
Preliminary studies published by Bolton et. al. (1994), examined the levels of 
NO and PA in neurovascular isolates from EAE-sensitised Lewis rats. The results 
sumarised in Figure 42 and Table 10 show that both NO and PA levels are elevated at 
the time of disease onset. Moreover, the increase in vasoactive mediator production in 
EAE coincides with aberrant BBB permeability in identical tissues.
Both NO and PA may be generated following activation of the N-methyl-D- 
aspartate (NMDA) subtype of glutamate receptor. Furthermore, NMDA receptor 
activity has recently been reported at neurovascular locations (Koenig et. al., 1992; 
Giese et. al., 1995). Therefore, it was of interest to determine whether the NMDA 
receptor was involved in the development of EAE, in particular the breakdown of 
neurovascular function.
8.1.1 Suppression o f EAE by Administering the NMDA Receptor 
Antagonist, MK801, during the Effector Phase o f Disease 
Induction
MK801, an in vivo active NMDA receptor antagonist, was selected to 
determine whether control of glutamate receptor activity can modulate EAE 
development and pathology.
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Figure 42: Nitrite levels detected in CNS cytosol preparations by Greiss assay 
Permission to present this work was kindly given by Gwen Scott. Cytosol 
preparations from the C, MP and CSp tissues of normal (open bar), CFA-inoculated 
(horizontal hatch bar) and EAE-sensitised (cross hatch bar) animals, were analysed by 
the Greiss Reaction (Green et. al., 1982; Scott et. al., submitted for publication). 
Results were expressed as pmoles nitrite / mg protein. * p < 0.05, ** p < 0.01, *** p 




p moles Nitrite / mg protein + SEM
Table 10: Polyamine levels detected in CNS blood vessel isolates
Permission to present this data was kindly given by Pennie Woodyer. Blood vessel 
isolates were collected from the C, MP and CSp tissues of normal and EAE animals 
at the height of disease. Polyamine extractions were dansylated and separated by thin- 
layer chromatography (Seiler, 1983). Assessment of the resultant fluorescent bands 
was made by densitometry and the findings expressed as a percentage increase above 
normal values.
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The first study examined the response of EAE-sensitised animals to the 
administration of two concentrations ofMK801, 0.15 and 0.3mg/kg body weight, 
from D7-12 PI. The dosing schedule involves the effector phase of disease which 
follows the ecephalitogenic priming of T cells during the induction stage. Observation 
of neurological symptoms on D12 PI showed an improved MNS in both 0.15 and 
0.3mg/kg treatment groups compared to vehicle controls (p < 0.05 and p < 0.01 
respectively, Table 11). Furthermore, the percentage change in body weight was 
clearly reduced in both treatment groups, attaining significance in the 0.15mg/kg 
group (p < 0.05, significantly different to vehicle control).
Table 11: Summary of Neurological Signs, Percentage Change in Body 
Weight and Plasma Corticosterone Levels in EAE-sensitised Lewis rats 
following MK801 Administration.






- - - 8 47.4 ±26.9
Vehicle 10 2.98 ± 1.08 11.7 ± 2.6 10 159.7 ± 115.6
0.15mg/kgMK801 6 1.17 ±1.47* 5.2 ±4.8# 6 70.2 ± 19.3
0.3 mg/kg MK801 
Therapeutic
6 0.42 ±1.02** 6.8 ±4.8 6 116.0 ±42.9
Vehicle 5 1.08 ±1.49 7.1 ±3.0 11 80.7 ±34.6
0.3 mg/kg MK801 6 0.42 ±0.80 7.3 ±3.7 8 71.3 ±28.7
0.6mg/kg MK801 5 0.10 ±0.22 8.1 ±3.7 6 67.0 ±11.1
a : MNS recorded on the day of sampling. Prophylactic doses of MK801 significantly 
reduced MNS, * p < 0.05, ** p < 0.01; ANOVA with Dunnett's test. 
b : % Weight change between final body weight and pre-disease weight. # p < 0.05, 
reduction compared to vehicle by 0.15mg/kg dose given prophylactically; ANOVA 
with Dunnett's test. 
c : No significant differences between groups; ANOVA.
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Administration of MK801 from D7 PI inhibited BBB dysfunction (Figure 43). 
Low dose MK801 suppressed, but not significantly, neurovascular disruption in all 
tissues. However, increasing the dose to 0.3mg/kg body weight significantly inhibited 
the protein extravasation into C, MP and CSp tissues (p < 0.05; 0.01; and 0.05 
respectively), bringing EVBE values to within normal limits. Analysis of the drug 
dose-response showed significant linear regression in all tissues (C, p = 0.002, 40% 
fit; MP, p = 0.008, 30% fit; CSp, p = 0.002, 39% fit).
The compound was found to be well tolerated in an examination of mean body 
weight profiles (Figure 44a). Indeed, analysis of percentage weight change 
demonstrated a significant reduction in weight loss for animals receiving low dose 
MK801 (Table 11).
8.1.2 Suppression of EAE by Therapeutic Administration o f the 
NMDA Receptor Antagonist, MK801
Following the suppression of neurovascular abnormalities and disease 
symptoms after prophylactic administration of MK801 during the effector phase of 
EAE, the efficacy of the receptor antagonist was assessed in a therapeutic dosing 
regime. Doses of 0.3 and 0.6mg/kg body weight were investigated and both 
concentrations appeared well tolerated by animals following an assessment of mean 
body weight profiles (Figure 44b).
The glutamate receptor blocker, MK801, demonstrated a restricted control of 
neurovascular dysfunction when using a dose of 0.3mg/kg (Figure 45). A significant 
reduction in abnormal permeability was noted in the C and a decreased BBB opening 
was seen in the MP and CSp. By increasing the dose to 0.6mg/kg body weight a 
significant restriction of extravasated protein was also recorded in the CSp (p < 0.05). 
The response in the MP did not improve and regression analysis did not demonstrate 
a significant relationship between dose and log response in the tissue (C, p = 0.005, 
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F ig u re  43: Inhibition of BBB Dysfunction during EAE by Prophylactic Administration of MK801 from D7 PI
MK801 was administered to EAE-sensitised animals for six days beginning on D7 PI and concluding on D12 PI. Examination of BBB 
permeability to protein was made on D 12 PI in normal (black column, n = 6), vehicle (open column, n = 10), 0.15mg/kg MK801 (horizontal 
hatch column, n = 6) and 0.3mg/kg MK801 (vertical hatch column, n = 6) groups of Lewis rats. * p < 0.05, ** p < 0.01 compared to vehicle- 
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Figure 44: Comparison of Body Weight Profiles from Studies of Prophylactic 
and Therapeutic MK801 Administration during EAE. Graph (a) shows the body 
weight profiles of 0.15 and 0.3mg/kg MK801 treated groups and vehicle controls (2 
and 1 respectively) from each study. Graph (b) shows the body weight profiles of 0.3 
and 0.6mg/kg MK801 treated groups and vehicle controls from four days pre­
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Figure 45: Inhibition of BBB Dysfunction during EAE by Therapeutic Administration of MK801 from Weight Loss
MK801 was administered to EAE-sensitised animals for three days beginning on the day of weight loss and concluding on the day of sampling. 
Examination of BBB permeability to protein was made in normal (black column, n = 6), vehicle (open column, n = 5), 0.3mg/kg MK801 
(vertical hatch column, n = 6) and 0.6mg/kg MK801 (cross hatch column, n = 5) groups of Lewis rats. * p < 0.05 compared to vehicle-dosed 
EAE controls; # no significant difference to normal values; analysis by Mann-Whitney U with Bonferroni correction.
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reduced in treatment groups but not found to differ from the MNS range of the 
vehicle dosed animals (Table 11).
Assessment of endogenous plasma steroid concentration found no significant 
variation in MK801 dosed groups compared to vehicle controls (Table 11). The 
receptor antagonist is not therefore generating the effects seen in EAE through a non­
specific elevation of corticosterone.
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8.2 Discussion
The work shown is the first report describing the suppressive effects of 
MK801 on pathological features characteristic of EAE. MK801 antagonises the 
actions of the NMDA-activated glutamate receptor by blocking the ligand-gated Ca2+ 
ion channel (Iversen, 1994). Prophylactic administration of MK801 reduced the 
development of neurological signs of EAE and significantly suppressed BBB 
breakdown. Furthermore, short-term therapeutic administration of the antagonist was 
also able to restrict neurovascular opening. Evaluation of MK801 effects in the 
development of EAE has reconfirmed the benefits of the double radioisotope 
technique in assessing the specific actions of novel compounds in the disease.
While this is the first study showing that control of NMDA-receptor activation 
can modify aspects of EAE, inhibition of glutamate-receptor activity has been 
demonstrated to be beneficial in other neurological conditions. Neuroprotection by 
antagonists of this subtype of glutamate receptor have been reported in animal models 
of focal cerebral ischaemia (Boast et. al'., 1988; Park et. al., 1988; Belayev et. al., 
1995), closed head trauma (Shapira et. al., 1993) and cold lesion injury (Koenig et. 
al., 1992). Furthermore, NMDA receptor-mediated neuronal injury by glutamate 
excitotoxicity is implicated in neurodegenerative conditions including Parkinson's 
(Zeevalk et. al., 1994) and Alzheimer's disease (Le et. al., 1995).
The effectiveness of MK801 in reducing neurovascular abnormalities and 
neurological deficits implicates NMDA receptor overactivation in the pathological 
events underlying EAE. Endogenous upregulation of NMDA receptor activity may be 
exerted at a number of ligand binding sites (Figure 46), including those of glutamate 
and glycine (Grimwood et. al. ,1993). Interestingly, Honegger et. al. (1989b) 
measured elevated glycine concentrations in the CNS of EAE-diseased animals and 
found levels 200% greater than control values. Furthermore, Reinhard and co­
workers noted that quinolinic acid, an endogenous NMDA receptor agonist and
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Figure 46: NMDA receptor
Recognised endogenous ligands and ion binding sites on the NMDA-subtype 











Mg Internal cell membrane
Phosphorylation
site
 I MK801 - blocks channel
' preventing ion movement
173
neurotoxin formed from tryptophan, was markedly elevated in the spinal cord during 
paralytic EAE (Reinhard et. al., 1992). However, the ligand was not increased in the 
brain at the height of disease, correlating with the pattern of BBB breakdown and 
lesion distribution noted for the timepoint (Leibowitz & Kennedy, 1972; Bolton et. 
al., 1984b; Reinhard et. a l, 1992). Therefore, atypical levels of excitatory amino 
acids capable of stimulating NMDA-receptor activity can be demonstrated in the CNS 
of neuroantigenically-sensitised animals. Information regarding glutamate receptor 
agonist levels in MS brains may soon be available with the advent of proton magnetic 
resonance spectroscopy (Richards, 1991). Interestingly, the technique has identified 
an increased glutamine-glutamate signal associated with proliferation in glial tumours, 
which may prove relevant to the occurrence of overt astrocytic hypertrophy within 
MS lesions (Confort-Gouny et. al'., 1993).
The NMDA subtype of glutamate receptor was until recent years thought to 
be located solely on neurons. However, through the use of specific antagonists 
NMDA receptor activity has now been demonstrated on brain capillary endothelial 
cells (Koenig et. al., 1992; Giese et. al., 1995) and more recently on mast cells 
(Purcell et. al., 1996). Activation of the NMDA receptor generates a Ca2+ influx into 
the cell, stimulating a series of Ca2+-dependent events. Of prime importance in 
neurological conditions involving loss of BBB integrity is the generation of NO and 
PA. Elevated ODC activity and individual PA concentrations have been demonstrated 
in a variety of experimental brain injury models concomitant with neurovascular 
damage (Dienel & Cruz, 1984; Fike et. al., 1994; Koenig et. al., 1989a,b). Down- 
regulation of ODC enzyme activity and leakage of BBB tracers was achieved by 
administration of MK801 following cold injury in rats, confirming a link between 
glutamate receptor stimulation and PA elevation (Koenig et. al., 1992). Interestingly, 
recent studies in acute EAE have demonstrated significant increases in PA putrescine, 
spermidine and spermine at the height of disease by thin-layer and high-performance
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liquid chromatography (Bolton et. al., 1994, Paul et. al., submitted 1996), suggesting 
a role for PA as mediators of BBB damage.
Targeting of upregulated ODC activity in the CNS has proved to be a viable 
site for pharmacological intervention in the CNS following cold injury (Trout et. al., 
1986) and tissue damage after dialysis probe implantation (Fage et. al., 1993). 
Interestingly, Purcell et. al. (1996) have demonstrated that histamine release from 
mast cells may be induced by PA. Furthermore, the induction of vasoactive amine 
release is Ca2+-dependent and may be attenuated by both NMDA receptor antagonists 
MK801 and ifenprodil (Purcell et. al. ,1996).
NO is a potent vasodilator which performs a variety of normal signalling 
functions when produced in picogram quantities. Preliminary studies in EAE have 
demonstrated the significant elevation of NO product nitrite in cerebral blood vessel 
isolates at the time of disease expression (Bolton et. al., 1994; Scott et. al., 1994). 
Further evidence of reactive nitrogen and oxygen species production in acute and 
hyperacute EAE has been reported by Honegger et. al. (1989a) and MacMicking et. 
al. (1992). Indeed, administration of the NO synthase inhibitor aminoguanidine has 
been observed to suppress both the duration and severity of EAE (Zhao et. al., 1996). 
Non-disease models of BBB opening and cerebral edema also demonstrate 
concomitant increases of NO (Mayhan, 1995), which may be attenuated by 
antioxidant administration (Zuccarello et. al., 1989; Ortego et. al., 1972).
NMDA receptor activation stimulates the upregulation of constitutive NO 
synthase activity, which is both Ca2+ and calmodulin dependent. At inflammatory sites 
the Ca2+- and calmodulin-independent cytokine-induced NO synthase, which is 
upregulated in activated macrophages and microglia, is generally considered to be the 
main source of elevated NO production (Nussler & Billiar, 1993). However, in the 
cerebral endothelium of EAE-diseased rats both constitutive and inducible NO 
synthase levels are significantly enhanced in lesion areas (Zhao et. al., 1996). 
Elevation of NO production via NMDA receptors may therefore account for local
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intercellular damage such as dysfunction of BBB transport and mitochondrial 
deficiencies (Draper & Hibbs, 1988; Packer & Murphy, 1994, 1995).
While NO and PA-mediated BBB damage may result from the activation of 
endothelial glutamate receptors, the importance of NMDA receptor-derived 
mediators diffusing from neuronal sites of elevated synthesis should not be 
discounted. Furthermore, NO is not the only free radical produced following Ca2+ 
channel opening. Superoxide and peroxinitrite also have important roles in 
neurotoxicity and possibly in EAE and MS (Lafon-Cazal et. al., 1993). Interestingly, 
following osmotic BBB insult there is an increase in free radical scavenging enzymes, 
including superoxide dismutase (Schuka et. al., 1993), which rapidly improves the 
abnormal vascular function. Whether an antioxidant enzyme response is elicited at all, 
or to a sufficient level to instigate recovery of the damaged neurovasculature of EAE- 
sensitised animals, has yet to be determined.
The putative role of upregulated NMDA receptor activity in BBB pathology 
allows further discussion of the sites of action of DEX, CSA and FK506 in correction 
of neurovascular abnormalities.
DEX consistently suppresses the induction of Ca2+ independent NO synthase 
activity, but Ca2+-dependent NO production is not affected (Radomski et. al. ,1990; 
Palmer et. al., 1992; Geller et. al., 1993; Demerle-Pallardy et. al., 1993). Elevation of 
ODC and PA synthesis is under glucocorticoid control and steroid-induced reductions 
have been demonstrated following cold injury of the neurovasculature (Koenig et. al, 
1989b) and in cerebral capillary isolates from treated EAE-sensitised rats (Bolton et. 
al., 1994). Therefore, glucocorticoids appear to be involved in the regulation of at 
least one NMDA-receptor stimulated pathway.
As previously mentioned the immunosuppressants FK506 and CSA bind to 
soluble FK-binding proteins and cyclophillins respectively. The drug-receptor 
complex then binds to the Ca2+-activated phosphatase, calcineurin, resulting in the 
inhibition of enzyme activity (Fruman et. al, 1992). NO synthase is a calcineurin
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substrate and the abundance of phosphorylated catalitically inactive NO synthase is 
enhanced by administration of FK506 and CSA (Dawson et. al., 1993). Accumulation 
of inactive enzyme suggests increased protection against glutamate-induced free- 
radical toxicity. Manev et. al. (1993) confirmed the protective effect of macrolides by 
preventing NMDA receptor initiated glutamate excitotoxicity in neuronal cell culture. 
Furthermore, the drug action was shown to be non-immunosuppressive and effective 
downstream from the site of receptor activation.
Mitochondria are important targets for oxidative damage and disruption of 
normal energy metabolism may contribute to cellular injury. Indeed, mitochondrial 
levels at the BBB are reduced during EAE (Claudio et. al., 1989; Oldendorf et. al., 
1977) and MS (Claudio, 1995). Elevation of reactive nitrogen and oxygen 
intermediates within mitochondria cause Ca2+ efflux and depolarisation which can be 
inhibited by the addition of CSA (Packer & Murphy, 1994, 1995). Furthermore, it is 
proposed that impairment of energy metabolism results in a deterioration of cell 
membrane function leading to a loss of Mg2+ block on NMDA receptors, thereby 
inducing persistent activation (Turski & Turski, 1993). Therefore, once initiated, 
mitochondrial aberrations and NMDA-receptor overactivation may be self- 
perpetuating.
Pharmacological determination of receptor involvement in the loss of 
neurovascular integrity in EAE has proved invaluable in previous mechanistic 
investigations. In particular, Goldmuntz, Brosnan and co-workers employed a 
receptor-specific antagonist to assess the involvement of adrenoreceptors in the loss 
of neurovascular integrity (Brosnan, 1985,1986; Goldmuntz et. al., 1986; Claudio et. 
al., 1992). Similarly, MK801 has clearly shown that pharmacological antagonism of 
the NMDA subtype of glutamate receptor improves the pathology and expression of 
EAE. MK801 cannot be used in the treatment of related human conditions as it is 
associated with serious side-effects (Olney et. al., 1989; Tricklebank et.al, 1989). 
Nevertheless, the prophylactic and therapeutic regimes were well-tolerated in the
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current investigation in EAE. Further research into the involvement of NMDA 
receptor activation in BBB permeability, particularly in EAE, using specific agonist 
and antagonist combinations, may further understanding of the mechanisms 
underlying loss of neurovascular integrity. Ultimately, the correction of abnormalities 
in receptor activation and cellular metabolism may present viable targets for 




A double radioisotope technique has been developed from published 
methodology to quantitate BBB permeability to circulating radiolabelled protein 
during EAE. The method is highly reproducible demonstrating minimal variation 
when assessing neurovascular integrity in normal animals. Furthermore, significant 
differences in BBB abnormalities can be detected between normal and EAE-sensitised 
rats at the height of disease. The reliability and sensitivity of the technique was 
repeatedly shown to be suited to the assessment of drug actions on abnormal BBB 
function.
Increased neurovascular permeability to protein was observed concomitant 
with the onset of neurological deficits in the Lewis rat model of acute EAE. The 
dysfunction was maintained throughout the acute episode and continued for a period 
after symptoms had resolved. The extent of extravasation into individual tissues was 
time-dependent and matched lesion predilection for CNS areas. However, no 
correlation between elevated neurovascular permeability and the severity of disease 
expression could be shown. The abnormal BBB function seen during EAE did not 
result from non-specific adjuvant effects.
DEX was shown to dose-dependently suppress both neurovascular opening 
and symptoms of disease when administered in a short-term therapeutic regime, 
supporting the evidence of steroidal control of barrier dysfunction seen in non- 
immune mediated models. Glucocorticoid-induced restoration of barrier function was 
also observed during recovery. Studies with the anti-glucocorticoid RU38486 during 
acute disease, suggests that DEX is acting through type II glucocorticoid receptors, 
which suppresses mediators of vascular damage from both CNS and systemic target 
cells.
The immunosuppressants CSA and FK506, were both effective in inhibiting 
BBB dysfunction during acute and recovery phases of EAE. Furthermore, results
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showed that CSA effected a greater reduction of protein extravasation when 
administered in the recovery phase. FK506 was equally effective at both timepoints, 
demonstrating a greater potency than CSA, particularly during the onset of EAE 
when complete suppression of barrier opening was achieved by the drug. Both drugs 
have the potential to control vasoactive mediator production by immune and non- 
immune cells. Further studies are required to determine the actions important to the 
control of neurovascular abnormalities in EAE.
Combined DEX and CSA treatment in the acute phase of EAE demonstrated 
highly significant inhibition of neurovascular dysfunction using drug concentrations of 
minimal individual effectiveness. In selected combinations the response was 
synergistic. Effective therapies employing reduced concentrations of pharmacological 
agents in combination may be of benefit to many conditions including neurological 
disorders such as MS.
The discovery that antagonism of the NMDA receptor elicits a beneficial 
response in EAE is a unique observation of great significance to the control of the 
disease. MK801 effectively reduced neurovascular disruption under both prophylactic 
and therapeutic regimes at a time period when both NO and PA, by-products of 
NMDA receptor activation, are elevated in untreated EAE animals. The suggested 
involvement of upregulated glutamate receptor activity in neurovascular perturbation 
supports similar reports in non-immune models of barrier dysfunction. A pivotal role 
for the NMDA-receptor in the development of BBB breakdown during EAE would 
reveal a number of candidate targets for therapeutic intervention at both receptor sites 
and along subsequent pathways eliciting vasoactive mediators. Ultimately, such 
findings may have important relevance to the understanding and treatment of BBB 
dysfunction in human conditions including MS.
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Future Directions
Implication of a role for the ionotropic NMDA subtype of glutamate receptor 
activity and downstream calcium-dependent mechanisms in the loss of BBB integrity 
and the development of EAE may offer important targets for therapeutic intervention 
in human conditions such as MS. Therefore the function of the NMDA receptor in 
neurovascular disruption during EAE requires clarification.
Firstly, neurovascular expression of the glutamate receptor needs to be 
confirmed in the Lewis rat under normal and diseased conditions. 
Immunohistochemical staining with antibodies specific for the NR1 subunit, which is 
an integral component of NMDA receptors, will demonstrate by light microscopy 
whether these receptors are located in neurovascular regions. The complex nature of 
the cellular arrangement at the BBB would necessitate the use of electron microscopy 
with immunogold labelling to identify whether receptor expression was at the 
endothelial layer, on pericytes or located on glial processes. Further studies employing 
double antibody labelling against the NMDA receptor subunits and an enzyme such as 
Na+-K+-ATPase known to be polarly distributed at the BBB could identify whether 
the receptor was selectively expressed on either the luminal or abluminal membranes.
A knowledge of receptor location is of primary importance for the successful 
antagonism of receptor stimulation and subsequent upregulation of membrane 
perturbator production. Were findings to show no NMDA receptor expression at the 
neurovascualture or a purely antiluminal distribution on the endothelial membrane 
drug studies should be directed towards an analysis of compounds capable of 
traversing the BBB and reaching neuronal and abluminal sites. Similarly, the action of 
mast cell-derived NMDA receptors may prove important were no receptors to be 
located neurovascularly in the Lewis rat. Hence drug administration should coincide 
with the interaction of mast cells, or mast cell-derived factors, and the 
neurovasculature leading to abnormal BBB function and progression of EAE.
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Following positive identification of NMDA receptor expression at 
neuroendothelial sites a full characterisation of the subunit composition would 
confirm whether a single subtype was involved in BBB dysfunction indicating possible 
links with other NMDA-associated conditions. Furthermore, pharmacological studies 
could be focused on receptor antagonists with actions against specific subunit 
combinations such as the NRl/NR2b antagonist ifenprodil.
Once the location and composition of NMDA receptors involved in the 
breakdown of neurovascular function and progression of EAE has been confirmed the 
factors controlling overstimulation of receptor function and the subsequent calcium- 
dependent processes implicated in BBB dysfunction can be studied. In vitro analysis 
of excitatory factor combinations on receptor-induced production of permeability 
mediators including NO and PA may highlight specific therapeutic targets. 
Furthermore, the effects of receptor upregulation can be studied on normal BBB 
characteristics displayed by endothelial cells grown in a glial coculture system, 
including polar distribution of enzymes and transporters, restricted permeability and a 
conserved ultrastructure. Successful pharmacological targeting of defined sites in 
vitro may subsequently be analysed in models of EAE by routine neurological, 
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Appendix
Physical data for Radionuclides
Hydrogen - 3 (Tritium)
The atom undergoes beta minus decay with a half life of 12.28 years.
3 3
H -»  He + B t -  = 12.28 years 
1 2 H 2 J
Maximum (3 Energy = 0.019MeV (100%)
Energy emission = 0.019MeV
Iodine -125
The atom undergoes electron capture decay with a half life of 60 days.
Principle Radiation Emissions:
Gamma = 0.035MeV (6.5%)
Kct X-rays = 0.027MeV (112.5%)
KP X-rays = 0.03 IMeV (25.4%)
Energy Emission = 0.177MeV
Indium - 111
The atom undergoes electron capture decay with a half life of 67 hours.
I l l  111 i
In —» Cd + y t -  = 67 hours
49 48 2
Principle Radiation Emissions:
Gamma = 0.17 IMeV (90%)
Gamma = 0.245MeV (94%)
Energy Emission = 0.850MeV
Indium -113m
The atom undergoes isomeric level decay with a half life of 100 minutes.
113tw 113 i
In —> In + y t -  = 100 minutes
49 49 1 2
Principle Radiation Emission:
Gamma = 0.393MeV(100%)
Energy Emission = 0.393MeV
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Abstract — Double radioisotope measurement of neurovascular integrity in Lewis rats inoculated for experimental 
allergic encephalomyelitis (EAE) showed abnormal elevation of albumin extravasation in the cerebellum, 
medulla-pons and cervical spinal cord at the time of clinical manifestation. Therapeutically administered 
dexamethasone (Dex) (0.1-1 mg/kg body weight) or cyclosporin A (CsA) (25-75 mg/kg body weight) dose- 
dependently reduced albumin movement across the blood-brain barrier (BBB). Dex at a dose of 1 mg/kg completely 
suppressed abnormal BBB permeability in all tissues (P<0.001), while CsA at the highest dose of 75 mg/kg achieved 
highly significant (P<0.001), but not complete, suppression of aberrant barrier leakage in the areas studied. The 
implications of these findings to possible drug action at the immunocompromised cerebrovasculature are discussed.
Keywords : blood-brain barrier, experimental allergic encephalomyelitis, dexamethasone, cyclosporin A.
A fundamental stage in the onset o f multiple sclerosis 
(MS) and the animal counterpart, experimental allergic 
encephalomyelitis (EAE), is the breakdown of normal 
blood-brain barrier (BBB) function. Principally, the 
BBB is composed o f a continuous endothelial cell layer, 
in close association with astrocytic processes on the 
abluminal surface. The endothelial cells of the cerebral 
vasculature possess a number o f unique properties, 
which include intercellular tight junctions, a reduced 
number o f pinocytotic vesicles, and a high electrical 
resistance (Risau & Wolburg, 1990). These special 
characteristics aid the enhanced selectivity o f the 
barrier, allowing movement o f only vital nutrients into 
the central nervous system (CNS), often by employing 
active transport mechanisms (Bradbury, 1985; Goldstein 
& Betz, 1986). Consequently, exposure o f neuronal 
tissue to vascular neurotoxins, ion fluxes or other delete­
rious systemic factors is prevented and homeostasis 
within the cerebral environment is maintained.
Barrier dysfunction in MS leads to oedema formation 
and inflammatory cell infiltration, which ultimately 
results in axon demyelination and gliotic scarring of 
the lesion (Adams, 1977). With the advent o f magnetic 
resonance imaging it has become possible to locate areas 
where the barrier has been breached by visualizing MS
lesions during growth and decline (Grossman et al., 
1988; Bastianelloef a/., 1990). Study o f  BBB disruption 
due to neuroimmune events has also been possible 
during the development o f EAE which presents a similar 
pattern o f lesion pathology to MS (Paterson, 1978). 
Initial work used the vascular tracer typan blue to 
visualize the abnormally permeable neurovasculature 
in EAE (Barlow, 1956) and later studies employing 
radiolabelled compounds quantitated the unregu­
lated entry o f plasma constituents into the CNS 
(Leibowitz, 1969; Leibowitz & Kennedy, 1972; Juhler 
et a l ,  1984).
High-dose steroid therapy for the management o f  
acute MS relapses has been shown to lessen the severity 
o f clinical disease and reduce lesion activity by 
undefined mechanisms (Troiano et al., 1987; Milanese 
et al., 1989). The glucocorticoids are known to facilitate 
water movement out o f oedematous sites, and scans 
using gadolinium-DTPA magnetic resonance imaging 
have recently shown reduced lesion enhancement in MS 
patients following steroid treatm ent suggesting drug 
effects at neurovascular sites (Kesselring et al., 1989; 
Barkhof et a l,  1991; Burnham et al., 1991). Similarly, 
trials with cyclosporin A (CsA) in MS have indicated a 
modest clinical effect at high doses, but the d rug’s
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therapeutic ability to modify BBB function has not been 
assessed (Rudge et al., 1989; The M ultiple Sclerosis 
Study Group, 1990; Ruutiainen et al., 1991).
Work by us and others, employing dexamethasone 
(Dex) and CsA in either prophylactic or therapeutic 
dosing regimes, has shown the dramatic curtailment o f  
symptom onset or progression o f  EAE, (Komarek & 
Dietrich, 1971; Levine & Sowinski, 1980; Bolton et al., 
1982a,b; Hinrichs et al., 1983; Bolton & Flower, 1989; 
Desai & Barton, 1989). The beneficial effects o f  Dex 
and CsA treatment on the course o f  EAE are thought to 
arise from a down-regulation o f  the immune response 
to encephalitogen. However, Dex and CsA may also 
influence the development of EAE by direct action on 
the BBB as several studies have shown the drugs or 
their degraded products accumulate w ithin or pass 
across the neurovasculature and provide control over 
abnormal permeability changes (Pardridge & Mietus, 
1979; Nooter et al., 1984; Long & Holaday, 1985; 
Begley et al., 1990).
As impairment o f cerebrovascular integrity is pivotal 
in the pathogenesis o f MS and EAE, limiting BBB dys­
function, whether short-term or for an extended period, 
may lessen the damage o f  target tissues and reduce 
neurological deficits. The aim o f  the present study was 
to investigate the ability o f  Dex and CsA to inhibit 
abnormal CNS blood vessel permeability during early 
neurological EAE. The results o f  the investigation are 




Inbred male Lewis rats, weighing 200-250 g, were 
selected from stock bred on site, with food (SDS, diet 
C.R.M.) and water available ad libitum.
Inoculation fo r  EAE
Animals were inoculated for EAE as previously 
described (Bolton & Flower, 1989). Briefly, an encepha- 
litogenic emulsion, consisting o f  equal parts o f  guinea- 
pig spinal cord, sterile phosphate-buffered saline (PBS), 
and incomplete Freund’s adjuvant was prepared and 
supplemented with 10 mg/ml Mycobacterium tuberculo­
sis HyjRa (Difco Laboratories). Each rat received 0.1 ml 
o f  inoculum per hind footpad. Control anim als received 
inoculum without spinal tissue. A m inim um  o f  five 
animals were used per treatment group.
Clinical assessment o f  EAE
Animal body weight was monitored daily throughout 
the course o f study, beginning day 0 post-inoculation 
(p.i.). Neurological signs were scored daily subsequent 
to observed weight loss, as follows: 1 = flaccid tail; 
2 = ataxic gait; 3 = partial paralysis o f  hindlim bs;
4 = complete hindlim b paralysis with associated 
incontinence.
Drug preparation and administration
Dexamethasone sodium phosphate (4 mg/ml, DBL, 
U.K.) was diluted in sterile PBS and adm inistered to 
EAE-sensitised animals subcutaneously twice daily for 
2 days from weight loss. Doses for steroid treatm ent 
were selected from previous studies (Bolton & Flower, 
1989), and ranged from 0.01 to 1 mg/kg body weight. 
Control sensitized animals received equivalent volumes 
o f  sterile PBS.
CsA (Sandoz Laboratories, Basle, Switzerland) was 
dissolved in olive oil at 25 mg/ml and single oral doses 
were given to EAE-inoculated rats, commencing on the 
day o f  weight loss for 2 days. Treatments were based 
on earlier work (Bolton et al., 1982b) and ranged from 
25 to 75 mg/kg body weight. Control sensitized animals 
received vehicle alone.
ulln-tropolonate labelling o f  red blood cells (RBC)
The method was developed from the studies o f  
Osman & Danpure (1987). Blood from adult W istar rats 
was collected by cardiac puncture in c itrate-phos- 
phate-dextrose (Sigma), and centrifuged at 300 g  for 
10 min. The plasma/white blood cell layer was collected 
and respun at 110#  for 15 min to generate cell-free 
plasma. The RBC layer was resuspended in Hepes saline 
buffer (Gibco) and washed three tim es at 300 g  
to remove leukocytes, resuspending at a final con­
centration o f  5 x 10* cells/ml. An addition was made 
o f  100 pi '"In-tropolonate [4 * 10~3 M tropolone 
containing 20pC i " 'In  (NEN) per ml for every
5 x 10s RBC, follow ed by incubation o f  the mixture 
at 37° for 20 min. The labelled cells were washed 
and resuspended at 5 * 10’ cells/0.5 ml cell-free plasma 
for in vivo use.
Quantitation o f  BBB permeability
The perm eability o f  the cerebral vasculature was 
determined for specific CNS tissues chosen on the basis 
o f  previous histological analysis to reflect areas o f  high 
and minimal transendothelial inflammatory cell infiltra­
tion o f  parenchymal tissue (Bolton et a l., 1984). The 
extravasation o f  rat serum albumin (RSA) (Sigma) into
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the defined neurological sites was quantitated using a 
variation o f the double radioisotope technique first 
described by Leibowitz & Kennedy (1972). Briefly, rats 
received intravenously (i.v.) lOpCi ,25I-RSA (prepared 
by a modification o f the Chloramine-T method described 
by McConahey & Dixon, 1980) under halothane/02 
anaesthetic, and 24 h later 5 * 10’ "'In-RBC. After 
4.5 min circulation o f the second isotope cardiac blood 
was collected into heparin-coated tubes, immediately 
followed by a lethal injection o f euthatal (RMB Animal 
Health Ltd). Cerebellum, medulla-pons, and cervical 
spinal tissues were dissected, weighed and the amount 
of " 'In  radioactivity recorded on the open channel o f a 
LKB minigamma counter (settings = 100—450 kev). 
Blood aliquots (100 pi) were counted simultaneously. 
Samples were stored at -20°C  and recounted 3 weeks 
later on the 125I channel (settings = 20-80 kev) following 
111 In decay. The individual isotope counts for each tissue 
were expressed in arbitrary units termed “blood 
equivalents” (BE) [equation(l)].
cpm / g Tissue
— ------ - -----------  x 100 = BE. (1)
cpm / ml Blood
The extravascular blood equivalent (EVBE), a measure 
o f the radiolabelled albumin which has crossed the BBB 
and accumulated within the CNS, was calculated by 
equation (2):
,J5I BE -  "'In BE = EVBE. (2)
Statistics
Results were analysed using the Mann-Whitney 17- 
test for non-parametric data.
RESULTS
Protein extravasation during EAE
Prior to determining the influence o f Dex and CsA 
on cerebrovascular permeability a profile o f protein 
extravasation was established during the development 
o f acute EAE (Fig. 1). Levels o f radiolabelled albumin 
traversing the BBB in normal and control animals were 
minimal (cerebellum 0.83 ± 0.09; medulla-pons 
1.11 ±0.19; cervical spinal cord 1.06 ± 0.09). Similarly, 
movement o f  protein across the neurovasculature in 
EAE-inoculated animals, 5 days p.i., remained within 
normal limits. The development o f clinical EAE, 
12 days p.i., coincided with a significant rise in EVBE 
values in all tissues (cerebellum 2.39 ±0.16; m edulla-




Fig. 1. Profile of protein extravasation (EVBE ± S.E.M.) for the 
cerebellum, medulla-pons and cervical spinal cord tissues from 
normal, CFA-inoculated and EAE-sensitized Lewis rats, during 










Fig. 2. The ability of Dex treatments (0.01-1.0 mg/kg body 
weight) to suppress increased BBB permeability in EAE- 
sensitized Lewis rats ( * /><0.05; **/><0.0I; ***P<0.001).
pons 8.84 ±1.36; cervical spinal cord 7.78 ±1 .10 : 
P<0.001). However, the increase in EVBE was not 
uniform throughout the CNS, with medulla-pons and 
cervical spinal tissues developing highly permeable 
barriers while vascular changes in the cerebellum were 
consistently lower.
The effects of therapeutic Dex administration on BBB 
permeability
The ability o f several therapeutically administered 
Dex concentrations to inhibit BBB disruption (Fig. 2) 
and suppress EAE symptoms (Table 1) was assessed 
by the dual radioisotope technique. Rats dosed with 
vehicle alone maintained the profile o f BBB breakdown 
characteristic of untreated EAE animals at day 12 p.i. 
Low-dose Dex (0.01 mg/kg body weight) had no 
significant effect on suppressing barrier breakdown or 
modifying the course o f EAE. Steroid administration
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Table 1. Incidence of neurological symptoms in EAE-sensitized 







Vehicle 18 2.73 ±0.30
0.01 5 3.50 ±0.50
0.1 11 1.63 ±0.32*
0.5 7 0.14 ± 0.14**
1 7 0**
CsA
Vehicle 16 1.91 ±0.22
25 5 1.20 ±0.72*
50 7 0.21 ±0 .15**
75 6 0**
*/», Number of rats per treatment.
Significance of difference from vehicle-treated group: *P<0.05; 
♦♦/^O.OOl.
at 0.1 mg/kg body weight exclusively restricted the 
movement o f radiolabelled albumin in spinal tissues 
(P^O.OS) and suppressed the development o f neuro­
logical signs (P<0.05) while other CNS areas remained 
unaffected. High concentrations o f Dex (0.5 and 
1.0 mg/kg body weight) dose-dependently inhibited 
barrier dysfunction in all tissues studied (/^O.OOl) and 
prevented the occurrence o f neurological deficits 
(/><0.001).
The effects o f  therapeutic CsA administration on BBB 
permeability
A range o f CsA concentrations was employed 
therapeutically to modify BBB function (Fig. 3) and 
suppress clinical deficits (Table 1). Vehicle control 
animals showed a highly disturbed neurovasculature 
correlating well with untreated time-matched EAE rats. 
Application o f low-dose CsA (25 mg/kg body weight) 
had a limited but significant inhibitory effect on 
abnormal neurovascular permeability within the 
cerebellum and cervical spinal cord (P<0.05) and 
partially suppressed the appearance o f symptoms 
(P<0.05). CsA administered at 50 mg/kg body weight 
restricted loss o f BBB integrity in all tissues (cerebellum 
P<0.05; medulla-pons P<0.01; cervical spinal cord 
F*<0.001) and displayed strong clinical suppression 
(7*<0.001). High-dose CsA therapy (75 mg/kg body 
weight) significantly inhibited aberrant BBB perme­
ability (f*<0.001) and abolished neurological signs 
(P<0.001) but, in contrast to steroid treatment, did not 










Fig. 3. The ability of CsA treatments (25-75 mg/kg body weight) 
to suppress increased BBB permeability in EAE-sensitized 
Lewis rats (*/><0.05; **P<0.01; * * * /><0.001).
DISCUSSION
The current study has reconfirmed the pattern of 
BBB breakdown following neuroantigenic challenge, 
as initially reported by Leibowitz & Kennedy (1972). 
Also, the heightened level o f  radiolabelled albumin 
accumulation within the spinal cord compared to the 
cerebellum reflects the earlier observation o f Rumjanek 
et al. (1984) who found a similar distinction between 
spinal and brain tissues when examining cellular accu­
mulation within the CNS. In particular, we have 
employed the dual radioisotope technique to examine 
the inhibitory action o f Dex and CsA on enhanced cere­
brovascular permeability during the onset o f neuro­
logical EAE, and our findings show that both drugs 
dose-dependently suppress BBB leakage and con­
comitantly curtail the development of paralytic disease. 
However, the ability to inhibit atypical neurovascular 
permeability did differ between the drugs, with only 
Dex completely counteracting aberrant barrier leakage.
EAE is a complex cell-mediated neurological 
condition, and pharmacological control over BBB break­
down and the sustained dysfunction o f the neuroendo­
thelium may be exerted at various stages in the 
manifestation of the inflammatory response to encepha- 
litogen. Prophylactic administration o f Dex or CsA 
to EAE-inoculated animals completely inhibits the 
neurological signs o f disease and the collection o f 
inflammatory cells on the abluminal side o f the cerebro- 
endothelium by preventing the initial sensitization to 
inoculum (Komarek & Dietrich, 1971; Bolton et al., 
1982a, b; Hinrichs et al., 1983; Bolton & Flower, 1989; 
Desai & Barton, 1989). Encephalitogenically sensitized 
immune cells are known to penetrate the BBB and enter 
the CNS parenchyma before the emergence of clinical 
EAE and would therefore be beyond the control o f a
I I NORMAL 
■ 1  VEHCLE
—  CsA 25mg
—  CsA 50mg 
■ 1  CsA_75mg
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therapeutic regime as used in the present study (Daniel 
et al., 1981; Traugott, 1989). However, treatment with 
Dex or CsA at disease onset may restrict further passage 
o f immunocompetent cells across the neurovasculature 
by interfering with encephalitogenic priming o f  lymph­
oid cells, or by suppressing the release o f  inflammatory 
mediators capable o f  disrupting the cerebral endo­
thelium (Bolton et al., 1986; Dupont, 1988; Lew et al., 
1988; Waage & Bakke, 1988). Alternatively, the drugs 
may counteract abnormal increases in neuroendothelial 
permeability by direct action on the vasculature. Indeed, 
the effects o f CsA in vivo cannot be solely accounted 
for by the inhibition o f  T-cell proliferation (Klaus & 
Chisholm, 1986). Furthermore, several workers have 
described the in vivo and in vitro accumulation o f  CsA 
within intact and isolated neuroendothelium from where 
the compound would have the potential to influence 
endothelial cell function (Nooter et al., 1984; Begley 
et al., 1990). Similarly, Dex readily crosses the BBB 
and would be capable o f  interacting with vessel 
constituents to modify an immunocompromised barrier 
(Hedley-Whyte & Hsu, 1986). Studies by Long & 
Holaday (1985) in normal rats provide strong evidence 
that endogenous steroids modulate the permeability o f  
the microvasculature as adrenalectomy caused a signi­
ficant increase in protein extravasation into CNS tissues 
which could be prevented by glucocorticoid adm ini­
stration.
The mechanisms through which Dex and CsA may 
exert their suppressive effects on the neurovasculature 
during early EAE are unclear but are the subject o f our 
ongoing studies. Drugs taken up by the neuroendo­
thelium would be available to modify intracellular 
processes which ultimately influence the continuity o f  
the BBB. Indeed, Dex and CsA-sensitive cerebroendo- 
thelial-dependent pathways, which result in the 
formation o f permeability-inducing factors, have been 
identified. In particular, the drugs can lim it receptor- 
dependent, enzyme-mediated polyam ine production
which has been closely linked to profound barrier 
disruption in non-immune models o f  neurovascular 
breakdown through gross physiological changes 
equivalent to those observed in the cerebroendothelium 
o f  animals with EAE (Trout et al., 1986; Claudio et al., 
1989; Koenig et al., 1989, 1992; Ryffel, 1993). 
Comparable receptor-dependent events, inhibitable by 
Dex and CsA, are also responsible for the generation o f  
the potent vasodilator nitric oxide which has been 
implicated in the early pathogenesis o f  EAE and 
together with the polyamines could exert profound 
disruptive effects on the cerebral vasculature 
(MacMicking et al., 1992; Moncada, 1992; Palmer et 
al., 1992; Moncada & Higgs, 1993; Ludowyk et al., 
1993; Muhl et al., 1993). Interestingly, prelim inary 
investigations by us have revealed the polyamine and 
nitric oxide content o f  CNS-derived vessels to be raised 
at the onset o f EAE, thus supporting an inductive role 
for these compounds in loss o f  BBB integrity (Bolton 
et al., 1994).
In conclusion, this investigation has determined the 
relative efficacies o f  Dex and CsA to suppress enhanced 
BBB permeability during early neurological EAE in the 
Lewis rat. The use o f a short therapeutic dosing regime 
to limit neurovascular damage has allowed considera­
tion o f  the drugs’ influence on the immunocompromised 
BBB in addition to their interruptive effects on neuro- 
immune cell generation. Studying the direct effects o f  
Dex and CsA on the cerebroendothelium during EAE 
may provide a specific and relevant site to target in 
attempting to control the central inflammatory events 
characteristic o f  the experimental and human demye- 
linating diseases.
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Pharmacological manipulation of blood-brain barrier (BBB) breakdown during recovery 
from experimental allergic encephalomyelitis (EAE) in the Lewis rat.
Paul, C. & Bolton, C. (1994) J. Physiol 480P, 11-12.
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There was a significant increase in BBB permeability in 
both C'R-EAE anti SFV oom|iared to controls (P <0-001). 
Table I shows that this increase in BBB permeability was 
significantly decreased by treatment with cimetidine. These 
results are consistent with a role for histamine in BBB 
opening in animal models of MS and that these effects are 
mediated via H, receptors. I t  is possible that preventing 
BBB permeability changes may be a useful therapeutic tool 
in MS.
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Pharmacological manipulation of blood-brain  
barrier (BBB) breakdown during recovery from  
experimental allergic encephalomyelitis (EAE) in 
the Lewis rat
C. Paul and C. Bolton
Pharmacology Group, School of Pharmacy & Pharmacology, 
University of Bath, Bath
The BBB is the highly selective vascular cell lining which 
maintains the homeostatic balance of the central nervous 
system (CNS), and loss of neurovascular function is a pivotal 
step in the pathogenesis of multiple sclerosis and the animal 
model EAE. The influx of unregulated plasma constituents 
and inflammatory cells into the CNS leads to characteristic 
oedema formation and myelin degradation. Previous studies 
have demonstrated enhanced permeability of the BBB 
during the acute phase of EAE in the Lewis rat and we have 
investigated the therapeutic effects of drugs to correct 
neurovascular disruption (Juhler el al. 1984; Paul &. Bolton, 
unpublished work). Using a modification of the Leibowitz 
and Kennedy double radioisotope technique employing 
'*4I-rat serum albumin as the permeability marker and 
mIn-red blood cells as the blood volume marker, we have 
extended our studies to examine neurovascular events 
during recovery following the loss of clinical signs and the 
resumption of body weight increases (Leibowitz & Kennedy, 
1972). Neurovascular disruption, measured in the 
cerebellum, medulla-pons and cervical spinal tissues, 
continued in recovery. Interestingly, in comparison to 
extravascular blood equivalent (EVBE) values recorded in
111'
acute EAE, |iermeability in the cereliclliim was exacerlwlctl 
during recovery (7-59 + 2-l in recovery, 3-02 + 0-82 acute 
EAE, means + S.E .M ., «> 5) while spinal cord permeability 
was reduced (3-6 +  0-63 in recovery, 9-58 + 1-47 acute EAE, 
means + s .e .m . ,  n> 5). The ability of drugs to decrease BBB 
permeability was found to be augmented during the 
convalescent period. For example therapeutic- 
administration of cyclosporin A (CsA) at 50 mg (kg body 
weight)-1 (BW) partially corrected cerebrovascular damage 
(Paul 4. Bolton, unpublished work), but when administered 
in recovery returned BBB function to normal in all tissues 
(P < 0  01, Mann-Whitney U test (MWU)). Similarly, low 
dose CsA (25 mg (kg BW)-1) and dexamethasone (01 mg (kg 
BW)-1), given during acute EAE, reduced permeability in 
selected CNS tissues but demonstrated significant barrier 
improvements in all areas when given during recovery 
(P <  0-05 MWU). In summary, the BBB remains 
dysfunctional following complete recovery from EAE. 
Furthermore, pharmacological control of barrier function is 
improved compared with therapeutic drug effacacies. The 
findings suggest that mechanistic differences in barrier 
abnormalities exist between the acute and the recovery 
phases of EAE which may be important in the long-term 
treatment of neurological conditions.
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Role of neurochemicals in  the blood-brain barrier 
permeability, cerebral blood flow, vasogenic 
oedema and cell changes in heat stress. 
Experimental observations in  the rat
H.S. Sharma*, J. Westmanf, F. Nybergt, J. Cervos- 
Navarro* and P.K. Dey§
*Institute of Neuropathology, Free University Berlin, 
Germany, Departments of t  Human Anatomy and 
X Pharmaceutical Biosciences, Biomedical Centre, Uppsala 
University, Uppsala, Sweden and § Department of 
Physiology, Institute of Medical Sciences, Banaras Hindu 
University, Varanasi-221005, India
The possibility that serotonin, prostaglandins and 
neuropeptides are involved in the secondary mechanisms of 
cell damage in heat stress (HS) was examined in a rat model 
using pharmacological approach. Animals (80-90 g, 
8-9 weeks old) were exposed to heat in a B.O.D. (biological 
oxygen demand) incubator for 4 h at 38 °C (relative 
humidity 45-50 %, wind velocity 20-25 cm s-*) (Sharma et 
al. 1991) and hyperthermia, behavioural symptoms, 
blood-brain barrier (BBB) permeability (Sharma el al. 
1992a), cerebral blood flow (CBF), brain oedema, and cell 
changes (Sharma el al. 19926) were examined. In separate 
groups of animals ketanserin (a serotonin, receptor
Aspects.of the biochemical pharmacology of neurovascular disruption in experimental 
allergic encephalomyelitis (EAE).
Bolton, C., Lees, P., Paul, C., Scott, G.S., Williams, K.I. & Woodyer, P. (1994) J. 
Neuroimmunol. 52(2), 113.
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demonstrated that a murine IgGl anti-class II MHC 
antibody (0X6) is able to both prevent and treat EAE 
in the Biozzi A B /H  mouse. We have confirmed that 
this antibody is poorly cytotoxic, allowing mechanisms 
of action other than depletion of antigen presenting 
cells to be assessed. Despite its effect on disease, 0X 6 
administration does not prevent priming of T cells in 
the draining lymph node, implying an alternative mech­
anism for regulation of the autoimmune disease pro­
cess.
Modulatory action of essential fatty acids on experi­
mental allergic encephalomyelitis (EAE)
L.S. Harbige, M.M. Morris, S. Amor
Department o f Immunology, Rayne Institute, UMDS,
St Thomas' Hospital, London, UK
Oral administration of linoleic, y-linolenic, a-lino- 
lenic, or eicosapentaenoic acid from safflower, fungal, 
linseed and fish oil sources.7 days after neuroantigen 
immunisation had differential effects on the clinical 
signs of EAE in Lewis rats. y-Linolenic acid-rich fun­
gal oil at 500 mg/kg of body weight was fully protec­
tive, although at doses of 200 and 1000 mg/kg only 
delayed the onset of disease. Linoleic acid-rich saf­
flower oil at 500, 750 and 1000 mg/kg decreased the 
severity of clinical EAE in a dose-dependent manner. 
a-Linolenic and eicosapentaenoic acid at 500 mg/kg of 
body weight prolonged the course of clinical EAE. The 
effects of these oils was also examined ex vivo in 
normal animals. Adhesion of lymphocytes from fungal 
oil treated rats to homologous brain endothelium was 
unaffected, although lymphocytes from safflower oil 
treated normal animals had 2-3-fold increase in adher­
ence compared to lymphocytes from untreated animals. 
Both oil treatments enhanced the T-cell proliferative 
response to concanavalin A. Analysis by flow cytometry 
of splenic lymphocytes from oil treated rats indicated 
that CD8+ but not CD4+ cell surface determinants 
were affected. In addition, the CD45+ determinant 
was affected by fungal but not safflower oil. This study 
suggests that oral administration of lipids have potent 
effects on EAE and may be useful in multiple sclerosis.
Aspects of the biochemical pharmacology of neurovas­
cular disruption in experimental allergic encephalo­
myelitis (EAE)
C  Bolton, P. Lees, C. Paul, G.S. Scott, K.I. Williams, 
P. Woodyer
Pharmacology Group, School o f Pharmacy and Pharma­
cology, University o f  Bath, Claoerton Down, Bath, BA2 
7AY, UK
Neuroimmune-associated cerebrovascular disrup­
tion is a characteristic feature of the experimental 
disease allergic encephalomyelitis (EAE). The precise 
mechanisms initiating blood-brain barrier breakdown 
are unknown but may require the production of perme­
ability-inducing factors to trigger vascular injury. Can­
didate mediators of neuroendothelial damage include 
the potent vasodilator nitric oxide (NO) and polyamines 
(PA) which cause gross perturbation of endothelial cell 
membranes (1,2]. Preliminary investigations by us have 
shown significantly elevated levels of NO, measured as 
nitrate product, in CNS blood vessel isolates from 
Lewis rats with EAE. Our studies have also revealed 
an increase in the PA content of neurovascular prepa­
rations. Interestingly, short-term therapeutic steroid 
administration during early EAE inhibits NO and PA 
formation and restores the normal permeability to the 
CNS vasculature [3]. Therefore, down-regulation of 
neuroendothelial-derived permeability factor may ac­
count, in part, for the suppressive effects of steroid 
treatment on the course of EAE.
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Adhesion molecules and the binding of lymphocytes to 
cerebral blood vessel walls
A.J. Vora \  D.C. Dumonde \  M.E. Perry b, K.A. 
Brown *
* Immunology, bAnatomy Group, UMDS, St Thomas' 
Hospital, London SEI 7EH, UK
Antibody blocking studies and immunocytochemical 
techniques were used to identify the adhesion 
molecules that promote the attachment of blood lym­
phocytes to vessel walls in sections of human brain. 
Lymphocyte binding was impaired (P  < 0.02) by anti- 
LFA-1 (46% inhibition) and anti-VLA-4 (mean 26% 
inhibition) antibodies. Counter-receptors for LFA-1 
and VLA-4 are ICAM-1 and VCAM-1 and they were 
present on 48% and 27% of exposed blood vessels, 
respectively. CD4+ T  cells were the most adherent of 
the lymphocyte subsets and lymphocyte binding was 
augmented following activation with IL-2 (mean 130% 
increase; P < 0.002). These results should benefit the 
development of agents to impede lymphocyte entiy 
across the blood-brain barrier.
This work was supported by The Henry Smith’s Char­
ity.
Restoration of blood-brain barrier integrity by dexamethasone and cyclosporin A 
combined dose therapy during experimental allergic encephalomyelitis.
Paul, C. & Bolton, C. (1994) J. Neuroimmunol. 54(1-2), 188.
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RESTORATION OF BLOOD-BRAIN BARRIER INTEGRITY BY 
DEXAMETHASONE AND CYCLOSPORIN A COMBINED DOSE THERAPY 
DURING EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS
C. Paul & C. Bolton
Pharmacology Group, School of Pharmacy & Pharmacology, University of Bath, 
Bath BA2 7AY, U.K.
Introduction: A focal point in pathogenesis of multiple sclerosis and the animal 
model experimental allergic encephalomyelitis (EAE) is the breakdown of blood- 
brain barrier (BBB) integrity. In EAE the abnormal BBB permeability can be 
reduced dose-dependently by therapeutic administration of either dexamethasone 
(Dex) or cyclosporin A (CsA). We now present evidence of enhanced drug action 
at the BBB when Dex and CsA are used in combination.
Materials and Methods: Drugs were administered for 2 days following symptom 
onset; Dex was injected sub-cutaneously twice daily in PBS; CsA in olive oil was 
given orally once daily. Albumin extravasation in the cerebellum, medulla-pons 
and cervical spinal cord was assessed by a modified double radioisotope technique. 
Results: CsA in combination with O.lmg/Kg Dex, a dose of minimal therapeutic 
benefit, demonstrated enhanced restoration of BBB function at 50, 35 and 
25mg/Kg. Improved correction of barrier permeability was also seen when 
50mg/Kg CsA was used in conjunction with 0.0Img/Kg Dex.
Conclusion: Low dose Dex enhanced the restorative action of CsA at the BBB. 
Therapeutically effective low dose combinations of Dex and CsA may result in 
fewer side effects and could therefore have important implications in the treatment 
of multiple sclerosis.
Immunomodulation of nitric oxide (NO) and its contribution to neurovascular 
permeability during experimental allergic encephalomyelitis (EAE).
Scott, G.S., Paul, C., Whitehouse, J., Williams, K.I. & Bolton, C. (1995) 
Inflammation Res. 44(Suppl.3), S233.
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Immunomodulation Of Nitric Oxide (NO) And Its Contribution To 
Neurovascular Permeability During Experimental Allergic 
Encephalomyelitis (EAE)
GS. Scott, C. Paul, J. Whitehouse, KI. Williams & C. Bolton 
Pharmacology Group, University Of Bath, Bath BA2 7 AY
Our initial studies demonstrated that the loss of cerebrovascular integrity 
in the animal model of multiple sclerosis, EAE can be suppressed by 
dexamethasone (Dex) and cyclosporin A (CsA). The mechanisms through 
which the drugs inhibit neurovascular breakdown are unclear but may 
involve a dual action on circulating inflammatory cells and the 
cerebroendothelium. The current study has shown that Dex but not CsA 
alters the circulating inflammatory cell composition in Lewis rat EAE. 
However, both agents reduced the levels of NO within central nervous 
system components. NO acts as a potent vasodilator and cytotoxic 
molecule, which is produced by inflammatory cells, and may contribute to 
neurovascular disruption during EAE. The corrective effects of Dex on 
the cerebrovasculature may therefore be mediated through suppression of 
NO or redistribution of inflammatory cells, whereas the effects of CsA 
may be elicited through NO inhibition..
